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ABSTRACT
The differential susceptibilities of warfarin-susceptible LAC-grey and
warfarin-resistant HC house mice to the anticoagulant effect of the oral
rodenticide 3-(a-acetonyl benzyl)-4-hydroxycoumarin (Warfarin) in terms of their
blood clotting times, were determined. The hypoprothrombinaemic effect of
both the R(+) and S(-) warfarin enantiomers was also investigated, in addition to
the standard test for warfarin-resistance in mice, the ability to survive on a diet
containing 0.025% warfarin for 21 days. Onto this base of knowledge of the
exact hypoprothrombinaemic responses evoked by treatment of both warfarin-
susceptible and warfarin-resistant mice with warfarin at various doses, a
structured analysis of the biochemical consequence(s) of expression of the major
warfarin-resistance gene, War, could be built. Thus, changes in the in vivo
pharmacokinetic parameters including half-life ( t | ) ,  plasma clearance (Cl^),
apparent volume of distribution (Vd ) and bioavailability (F) were documented
aPP
for both R(+) and S(-) warfarin in both males and females of the two mouse 
strains. Similarly, in vitro hepatic microsomal metabolite profiles following 
pretreatment with warfarin, phenobarbitone, (3-naphthoflavone and clofibrate, 
excretion of unchanged warfarin enantiomers and warfarin metabolites and 
finally plasma protein binding parameters were determined in LAC-grey and HC  
mice. Therefore, it was possible to correlate changes in the pharmacokinetics, 
metabolism and disposition of warfarin in these mice with their differential 
anticoagulant sensitivities. Accordingly, the biochemical mechanism(s) of the 
expression of the major warfarin-resistance gene, War, has (have) been proposed 
to be due, at least in part, to a combination of a greater plasma clearance of the 
more potent S(-) warfarin enantiomer in females, a larger hepatic uptake of the 
same enantiomer in both sexes, and a greater degree of plasma protein binding of 
both enantiomers of warfarin.
CONTENTS PAGE
CHAPTER 1 -  INTRODUCTION
1.1 Synthesis of Vitamin K-Dependent Blood Clotting 
Factors and the Vitamin K Cycle.
1.2. Antagonism of the Physiological Role of Vitamin K 
by Anticoagulants.
1.3. Mechanisms of Warfarin-Resistance.
1.4. Pharmacokinetics and Metabolism of Warfarin
Absorption
Distribution
Metabolism
Excretion
1.5. Objectives of the Present Study.
CHAPTER 2 -  MATERIALS AND METHODS 
Materials 
Methods
2.1. In Vivo Studies
2.1.1. Animals
2.1.2. Toxicity Studies
2.1.3. Pharmacokinetics
2.1.4. Warfarin Excretion Studies
2.1.5. Plasma Protein Binding Studies
2.2. In Vitro Studies
2.2.1 Microsomal Metabolism of Warfarin
2.2.2. Plasma Protein Binding Studies
2.2.3. Synthesis of Sodium Salts of Warfarin Enantiomers
1
5 
‘  10
15
23
24
25
25
26
29
3 2
3 4
36
39
41
Page
CHAPTER 3 -  STUDIES ON THE TO XIC ITY OF, AND A N T I­
COAGULANT RESPONSE TO, ORAL WARFARIN  
ADMINISTRATION IN  WARFARIN-RESISTANT 
AND SUSCEPTIBLE MOUSE STRAINS
3.1. Introduction
4 3
3.2.
3.3.
Experimental Objectives 
Experimental Design
4 6
4 7
3.4. Results 4 8
3.4.1. The Hypoprothrombinaemic Response of Warfarin- 
Susceptible and Warfarin-Resistant Mice to 
Racemic Warfarin Administration.
4 8
3.4.2. The Stereospecific Hypoprothrombinaemic Response of 
Warfarin-Susceptible and Warfarin-Resistant Mice to 
Administration of R(+) and S(-) Warfarin Enantiomers
7 4
3.4.3. Differential Toxicity of 0.025% (w/w) Racemic Warfarin 
to Warfarin-Susceptible and Warfarin-Resistant Mouse 
Strains in a 21-day Feeding Trial.
7 8
3.5. Discussion
81
CHAPTER 4 -  PLASMA CONCENTRATION-TIME PROFILES OF 
R(+) AND S(-) WARFARIN ENANTIOMERS 
AFTER INTRAVENOUS AND ORAL ADMINIS­
TRATION OF RACEMIC ANTICOAGULANT TO  
WARFARIN-SUSCEPTIBLE AND W ARFARIN- 
RESISTANT MICE
_ ...--------
4.1. Introduction 9 6
4.2. Experimental Objectives 1 0 0
4.3. Experimental Design 1 0 1
4.4. Results
4.4.1. Intravenous Administration of 16mg/kg Racemic Warfarin 1 0 2
4.4.2. Oral Administration of 16mg/kg Racemic Warfarin 1 1 3
4.5. Discussion 1 1 7
Page
CHAPTER 5 -  IN  VITRO' HEPATIC MICROSOMAL METABOLISM  
OF R(+) AND S(-) WARFARIN ENANTIOMERS IN  
UNTREATED-, W ARFARIN-, PHENOBARBITONE-, 
AND 3-NAPHTHOFLAVONE-PRETREATED  
WARFARIN-SUSCEPTIBLE AND W ARFARIN- 
RESISTANT MICE
5.1. Introduction
5.2. Experimental Objectives
5.3. Experimental Design
5.4. Results
5.5. Discussion
CHAPTER 6 -  UR INARY AND FAECAL EXCRETION OF]14c1 
W ARFARIN IN  WARFARIN-SUSCEPTIBLE 4
LAC-GREY AND WARFARIN-RESISTANT HC  
MICE
6.1. Introduction
6.2. Experimental Objectives
6.3. Experimental Design
6.4. Results
f l4  “I
— -----6.4.1. Total I CJ Urinary and Faecal Excretion Rates in
Warfarin-Susceptible and Warfarin-Resistant Mice.
6.4.2. Excretion of R(+) and S(-) Warfarin Enantiomers and 
Conjugates in LAC-Grey and HC Mice.
6.4.3. Excretion of Warfarin Metabolites and Their Conjugates 
in Urine and Faeces of LAC-Grey and HC Mice.
1 2 6 
. j i f s x
1 3 8
1 3 9  
1151
1 6 4  
1 68 
1 6 9
1 7 0  
1 7  3 
1 7 7
6.5. Discussion 1 8 4
Page
CHAPTER 7 -  PLASMA PROTEIN BINDING OF R(+) AND S(-) IN  
WARFARIN-SUSCEPTIBLE LAC-GREY AND  
WARFARIN-RESISTANT HC M ICE
7.1. Introduction
7.2. Experimental Objectives
7.3. Experimental Design
7.4. Results
7.4.1. In Vitro Binding Studies
7.4.2. In Vivo Binding Studies
7.5. Discussion
CHAPTER 8 -  DISCUSSION
WARFARIN METABOLISM AND DISPOSITION IN  
WARFARIN-SUSCEPTIBLE AND W ARFARIN- 
RESISTANT MOUSE STRAINS
REFERENCES
1 9  3
1 9  8 
1.1 ]9 9
2 0 0
I • . : ...
! 2 0 0 
•2 0 3 
2 0 5
21  5
2 2 6
C H A P T E R !
INTRODUCTION
1.1. SYNTHESIS OF VITAM IN K-DEPENPENT BLOOD CLOTTING FACTORS
AND THE VITAMIN K CYCLE
Vitamin K was discovered in the early 1930’s when Dam and his co- 
workers investigated the effect of a cholesterol-free diet on chickens
(Dam, 1935). The animals developed a bleeding tendency which could be
counteracted by the administration of a fat-soluble component which was also 
missing from the cholesterol-free diet. This compound was designated 
'Koagulations Vitamin' (vitamin K), and found to be essential in the synthesis of 
blood clotting factors. Until quite recently, the sole vitamin K-dependent 
clotting factor proteins were thought to be factors II (prothrombin), VII, IX  and 
X. However, 3 further proteins have been identified as both vitamin In­
dependent, and involved in the coagulation of blood. These are proteins C, S and 
Z (Sugo et al 1985; Stern et al 1986; H0jrup et al 1985). A ll the blood clotting
factors mentioned above-are-similar in that they contain the-amino acid y  -  ------------
carboxyglutamic acid (Gla). The vitamin K-dependent step in the synthesis of 
these clotting factors involves the post-translationaly-carboxylation of glutamic 
acid (Glu) residues into the aforementioned y  -carboxyglutamic acid (Gla) 
residues by the enzyme, vitamin K-dependent carboxylase (Nelsestuen et al 1974;
Stenflo et al 1974). y  -Carboxyglutamic acid residues are required for the 
calcium-dependent interaction between prothrombin and a negatively-charged 
phospholipid surface which is essential for the activation of the prothrombin to 
thrombin. Although less extensively studied, similar interactions are important
for the physiological responses of the other y-carboxyglutamic acid-containing 
plasma proteins. Vitamin K-dependent carboxylase is a microsomal enzyme and 
has been shown to catalyse y-carboxylation of glutamic acid residues in other 
tissues, most notably bone (Gallop et al 1980; Price, 1983), kidney (Hauschka et 
al 1976), lung (Bell, 1979) and placenta (Friedman et al 1979).
Both vitamin K and vitamin K-dependent carboxylase are present in the 
rough endoplasmic reticulum (RER) of the liver, and the carboxylase enzyme 
requires the reduced form of vitamin K, vitamin Kh^ (hydroquinone) as a co­
factor (Sadowski et al 1976). Evidence has been presented to show that vitamin 
K 2,3-epoxide is a product of this reaction (Larson et al 1981), and that the 
enzyme vitamin K reductase, using dithiothreitol (DTT) as a co-factor in vitro, 
catalyses this conversion (Wallin and Suttie, 1981; Whitlon et al 1978). Epoxides 
are generally unstable compounds and are converted to more stable (and less 
reactive) compounds by a further reductase enzyme. Liver contains an epoxide 
reductase (vitamin K epoxide reductase) capable of converting the 2,3-epoxide 
back to the quinone form of the vitamin, so forming the vitamin K cycle (Figure
1.1.). In vitro dithiothreitol (DTT) is an effective reducing agent for this 
reaction (Whitlon et al 1978) but the physiological reducing agent has not been 
identified. The enzyme, vitamin K epoxide reductase, is 15% stereoselective for 
the R(+) enantiomer of the vitamin K 2,3-epoxide. The epoxide may therefore 
exist as two enantiomers; the physiologically predominant form has been 
tentatively assigned the (2R,3S) configuration (Paterson et al 1981). Figure 1.1. 
indicates what many studies on the mechanism of the carboxylation reaction 
stress; that is, the close relationship of vitamin K-dependent carboxylase to the 
microsomal vitamin K reductase (Willingham and Matschiner, 1974; Bell, 1978; 
Suttie et al 1980). Both activities are concentrated in the rough endoplasmic
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reticulum (Carlisle and Suttie, 1980) and tend to fractionate together (Wallin and 
Suttie, 1982). Both utilise the hydroquinone form of vitamin K as a substrate 
(Sadowski et al 1977) and have similar activity with different homologues of the 
vitamin (Friedman and Smith, 1979). High concentrations of CN” will uncouple 
epoxidation from carboxylation (Larson et al 1981) therefore leading to high 
epoxide to y  -carboxyglutamic acid ratios. I t  seems significant that data to
support a hypothesis that carboxylation can proceed in the absence of
epoxidation has not been presented. Thus, the two reactions are linked such that 
subsequent to vitamin K 2,3-epoxide formation, glutamic acid residues on
precursor proteins form carboxyglutamic acid residues in the now mature
clotting factors. This linkage is thought to occur via a common intermediate, 
postulated to be a hydroperoxide of vitamin K (Paterson et al 1981). 
Accordingly, it is clear that the formation of vitamin K-dependent clotting 
factors relies on the normal functioning of the vitamin K cycle. Interferance 
with any part of this system will give abnormal clotting factor formation or 
function, thus causing incoagulable blood.
1.2. ANTAGONISM OF THE PHYSIOLOGICAL ROLE
OF VITAM IN K  BY ANTICOAGULANTS
The first anticoagulant was discovered in the mid- 1920's, causing the 
development of a haemorrhagic disease in cattle. The production of 3,3'- 
methylenebis-(4-hydroxycoumarin)-(dicoumarol) (Figure 1.2.) was traced to 
stacks of improperly cured sweet clover hay (Link, 1953-34-) and the synthetic 
equivalent was synthesised in 1940 (Deckert, 1974). The discovery of dicoumarol 
received the immediate attention of the medical profession, anxious to use the 
compound clinically in the prophylactic treatment of thromboembolic disease. 
Since these early studies, research has lead to the development of a large group 
of 4-hydroxycoumarin based compounds of clinical significance, the oral 
anticoagulants. Of these, 3-(a-acetonylbenzyl)-4-hydroxycoumarin (Warfarin) 
(Figure 1.2.) quickly became a leader in clinical anticoagulant therapy.
Since it's synthesis by Ikawa in 1942, and the discovery of it's high 
anticoagulant activity in rats and mice, warfarin first found extensive 
application as a rodenticide (Deckert, 1974). However, soon after this time in 
1932,-the-water-soluble sodium salt of warfarin was introduced~into clinical 
anticoagulant therapy becoming the leading anticoagulant in clinical practice, as 
well as in rodenticidal action.
Warfarin and the other 4-hydroxycoumarin anticoagulants act by 
inhibiting the vitamin K-dependenty-carboxylation of clotting factors II, VII, IX  
and X at a post-ribosomal stage in the liver, leading to a build-up of biologically 
inactive precursor clotting proteins named PIVKA's (proteins induced by vitamin 
K antagonism) (Brozovic, 1976; Friedman et al 1977). Thus, a spectrum of
Figure 1.2.. The Structure of Warfarin
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partially carboxylated clotting factor precursors is present in the plasma of 
warfarin-treated humans, rats or mice (Brozovic, 1976; Friedman et al 1977). 
The oral anticoagulants therefore act directly to antagonise the physiological 
role of vitamin K in blood clotting factor synthesis. A t the molecular level, the 
action of warfarin upon the enzymes of the vitamin K cycle has been studied in 
detail, subsequent to the finding that in both humans and rats, warfarin 
administration caused a relative increase in vitamin K 2,3-epoxide and 
metabolites of the vitamin more polar than the epoxide (Caldwell et al 1979). 
These hydroxylated metabolites of vitamin K found after warfarin treatment 
were consistent with the hypothesis that warfarin may interfere with the 
synthesis of vitamin K-dependent clotting factors by inhibiting the regeneration 
of vitamin K from it's 2,3-epoxide (McBurney et al 1978). The general hypothesis 
that warfarin exerts it's effect on clotting factor synthesis by inhibition of the 
enzyme vitamin K epoxide reductase (Figure 1.1.) is well supported (Ren et al 
1977; Wingard and Levy, 1973; Willingham and Matschiner, 1974). In addition to 
it's action here, it  is suggested that warfarin is able to inhibit vitamin K - 
dependent carboxylase, but at millimolar concentrations, whereas only 
micromolar concentrations of warfarin are needed to inhibit vitamin K epoxide 
reductase and vitamin K reductase (Whitlon et al 1978). However, the 
biologically important site of action of warfarin and other 4-hydroxycoumarin 
anticoagulants has been established as the inhibition of the enzyme vitamin K 
epoxide reductase.
The mode of antagonism of vitamin K epoxide reductase is unclear, since 
warfarin does not appear to be a classical competitive or non-competitive 
inhibitor of vitamin K (Lowenthal and MacFarlane, 1964). Olson (1974) had 
proposed that warfarin allosterically alters a vitamin K receptor protein. It  has
also been suggested that the oral anticoagulants are mechanism-based suicide 
inactivators of vitamin K epoxide reductase (Silverman, 1980 and 1981) such that 
warfarin is converted by vitamin K epoxide reductase to a hypothetically 
reactive diketo form by tautomerism. This active molecule then undergoes 
attack by active-site nucleophiles, which become acylated, thereby inactivating 
the enzyme.
By inhibiting vitamin K metabolism, warfarin is able to inhibit the 
synthesis of vitamin K-dependent blood clotting factors, and so effect 
anticoagulation. The extent of this anticoagulation depends not only on the dose 
of warfarin administered, but also on the species, sex and strain of animals under 
observation. In addition, warfarin is a chiral molecule (Figure 1.2.) with S(-) 
warfarin being more potent than it ’s R(+) enantiomer in both man and the rat 
(Eble et al 1966; Hewick and McEwen, 1973). Therefore many factors contribute 
to the overall anticoagulant response elicited in any individual. These factors 
are discussed in greater detail in Chapter 3 of this thesis.
1.3. MECHANISMS OF WARFARIN RESISTANCE
Genetically-determined warfarin-resistance has been reported in man, 
the rat and the mouse. In addition, various types of warfarin-resistance have 
been documented in humans, which are not hereditary. Dietary warfarin- 
resistance is caused by an excess nutritional intake of vitamin K and is reversible 
upon discontinuation of the excess intake. Acquired warfarin-resistance is 
manifested by an initial response to warfarin which decreases upon repeated 
administration. This thesis deals with only the genetically-determined resistance 
to warfarin anticoagulation, the understanding of which is important for both 
effective anticoagulant therapy in man, and control of warfarin-resistant rats 
and mice using rodenticides.
Genetically-determined warfarin-resistance has been quite extensively
studied in both humans and rats. However, relatively little  data is available
describing warfarin-resistance in mice. Early studies revealed that in the rat a
2single autosomal dominant gene, Rw , was responsible for warfarin-resistance, 
and that different populations of warfarin-resistant rats had different levels of 
resistance and presumably different warfarin-resistant genes (Greaves and 
Ayres, 1967; Lund, 1972). It  was noted soon afterwards that a slower absorption 
(Price-Evans and Shephard - unpublished data, 1966), a faster rate of warfarin  
metabolism (Hewick, 1972; Townsend et al 1973), or faster excretion of warfarin  
were not responsible for the observed warfarin-resistance. In addition, 
Hermondson et al (1969) found that heterozygous Welsh-type warfarin-resistant 
rats required twice as much and homozygous resistant rats, 20-times as much 
vitamin K as normal rats to restore their blood clotting activities to normal 
levels after being fed a vitamin K-deficient diet. These results were explained
based on the assumption that vitamin K and the oral anticoagulants were in 
competition for a site on a protein necessary for the synthesis of vitamin K - 
dependent clotting factors. The same authors postulated that a mutation in the 
warfarin-resistant rats may have lowered the affinity of the protein binding site 
for vitamin K, and simultaneously, greatly reduced the affin ity for 
anticoagulants such as warfarin. In support of this theory, ribosomes from  
normal rats were found to bind 2-3 times as much warfarin as were those from 
warfarin-resistant rats (Hermondson et al 1969). The nature and location of this 
binding protein was partially elucidated by Zimmerman and Matschiner (1972), 
who showed that in the presence of warfarin, vitamin K epoxide accumulated to 
a lesser degree in warfarin-resistant, compared with warfarin-susceptible rats. 
These workers concluded that the enzyme, vitamin K epoxide reductase, was less 
sensitive to warfarin inhibition in warfarin-resistant rats (Figure 1.1.), so 
conferring warfarin-resistance. Those findings were also substantiated by Bell 
and Caldwell (1973) and Leek and Park (1981). However, although this 
explanation of the biochemical manifestation of warfarin-resistance is true for 
the population of warfarin-resistant rats investigated in these studies, more than 
one population of warfarin-resistant rat is in existence, and these have differing  
warfarin susceptibilities (Greaves and Ayres, 1967). M acNicoll (1985) has 
recently shown that in rat strains which were homozygous for either Scottish 
(HS) or Welsh (HW) resistance genes, the expression of the Welsh warfarin- 
resistance gene resulted in an altered hepatic vitamin K epoxide reductase 
enzyme, as discussed above. I t  was shown (MacNicol 1 et al 1984) however, in the 
H5 rat strain, that gene expression may have produced alterations in hepatic 
vitamin K reductase, and that the vitamin K epoxide reductase was apparently 
unchanged (Figure 1.1.). Clearly, further studies of vitamin K metabolism are 
needed in order to establish the biochemical mechanism(s) of warfarin-resistance 
in more than one anticoagulant resistant rat strain.
In man, hereditary resistance to oral anticoagulant drugs has been 
reported in several kindreds (O’Reilly et al 1964; O'Reilly, 1970; Holt and 
Freytes, 1983), although i t ’s incidence has been defined as extremely rare. In 
these cases the individuals required doses of warfarin in excess of 20-times the 
normal before therapeutic effects were seen. Plasma warfarin concentrations 
were correspondingly elevated, suggesting that there was no alteration in 
warfarin metabolism, although all the patients were sensitive to the antidotal 
action of vitamin K; and studies of the families showed that the warfarin- 
resistance was inherited as an autosomal dominant tra it, as was indicated 
previously in the rat (Greaves and Ayres, 1967). Results from the human studies 
mentioned above were all consistent with the hypothesis that the basis for 
hereditary warfarin-resistance was a mutation in the warfarin 'receptor' vitamin 
K epoxide reductase, so that it's affinity for vitamin K was moderately 
decreased, while the affinity of the enzyme for warfarin was markedly 
diminished, a similar phenomenon to that reported in the warfarin-resistant rat 
(Bell and Caldwell, 1973).
In contrast to the quite extensive investigations of warfarin-resistance in 
the rat and man, few studies designed to investigate the biochemical 
manifestations of warfarin-resistance in mice have been reported. This is in part 
due to the fact that large interindividual, sex and strain differences in the 
hypoprothrombinaemic (clotting factor decrease) response to warfarin  
administration were seen within warfarin-susceptible and warfarin-resistant 
strains of mice (Rowe and Redfern, 1968; Rowe and Bradfield, 1975) making 
accurate comparisons between different mouse strains almost impossible. The 
identification of the major warfarin-resistance gene, War, on chromosome 7 in 
the house mouse (Wallace and MacSwiney, 1976) implied that it  would be possible
to develop physiologically-similar warfarin-susceptible and warfarin-resistant 
mouse strains. A most striking difference relating to warfarin-resistance in the 
mouse, compared with the rat, was the lack of any report suggesting an 
increased dietary requirement of vitamin K in the warfarin-resistant house 
mouse, a finding substantiated in our laboratory (Ayres -  unpublished data). 
Warfarin-resistant rats of the Welsh strain required a 20-fold increase in normal 
dietary vitamin K when homozygous for warfarin-resistance (Hermondson et al 
1969) in order to maintain normal blood clotting function. This difference 
indicated that the mechanism(s) of warfarin-resistance may not be the same in 
the Welsh rat and the house mouse. Studies undertaken by Lush and co-workers 
in mice (Lush and Arnold, 1975; Lush, 1976) showed correlations between 
hexobarbitone sleeping times, zoxazolamine metabolism and warfarin-resistance. 
In females of 16 strains of mice, there was a highly significant (p<0.005) inverse 
correlation between hexobarbitone sleeping time and warfarin survival. Wood 
and Conney (1974) showed that a particular strain of mice (DBA/2J) had a much 
higher activity of coumarin 7-hydroxylase than did mice of the other strains 
studied; the difference being determined by an allele of a single gene, Coh, on 
chromosome 7. The same authors also reported that DBA/2J mice were less 
sensitive to the lethal effects of warfarin and suggested that the two findings 
were related, since warfarin was a coumarin derivative and was detoxified by 
hydroxylation. However, Lush and Arnold (1976) found that in 16 strains of mice, 
the possession of high coumarin-hydroxylating ability did not necessarily afford 
protection against warfarin-poisoning and concluded that warfarin-resistance in 
mice may be due to the presence of a novel hydroxylase, although clearly not 
coumarin 7-hydroxylase. This postulate is confirmed by the fact that the genes, 
Coh and War, are mapped at opposite ends of chromosome 7, therefore they are 
unlikely to be allelic, and cannot be proposed to show the same biochemical 
manifestation, ie, to cause warfarin-resistance.
Thus, at the present moment, relatively little  information is available 
which evaluates the hereditary resistance of mice to warfarin anticoagulation, 
although a possible link with warfarin metabolism has been documented. In the 
following chapters of this thesis, the metabolism and disposition of warfarin in 
both warfarin-susceptible and warfarin-resistant mice will be probed, in order to 
attempt to elucidate the biochemical mechanism(s) of warfarin-resistance.
1.4. PHARMACOKINETICS AND METABOLISM OF WARFARIN
Absorption
The systemic availability of a drug depends upon the degree of 
absorption of that drug into the blood stream. The absorption of drugs may be 
affected by various factors including the solubilising effects of intestinal fluids, 
gastrointestinal tract (GIT) m otility, gut wall metabolism, pH and the anatomical 
site of absorption. Early reports of drug absorption (Schanker et al 1958), 
undertaken in order to probe the nature of the mechanisms of drug absorption, 
provided a number of tentative predictions to delineate the characteristics of 
the barrier between the intestinal lumen and blood plasma. These authors 
speculated that organic electrolytes should be readily absorbed from solution if  
the unionised form is lipid-soluble and if the pKa for an acid is greater than 2, 
and for a base, is less than 11. In actual practice however, factors other than 
the dissociation constant and lipid solubility of a drug may lim it it's intestinal 
absorption as described above, although these are less important. Thus, warfarin 
being a weak organic acid with a molecular weight of 308 and a pKa of 5.05, 
should show rapid and complete absorption in the rat, rabbit and man. Indeed, 
several reports have shown that this is the case (Julkunen et al 1971; Aggeler and 
O'Reilly, 1966; Deckert, 1974). Both warfarin and it's sodium salt are rapidly 
absorbed from the stomach and duodenum as well as in the intestine. This would 
appear contrary to the accepted pH-partition theory outlined above, where drug 
may only be absorbed in it's dissociated form. However, in the duodenum where 
at pH 8 warfarin is virtually totally in it's ionised form, the anticoagulant is 
extremely rapidly absorbed. It  therefore seems probable that warfarin may be 
absorbed in the intestine in substantial amounts, whereas the stomach and 
rectum appear to behave normally with respect to the pH-partition theory, ie,
only unionised drug is absorbed. In general, Kakemi et al (1969) also presented 
evidence supporting the view that drugs are absorbed both in undissociated and 
dissociated forms. In man and the rat, peak plasma concentrations occur 
between 26 and 60 minutes and 20 and 35 minutes respectively (Breckenridge and 
Orme, 1973; Anderson, 1967) and absorption is complete within l i - 2  hours in 
both the rat and humans. Absorption of warfarin by a transcutaneous, rather 
than a gastrointestinal route, has been documented where fata l intoxication was 
caused, indicating that significant absorption of warfarin through the skin had 
occurred (Fristedt and Sterner, 1965; Martin-Bouyer et al 1983).
The fact that the enantiomers of warfarin have differing biological 
activity, S(-) warfarin being 5.5-6.6 times more active in rats, and 3.8 times 
more active in man than R(+) warfarin, has been shown to be due to factor(s) 
other than differential stereoselective absorption of the enantiomers. R(+) and 
S(-) warfarin are absorbed from the gastrointestinal tract to the same extent 
(Lewis et al 1974; O'Reilly, 1974). In summary, warfarin (both R(+) and S(-) 
enantiomers) is absorbed extremely well after oral administration and therefore 
almost 100% of the dose reaches the circulation and is thus potentially available 
for pharmacological action in the body.
Distribution
A fter being absorbed from the gastrointestinal tract and passing into the 
plasma, warfarin next enters various tissues; liver being the organ of 
consequence with respect to its anticoagulant action. Each anticoagulant has it's 
own rate of biotransformation, which determines in part the duration of 
response. The onset of the hypoprothrombinaemic response lags behind the 
plasma warfarin level, due to the in vivo survival of the relevant clotting
factors. The tissue distribution of warfarin has been documented in the rat 
(Anderson, 1967). A fter intravenous administration, warfarin is quickly 
distributed throughout the plasma and the liver shows the greatest affinity of 
any tissue; this affinity is maintained over 48 hours. A lesser degree of tissue 
uptake by the kidney, heart, skeletal muscle, brain and skin occurs, although this 
uptake probably reflects blood distribution rather than actual uptake of warfarin. 
This uptake of warfarin by tissues other than the liver is interesting, since 
vitamin K-dependent clotting factor synthesis occurs solely in the liver. 
However, there are other vitamin K-dependent proteins containing 
■^-carboxyglutamic acid, other than clotting factors present in these tissues 
(Gallop et al 1980; Friedman et al 1979; Bell, 1979). Consequently, warfarin may 
have an effect on these proteins by antagonising the action of vitamin K in these 
extrahepatic tissues. Thus, hepatic uptake has a major quantitative effect on 
warfarin distribution. This uptake, however, is concentration-dependent in that 
uptake decreases with increasing drug concentration, causing the apparent 
volume of distribution, Vd of warfarin to decrease with increasing dose 
(Takada and Levy, 1980).
Differences in drug distribution between species, strains and sexes also 
depend on variations in drug binding to plasma proteins. Warfarin is highly bound 
to plasma proteins, as indicated by the figures of 96, 97 and 93% bound in the 
human, rat and dog respectively (O'Reilly et al 1963; O'Reilly e t al 1964; Aggeler 
and O'Reilly, 1966). Warfarin is bound to albumin of the plasma proteins and is 
therefore largely partitioned in the plasma compartment and in it's bound form is 
pharmacologically inactive, and protected from biotransformation and excretion. 
Only the unbound (free) drug in the plasma is in equilibrium with it's sites of 
action and biotransformation, and susceptible to glomerular filtra tion . Changes
in the total plasma warfarin concentration are therefore accompanied by similar 
relative changes in the concentration of the free and active drug. The binding of 
warfarin to albumin is readily reversible. The bound drug constitutes a reservoir 
in the body and is gradually released as biotransformation lowers the 
concentration of the free anticoagulant. The high degree of binding of warfarin 
to albumin is an important factor in it's long plasma half-life. A full description 
of the binding of warfarin to plasma proteins, particularly albumin, in qualitative 
and quantitative respects, and at the molecular level, is provided in Chapter 7, 
Section 7.1. Therefore, the kinetics of warfarin binding will not be discussed 
here.
Metabolism
Warfarin is metabolised by mixed-function oxidase enzymes in hepatic 
microsomes where it is extensively hydroxylated (Ikeda et al 1968). In addition, 
the anticoagulant has been shown to undergo keto reduction to warfarin alcohols, 
each enantiomer of warfarin yielding 2 diastereoisomeric products. This 
reduction is most likely catalysed by the NADPH-dependent enzyme warfarin 
reductase, present in the soluble fraction of both human and rat liver (Hewick 
and Moreland, 1975). The two enantiomers of warfarin differ in their metabolic 
routes. In man, S(-) warfarin is oxidised preferentially to 7-hydroxywarfarin and 
reduced to the 5,5 warfarin alcohol, whereas R(+) warfarin is reduced to the R,S 
warfarin alcohol (Lewis et al 1974). Hydroxylation of warfarin in the 6-position 
(Figure 1.2.) occurs in equal amounts in both enantiomers. The patterns of 
warfarin products therefore vary from R(+) and S(-) warfarin. In addition, 
differential metabolite patterns have been shown following induction of 
cytochrome P-450 in rats by phenobarbitone and cytochrome P-448 by 3- 
methylcholanthrene. The warfarin binding and warfarin metabolite profiles
produced by hepatic microsomal preparations have been used in order to probe 
the heterogeneity of cytochrome P-450s. In this respect, uninduced rat 
cytochrome P-450 yields a modified type II difference spectra with both R(+) and 
S(-) warfarin. Phenobarbitone-induced microsomes also yield modified type II 
difference spectra. 3-methylcholanthrene induction yields type I spectra with 
R(+) warfarin, but a modified type II spectra is seen with S(-) warfarin. Thus, 
R(+) and S(-) warfarin seem to bind to 2 separate forms of cytochrome P-450 and 
cytochrome P-448, all of which differ from uninduced cytochrome P-450. The 
variety of monohydroxylated metabolites of R(+) and S(-) warfarin are a 
consequence of the interactions with these different forms of cytochrome P-450 
in vivo (Fasco et al 1976). The biotransformation of warfarin is therefore quite 
complex, and involves keto reduction to warfarin alcohols, dehydration of 
warfarin alcohol resulting in ring closure, hydroxylation reactions yielding the 
regioisomeric products 41-, 6-, 7- and 8-hydroxywarfarin and various conjugation 
reactions (Testa, 1981). As described earlier, in man, the structural selectivity 
of these reactions appears to be highly diversified. In the rat, keto reduction is 
also substrate stereoselective for S(-) warfarin and product stereoselective for 
the S-alcohol. This means that the S,S warfarin alcohol is preferentially  
produced from racemic warfarin as compared to the 3 other diastereoisomers 
(R,R; S, R or R,S warfarin alcohols). The structural selectivity of the various 
hydroxylation reactions combines product regioselectivity in that various 
positions of potential hydroxylation exist, and substrate stereoselectivity in that 
the various routes of hydroxylation affect the two warfarin enantiomers 
differentially. Furthermore, a number of factors such as animal species and the 
use of inducers, as shown above, considerably modify the structural selectivities 
of warfarin hydroxylation. These findings are leading to the belief that 
cytochrome P-450 multiplicity is one of the factors accounting for the metabolic
differences detected between animal species, strains and organs. Cytochrome P- 
450 indeed exists in an undetermined number of forms, several of which can be 
separated and reconstituted in their active form (Guengerich, 1979). In the case 
of warfarin, widely different product regioselectivities and substrate 
stereoselectivities have been characterised using microsomes from variously 
induced animals, or various purified forms of cytochrome P-450 (Kaminsky et al 
1979 and 1980). Marked differences are evident between liver microsomes from 
uninduced, phenobarbitone-induced, 3-methylcholanthrene-induced and 8- 
naphthoflavone-induced rats and mice. The functional characterisation of these 
uninduced or induced cytochrome P-450 forms for warfarin enantiomers are 
discussed in great detail in Chapter 5 of this thesis, with reference to both 
species, strain and organ differences in warfarin metabolism. Warfarin 
metabolites are also conjugated by the addition of mainly glucuronide and 
sulphate moieties making them more water-soluble, and therefore more liable to 
be eliminated from the body (Testa, 1981).
Excretion
Since warfarin is extensively metabolised, it  would be expected that 
excretion products would comprise mostly warfarin metabolites and little  
unchanged warfarin. Such is the case in the species studied, including man, the 
rat, guinea-pig and rabbit, where excretion of unchanged warfarin constitutes 2, 
7, 13 and 2% respectively, of the administered dose (Goldwell et al 1974; Wong et 
al 1978; Wong and Solomonraj, 1980). Biliary and urinary excretion are the major 
routes of elimination of warfarin and its metabolites from the body. Species 
differences in warfarin excretion occur mainly in the percentage of the dose 
eliminated via the urinary or biliary routes. For example, in the rabbit, the bile 
appears to be only a minor excretory route for warfarin and it's metabolites. In
the first 6 hours of dosing, approximately 6% of the administered dose is 
recovered by this route. Very little  of the drug is eliminated in bile after this 
time. The low biliary excretion in the rabbit (Wong and Solomonraj, 1980) is in 
contrast to that in the rat (Coldwell et al 1974) and guinea-pig (Wong et al 1978) 
in which significant amounts of warfarin and it's metabolites are eliminated in 
the bile. As a consequence of the high biliary excretion in the rat, 
approximately 35% of the administered dose is recovered in the faeces (Coldwell 
et al 1974). In the guinea-pig, however, a majority of the drug eliminated by the 
bile undergoes enterohepatic circulation (the drug is excreted from bile into the 
intestine where reabsorption takes place) and is finally disposed of by the kidney 
(Wong e ta l  1978).
Examination of the biliary metabolites in the rabbit shows that the 
majority are glucuronide conjugates (approximately 70%) or highly polar 
metabolites (approximately 10%), with only a small amount of unconjugated drug 
being present (Wong and Solomonraj, 1980). On the other hand, the biliary 
metabolites in the rat (Coldwell et al 1974) and guinea-pig (Wong et al 1978) 
contain a relatively larger amount of unconjugated warfarin and hydroxylated 
warfarin metabolites. This difference is probably related to the threshold 
molecular weight for biliary excretion in these species. Since the threshold 
molecular weight for biliary excretion is approximately 500 in the rabbit, 
whereas in the rat and guinea-pig they are approximately 300 and 400, 
respectively (Hirom et al 1972), it  is not surprising to find that only bulky polar 
metabolites (mainly glucuronides) can be eliminated into the bile in the rabbit. 
Possibly, this explains why the biliary excretion of warfarin in this species is 
relatively low, compared to that in the rat and guinea-pig. The biliary excretion 
of warfarin in the human is unknown. However, since it  has been suggested that
the threshold molecular weight for biliary elimination in man is above 500 
(Williams, 1971) it is to be expected that the human will resemble more closely 
the rabbit than the rat or guinea-pig in the biliary excretion of warfarin.
The exact nature of the excretion patterns of warfarin metabolites, 
conjugates and unchanged drug in each species will be discussed in detail in 
Chapter 6, where comparisons with the excretion patterns of both warfarin- 
susceptible LAC-grey and warfarin-resistant HC mice will be made.
1.5. OBJECTIVES OF THE PRESENT STUDY
The objectives of this study were to determine the differential 
susceptibilities of warfarin-susceptible LAC-grey and warfarin-resistant HC 
house mice to the anticoagulant effect of the oral anticoagulant rodenticide 3- 
(a-acetonylbenzyl)-4-hydroxycoumarin (Warfarin), in terms of their blood 
clotting times. In addition, the biochemical mechanism(s) manifested by 
expression of the major warfarin-resistance gene, War, will be probed. The 
possible alterations of pharmacokinetic mechanisms describing the metabolism 
and disposition of both R(+) and S(-) warfarin enantiomers will also be 
investigated in both strains of mouse.
CHAPTER 2
MATERIALS AND METHODS
MATERIALS
Racemic warfarin (3-a-acetonyl benzyl-4-hydroxycoumarin) was 
purchased from Ward Blenkinsop and Co Ltd (London, England); R(+) and S(-) 
warfarin enantiomers were kindly provided by Dr B K Park (Department of 
Pharmacology, University o f Liverpool); and racemic J ^ c J  -  warfarin (3 -a - 
acetonyl [ * C]  benzyl-4-hydroxycoumarin was obtained from Amersham 
International, (Amersham, Buckinghamshire, England). Phenobarbitone sodium, 
3 -naphthoflavone and clofibrate were obtained from British Drug Houses (BDH) 
(Poole, Dorset, England), Sigma Chemical Company (Poole, Dorset, England) and 
IC I (Macclesfield, Cheshire, England), respectively. 3-D-Glucuronide 
glucuronosohydrolase (crude solution), phenolphthalein glucuronic acid substrate 
solution, carbobenzyloxy-L-proline, and 3-nicotinamide adenine dinucleotide 
phosphate (tetra sodium salt, reduced form) were purchased from Sigma 
Chemical Company; 2,5 diphenyloxazole (PPO), l,4-Bis(5-phenyloxazol-2-yl) 
benzene (POPOP), dicyclohexylcarbodiimide, and sodium ethoxide were all 
obtained from Aldrich Chemical Company (Gillingham, Dorset, England). Acacia 
gum, heparin and Unisolve 100 liquid scintillant were purchased from Hopkin and 
Williams (Chadwell Health, Essex, England), BDH and Koch-Light Laboratories 
Limited (Colnbrook, Buckinghamshire, England), respectively.
All solvents were purchased from Rathbum Chemicals Lim ited  
(Walkerburn, Scotland), and were of HPLC grade. All other chemicals and 
reagents were of analytical grade and purchased from the British Drug Houses 
(BDH).
METHODS
2.1. IN  VIVO' STUDIES
2.1.1 Animals
Two strains of mice were used throughout these studies, one warfarin- 
susceptible (L AC-grey) and the other warfarin-resistant (HC - Homozygous 
Cambridge). The warfarin-resistant HC strain was bred at the Ministry of 
Agriculture, Fisheries and Food, following the identification of a major gene, on 
chromosome 7, coding for warfarin resistance in a wild colony of mice at the 
Plant Breeding Institute, in Cambridge (Wallace and MacSwiney, 1976) and the 
incorporation of this gene into a warfarin-resistant wild-derived strain of mouse 
named PBI. The HC-homozygous strain has the wafarin-resistance gene from the 
PBI, introduced into a laboratory warfarin-susceptible strain (LAC-grey). A ll 
PBI/LAC-grey progeny were known to be heterozygous for warfarin resistance 
and from this F^ generation, 6  further generations of heterozygous animals were 
mated. Subsequently, warfarin-resistant animals were tested for warfarin- 
resistance by using a standard 21-day feeding tria l of 0.025% (w/w) warfarin in 
medium oatmeal (Rowe & Redfern, 1967). Warfarin-resistant animals were those 
which did not succumb to anticoagulant toxicity within this time. Mice were 
genotyped as homozygous or heterozygous by measuring the effects of warfarin  
treatment on blood clotting times of their progeny and calculating the ratio of 
warfarin-susceptible mice (those with long blood clotting times, ie; incoagulable 
blood) to warfarin-resistant mice (short blood clotting times, ie, around 20-30 
seconds). By this method, mice were classified as homozygous or heterozygous 
for warfarin resistance or as warfarin-susceptible. Homozygous w arfarin- 
resistant mice constituted the beginnings of the HC strain. The development of
the HC warfarin-resistant strain has allowed direct biochemical and biological 
comparison between closely-related warfarin-resistant (HC) and warfarin- 
susceptible (LAC-grey) animals in studies designed to elucidate the mechanism 
of warfarin-resistance in the house mouse.
For all experiments, male and female mice of both warfarin-resistant 
(HC) and warfarin-susceptible (LAC-grey) strains were employed independently 
in order to investigate sex differences in warfarin-resistance. All animals were 
70-90 days old, housed in plastic cages with sawdust bedding and wire tops, and 
maintained on Rodent D iet 41B (Oxoid Limited, Cambridge) and tap water ad 
libitum. A 12-hour light cycle was in operation in the animal rooms, whereby 
darkness was in effect from 6 pm to 6 am and light from 6 am to 6 pm, with a 
temperature of 21°C and 50% humidity.
2.1.2. Toxicity Studies
Dosage Regimen and Sample Collection
In studies designed to determine the toxicity of racemic or enantiomeric 
warfarin male and female animals of both warfarin-resistant and warfarin- 
susceptible strains were divided into groups of 1 0 , each group having the same 
mean age. Doses of racemic or enantiomeric warfarin were administered in 
0.5% acacia gum (O.lml/lOg) by oral intubation under light ether anaesthesia, 
each dose being administered daily for 4 days. Male and female warfarin- 
susceptible LAC-grey mice were treated with doses of 4, 8 , 16, 32 or 
64mg/kg/day racemic warfarin. Similarly, male and female warfarin-resistant 
HC mice received doses of 4, 8 , 25, 50, 100, 200 or 400mg/kg/day and female HC  
mice only were treated with 800mg/kg/day racemic warfarin. When dosed 
separately, the R(+) and S(-) enantiomers of warfarin were administered at a 
dose of 16mg/kg/day to male and female warfarin-susceptible mice and at a dose 
of 50mg/kg/day for 4 days to warfarin-resistant mice of both sexes.
For the 21-day feeding tria l for warfarin-resistance, animals of each 
strain and sex were housed individually in cages with open wire-mesh bottoms, 
provided with tap water ad libitum and 0.025% racemic warfarin in medium 
oatmeal after an acclimatisation period of 5 days on a medium oatmeal diet, the 
weight of food eaten and therefore the amount of warfarin consumed, was 
recorded each day for 21 days. Surviving mice after this time were judged to be 
warfarin-resistant. A ll mice were autopsied for symptoms of anticoagulant 
poisoning, such as internal haemorrhages. Blood samples were obtained for the 
determination of blood clotting times, as follows:
Samples of lOOpl venous blood from the intra-orbital sinus of the mice 
were collected into Natelsson capillary tubes (Shandon Southern Products 
Limited) containing 8 pl of 3.2% trisodium citrate 2 H 2 O to prevent coagulation, 
immediately transferred to non-activating plastic tubes, and kept on ice until 
analysis. All blood sampling procedures were carried out under ether 
anaesthesia.
Toxicity Data
The toxicity of both racemic and enantiomeric warfarin was assessed by 
recording the number of deaths of mice in each dose group, and the number of 
days after first dosing on which death occurred. A ll mice were examined to 
determine whether death was due to the anticoagulant effect of warfarin, or 
some other factor. All the data presented represent only deaths due to 
haemorrhage.
Determination of Blood Clotting Times
Blood clotting times were determined prior to warfarin dosage in both 
sexes and strains of mice and subsequently each day for 1 1  days or until the 
blood clotting time had returned to the pre-dose levels. Blood clotting times 
were determined for whole blood using Normotest, a standardised reagent for 
this purpose (Nyegaard and Co., Oslo, Norway). The reagent was a lyophilised 
product containing rabbit brain thromboplastin and modified bovine plasma. The 
thromboplastin component was free from coagulation factors and intermediates, 
and the modified bovine plasma contained all the clotting factors except the 
vitamin K-dependent factors II, VII, IX  and X, essential for blood coagulation.
The reagent was reconstituted with distilled water, and pipetted into 
fibrocups (250pl) (BBL, Division of Becton, Dickerson and Co, Cockeyville, MD, 
USA) and placed on the heating block of a fibrosystem coagulometer (BBL, as 
above) at 37°C for at least 3 minutes. To the reagent was added 25pl of venous 
blood, the coagulometer tim er and stirrer simultaneously starting. The tim er 
stopped when fibrin strands had formed in the sample, so recording the blood 
clotting time in seconds. A ll blood clotting times were determined from 
triplicate analyses on the same sample.
Standard curves of blood clotting times plotted against percentage 
clotting activity were constructed using various dilutions of pooled blood samples 
from untreated male or female mice of both warfarin-resistant (HC) and 
warfarin-susceptible (LAC-grey) mouse strains.
2.1.3. Pharmacokinetics
Dosage Regimen and Sample Collection
Warfarin-resistant (HC) and warfarin-susceptible (LAC-grey), male and 
female mice were divided into groups of 3 and were dosed either with 16mg/kg 
racemic warfarin in 0.5% acacia gum by oral intubation, or with 16mg/kg 
racemic sodium warfarin in 0.9% (w/v) saline intravenously via the tail-vein. In 
both cases, blood samples were collected at 1, 15, 30, 60, 90, 120, 180, 240 and 
300 minutes after administration of the single dose, using 3 mice per time-point. 
Blood was collected after cervical dislocation and decapitation of the animals, 
into non-activating plastic tubes containing 4 units of heparin/lOOpl. The 
samples were then centrifuged at 3000rpm for 5 minutes, the plasma was 
decanted and stored at -20°C until analysis of warfarin enantiomers took place. 
In addition, livers were excised from the animals at the time-points indicated 
above, weighed, perfused, homogenised singly in 5ml of 0.9% (w/v) saline and 
stored at -20°C  until analysis.
Analysis of R(+) and S(-) Warfarin Enantiomers
The extraction, derivatization and high pressure liquid chromatographic 
(HPLC) analysis of plasma warfarin enantiomers was carried out according to a 
method based on that of Banfield & Rowland (1983). Extraction of both R(+) and 
S(-) warfarin from plasma (0.2ml) and liver homogenate (0.5ml) samples was 
undertaken as described for plasma. Derivatization of warfarin enantiomers, 
however, differed slightly from the published method. This procedure involved 
esterification with carbobenzyloxy-L-proline (CBZ-proline) using imidazole as a 
catalyst and dicyclohexylcarbodiimide as condensing agent. To the plasma or 
liver extract was added CBZ-proline (50pl:100mg/ml in acetonitrile (ACN)), 
imidazole (50pl:lm g/m l in ACN) and dicyclohexylcarbodiimide (50pl:100mg/ml
in ACN) these amounts of reagent had been judged non-rate-limiting in control 
experiments. The mixture was vortexed for approximately 10 seconds, and the 
reaction was allowed to proceed for 2  hours, whereafter the tubes were 
centrifuged at 3000rpm for 5 minutes and aliquots (75pl) of supernatant were 
analysed by high performance liquid chromatography (HPLC). No internal 
standard was used in these analyses. A Waters Associates (Harrow, Middlesex, 
England) liquid chromatograph was used for this purpose, which comprised three 
model M6000A pumps, a model 710B autoinjector, a model 720 systems 
controller, a model 740 data module and a model 481 variable wavelength 
ultraviolet detector, set at 313nm and 0.002 AUF5 sensitivity. The column (250 
x 4mm) was packed with normal-phase, microparticle silica, 5pm (partisil 
5/Whatman). All solvents and buffers were filtered through 0.22pm membranes 
(Millipore, Bedford, Mass, USA) and degassed prior to use. Chromatographic 
separation of warfarin enantiomers was carried out using hexane-ethyl acetate- 
methanol-acetic acid in the ratio 80:20:0.25:0.40 at a flow rate of 2ml/min. 
Samples of derivatized R(+) and S(-) warfarin were quantitated after external 
standard calibration of the data module using derivatives of known quantities of 
R(+) and S(-) warfarin. Control experiments were performed using both plasma 
and liver homogenate samples to which had been added known amounts of R(+) 
and S(—) warfarin. Extraction efficiencies for both enantiomers were found to be 
95-99% for plasma and 85-89% for liver homogenates. A typical chomatograph 
of blank plasma spiked with authentic S(-) and R(+) derivatized warfarin is shown 
in Figure 2.1.
Figure 2.1. Chromatograph Showing the Separation of R(+) and S(-) 
Warfarin Enantiomers by HPLC
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2.1.4. Warfarin Excretion Studies 
Dosage Regimen and Sample Collection
Mice of each sex and strain were divided into groups of 3. Each animal
Buckinghamshire, England) per 0.04kg body weight, diluted with non-radioactive 
racemic warfarin to give a final dose of 16mg/kg, administered intravenously via
177pCi/mg (2.04 Bq/mmole, 6.35 mBq/mg).
The animals were housed in metabowls (Jencons Scientific Limited, 
Leighton Buzzard, Bedfordshire, England) and were maintained as previously 
described in Section 2.1.1. Total amounts of urine and faeces excreted were 
collected separately over three time periods, 0-6, 6-24, and 24-48 hours after 
dosing, and stored frozen at -20°C  until analysis.
Determination of Total Radioactivity in Urine and Faeces
Aliquots of lOOpl urine or lOOmg faeces, suspended in 200pl distilled
(Koch-Light Laboratories Limited) liquid scintillation cocktail in a Packard 
model 4530 liquid scintillation counter. Counts were recorded from channel B 
and corrected for counting efficiency using a quench curve of counting
Analysis of R(+) and S(-) Warfarin Enantiomers
Urine and faeces were analysed for unchanged R(+) and S(-) warfarin, as 
well as glucuronidated/sulphated R(+) and S(-) warfarin. Extraction, 
derivitization and HPLC analysis of the warfarin enantiomers from urine and
warfarin (Amersham International, Amersham
the tail vein. The specific activity of warfarin used was 55mCi/mmole,
water, were analysed for total warfarin content, using Unisolve 100
efficiency versus ratio for counting.
faeces was carried out as previously described for plasma and liver homogenates 
in Section 2.1.3. with the exception that in this case, detection of the 
radioactive enantiomers was effected using model number LB 505HS Berthold 
radioactivity detector (Laboratory Impex, Teddington, Middlesex, UK). A liquid 
scintillant flow cell of volume 2 ml was fitted , and the column eluant was mixed 
50:50 with a liquid scintillation cocktail containing toluene, PPO and POPOP 
(2.51:10g:0.5g) using a Berthold model No. LB 5034 splitter-mixer.
Sample volumes of 0.25, 0.5 or 1.0ml of urine were extracted, depending 
on the total volume produced by each animal. Similarly, 50 or lOOmg of faeces 
was suspended in 0.5ml or 1.0ml of distilled water depending on the total weight 
of faeces excreted per time period.
In addition, any glucuronide/sulphate conjugates of unmetabolised R(+) or 
S(-) warfarin were quantitated following treatment of separate urine and faeces 
aliquots with 2 0 0 pl 3 -glucuronidase, aryl sulphatase, a mixed preparation from 
Helix Pomatia. The specific activity of 3-glucuronidase was 102,000 units/ml 
and that of sulphatase was 4,400 units/ml. Control experiments were performed 
using urine and faeces samples to which phenolphthalein glucuronic acid 
substrate solution had been added in differing amounts. These samples were then 
incubated at 37°C in a shaking water both overnight in the presence of sodium 
acetate buffer pH 5.0 and differing amounts of 3-glucuronidase. Hydrolysis of 
the phenolphthalein glucuronide liberated free phenolphthalein which was 
coloured pink at pH 10.4. The rate of colour formation was measured using a 
DM5 100 Varian spectrophotometer to determine the optimum amount of 3- 
glucuronidase needed for subsequent sample hydrolyses. This procedure ensured 
that the amount of 3 -glucuronidase added to the urine and faeces samples was 
not rate-lim iting.
A fter incubation with 3-glucuronidase/sulphatase, the urine and faeces 
samples were extracted, derivatized and the amounts of f * c ]  and R(+) and S(-) 
warfarin quantitated by HPLC as described previously (Banfield & Rowland, 
1983). The amounts of glucuronidated/sulphated warfarin enantiomers were then 
determined by subtracting the amount of unchanged R(+) or S(-) warfarin from 
that found after treatm ent with 8 -glucuronidase/sulphatase. Control 
experiments using urine and faeces samples spiked with known quantities of 
M  warfarin indicated extraction efficiencies for both R(+) and S(-) warfarin 
of 90-95% for urine and 85-89% for faeces. All extractions were carried out in 
triplicate and all analyses were performed in duplicate.
Analysis of Warfarin Metabolites
« Warfarin metabolites were analysed in urine and faeces, both before and 
after hydrolysis with 8 -glucuronidase/sulphatase. Extraction of warfarin 
metabolites was performed using the method published by Banfield & Rowland 
(1983). Extraction efficiencies from urine and faeces samples spiked with 
warfarin metabolites were 87-93% for urine and 84-87% for faeces. Analysis of 
warfarin metabolites by reversed-phase HPLC is described in Section 2.2.1 - 
Analysis of Warfarin Metabolites.
2.1.5. Plasma Protein Binding Studies 
Dosing Regimen and Sample Collection
Groups of 3 male or female, warfarin-resistant and warfarin-susceptible 
mice were dosed as in the pharmacokinetics study (Section 2.1.3.) with 16mg/kg 
racemic sodium warfarin in 0.9% saline via the tail vein. Blood samples were 
collected at 1 minute, 3 hours and 6  hours after dosing by the method previously 
described (Section 2.1.3.) and plasma samples were stored at -20°C  until
analysis. Similarly, blank plasma was obtained from groups of 25 untreated mice 
of each strain and sex and pooled for use in in vitro studies of plasma protein 
binding (see Section 2.2.2.).
Separation of Free and Bound Warfarin
Separation of the free fraction of warfarin from that bound to plasma 
proteins was effected using ultracentrifugation in Amicon Centrifree 
Micropartition Systems (Amicon Limited, Gloucestershire, UK). Plasma samples 
from the warfarin-dosed animals were allowed to thaw, and equilibrated in a 
shaking water bath at 37°C for 10 minutes. Aliquots of 300pl plasma were then 
pipetted with care into the top reservoir of the C entrifree filte r unit and 
centrifuged at 3000rpm for 40 minutes in an MSE 18 centrifuge, using a number 
69181 fixed-angle rotor head. For all experiments, both the centrifuge bowl and 
rotor head were allowed to equilibrate at 37°C before the plasma samples were 
centrifuged. During centrifugation the plasma protein-bound warfarin was 
retained on top of the filte r, whilst the free fraction, because of it's smaller 
molecular weight, was able to pass accross the membrane and collect in the 
bottom reservoir of the filte r unit. The free fraction of warfarin was stored at - 
20°C until analysis of free R(+) and S(-) warfarin was carried out by the method 
of Banfield & Rowland (1983), with modifications as described in Section 2.1.3.
Determination of Plasma Proteins
The concentration of plasma proteins in each sample was determined by 
the method of Lowry et al (1951). In addition, samples of the supernatant (free 
fraction of warfarin) after ultracentrifugation were analysed for protein in order 
to verify that no protein-bound material was present.
2.2 IN  VITRO' STUDIES
2.2.1 Microsomal Metabolism of Warfarin 
Dosage Regimen
Male and female, warfarin-resistant and warfarin-susceptible mice were 
divided into groups of 1 0  and dosed with either phenobarbitone sodium (0 .1 % 
(w/v) in drinking water for 6  days), 8 -naphthoflavone (80mg/kg intraperitoneally 
in corn oil for 3 days), clofibrate (250mg/kg in 0.9% (w/v) saline intraperitoneally 
for 3 days) or racemic warfarin 4 or 64mg/kg orally in 0.5% acacia gum for 3 
days). Control animals were untreated, or received corn oil, or 0.9% (w/v) saline 
intraperitoneally for 3 days, or 0.5% (w/v) acacia gum orally for 3 days. All 
mice were killed by cervical dislocation 24 hours after the last dose, their livers 
were excised immediately and hepatic microsomes prepared as follows:
Preparation of Mouse Hepatic Microsomes
The microsomes were prepared by the method of calcium precipitation 
as previously described (Cinti, et al 1972) from pooled livers of 10 mice. All 
procedures were carried out at 4°C  and centrifugation was undertaken using an 
MSE 18 centrifuge with a model No 69181 fixed-angle, 8  x 50ml rotor head. 
After preparation microsomes were resuspended in 50mfD potassium phosphate 
buffer pH 7.25 containing 20% (v/v) glycerol and were stored in 2ml aliquots at 
-  80°C until analysis. Hepatic microsomes could be stored in this manner for 
several months without loss of cytochrome P-450 activity.
Cytochrome P-450 and Protein Determinations
Cytochrome P-450 concentrations for each group of microsomes were 
determined from the reduced-carbon monoxide (CO) versus the reduced
difference spectra ^ ^ 4 5 0 . 4 9 0  = 91mM"’^cm~ ^ ) according to the method of 
Omura &  Sato (1964) using a Varian DMS 100 spectrophotometer in the split 
beam mode at 20°C - 1°C .
Protein concentrations were determined by the method of Lowry et al 
(1951) using bovine serum albumin to construct a standard curve.
Microsomal Metabolism of Warfarin Enantiomers
The in vitro metabolism of R(+) and S(-) warfarin by mouse liver 
microsomes was performed using the method of Kaminsky et al (1979) with 
modifications:- reaction mixtures contained, in a total volume of 1.65ml of 
50mM TRIS-HC1 buffer pH 7.4 and 5mM M gC^, 8 mg of microsomal protein and 
0.33pmoles of R(+) or S(-) sodium warfarin. The mixture was pre-incubated with 
shaking at 3 7 °C  for 1 minute and NADPH was added to initiate the reaction, 
such that the final concentration in the incubation mixture was Im M . The 
reaction was allowed to proceed for 1 0  minutes (metabolite production under 
these conditions was linear up to and including 1 0  minutes) and was thereafter 
terminated by rapidly cooling in an ice-bath and filtration through a pad of 
millipore filters (1 x 1.2pm and 2 x 0.22pm) in a 13mm Swinnex filte r unit. 
Control and blank experiments were performed where warfarin or NADPH were 
omitted from the incubation mix, respectively, all other procedures being 
identical to those described above. The supernatant was stored at -20°C  and 
analysed by HPLC for warfarin metabolites. All incubations were performed in 
triplicate.
Analysis of Warfarin Metabolites
Quantitative high-pressure liquid chromatography of warfarin, its
i
diastereoisomeric alcohols and 4 -, 6 -, 7-, 8 - and benzylic hydroxylated 
metabolites was accomplished using a method based on that of Fasco et al 
(1977). A Waters Associates (Hartford, Cheshire, UK) liquid chromatogaphy was 
used, which comprised three model M6000A pumps, a model 710B autoinjector, a 
model 720 systems controller, a model 740 data module and a model 481 variable 
wavelength ultraviolet detector, set at 313nm. The column (300 x 4mm) was 
packed with reversed-phase microparticle silica, lOptntpBondapak/C^g, Waters 
Associates). All solvents and buffers were of HPLC grade where possible, 
filtered through 0.22pm membranes (Millipore, Bedford, Mass, USA) and 
degassed before use. Chromatographic separation of warfarin and its 
metabolites was carried out using two solvents:- solvent A (water plus 1.5% 
(v/v) acetic acid, buffered to pH 6.0 with sodium hydroxide), and solvent B 
(acetonitrile plus 1.5% (v/v) acetic acid) at a flow rate of 2ml/minute. A m ulti- 
step gradient was operated via the system controller, starting with 1 0 0 % solvent 
A to concentrate the 200pl sample onto the top of the column prior to elution. 
The metabolites of warfarin were eluted with optimum separation in a ratio of 
solvent A:solvent B (69:31). Re-equilibration of the column was readily
accomplished by washing with solvent A for 5 minutes. External standard 
calibration of the system was performed using varying concentrations (0.02 -4pg) 
of authentic warfarin metabolites which were concentrated on the column and 
eluted as described. The peak areas of each hydroxylated metabolite of 
warfarin, calculated by the data module, over the concentration range 
investigated, were plotted against the corresponding concentration of 
metabolite, to give a straight line indicating the correct integration parameters 
had been programmed into the data module. The chromatographic separation
was independent of load volume. Aliquots of the supernatant from microsomal 
metabolism studies (10-200pl) were injected directly onto the HPLC column and 
eluted as previously described. A typical HPLC separation of the synthetic 
metabolites of warfarin is illustrated in Figure 2.2.
2.2.2 Plasma Protein Binding Studies
Blank plasma was obtained from groups of 25 male and female warfarin- 
resistant and warfarin-susceptible mice and pooled as described previously 
(Sections 2.1.3. and 2.1.5.)
Incubation of Plasma with Warfarin
Incubation mixtures contained, in a total volume of 510pl plasma:10pl of 
racemic sodium warfarin in 67mM potassium phosphate buffer, pH 7.4, to give 
final warfarin concentrations of 20, 50, 100, 150, 180 or 200mM in the incubation 
mixture. The mixture was incubated with shaking at 37°C for 10 minutes by 
which time in control experiments binding was judged to be complete. The 
plasma/warfarin mixture (500pl) was transfered to the top reservoir of an 
Amicon Centrifree Filter Unit. All subsequent procedures were carried out as 
described in Section 2.1.5. (separation of free and bound warfarin) for in vivo 
plasma protein binding studies. All incubations were carried out in triplicate.
Analysis of Free Warfarin Enantiomers
The extraction, derivatization and HPLC analysis of R(+) and S(-) 
enantiomers of warfarin in the free fraction was carried out as previously 
described (Section 2.1.3.). All analyses were carried out in duplicate.
Major Metabolites by HPLC
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2.2.3. Synthesis of Sodium Salts of Warfarin Enantiomers
R(+) or S(-) warfarin (308mg) was dissolved in 5ml of absolute (dry) 
ethanol by heating at 60°C. Likewise, sodium ethoxide (a 2% dispersion in oil) 
was dissolved (323.8mg) in 3ml of absolute (dry) ethanol. The la tter solution was 
added dropwise to the stirred solution of warfarin at 50-60°C. The reaction was 
allowed to proceed for 13 minutes, when a sample of the reaction mixture was 
chromatographed by thin-layer chromatography (TLC) in diethyl ether. 
Comparison of the mobility (R f) of the sample with the R f of authentic standards 
of R(+) or S(-) warfarin and their sodium salts. This procedure showed the 
reaction to be complete. The mixture was allowed to cool before the ethanol 
was evaporated using a rotary evaporator. The residue was dissolved in distilled 
water and washed to remove any unreacted R(+) or S(-) warfarin by addition of 2 
x 10ml diethyl ether, with vigorous shaking in a separating funnel. TLC analysis 
was performed on both the ether fractions and the aqueous phase to verify that 
the reaction had been completed. The aqueous phase was then shell-frozen using 
cardice and acetone and lyophilised over night. The purity of the product was 
determined by HPLC quantitative analysis using the method of analysis of 
warfarin and it's hydroxylated metabolites (Section 2.2.1.)
Warfarin Warfarin, Sodium Salt
Radiochemical Purity of P ^ c ]  Warfarin
Before use, the radiochemical purity of warfarin was checked and
a clean-up procedure undertaken. This involved thin-layer chromatography
(TLC) on silica gel in tolueneimethanol (90:10). Firstly, non-radioactive racemic
warfarin was applied as 2-5pl spots on the origin of the silica gel TLC plate, and
run in the system described above to determine the R f value of warfarin. A fter
elution, the warfarin spots could be observed under an ultraviolet light. 250|jCi
of warfarin was dissolved in 20pl toluene and applied to a TLC plate,
alongside samples of authentic non-radioactive warfarin. The plate was
chromatographed as described. The solvent front was marked once
chromatography was complete, and the plate was immediately examined under 
[*14 1ultraviolet light. I CJ warfarin and warfarin bands were seen at the same Rf
Q 4 1 F"l4 1value, and the C band was scraped off the plate whilst still wet. The C
warfarin was removed from the silica gel by extraction with ethyl acetate and
r~14 1filtering. The total amount of C warfarin collected was determined by 
analysing an aliquot by liquid scintillation counting. The recovery of K ]  
warfarin was found to be 226.14pCi out of 250pCi which corresponds to 90.5%
CHAPTER 3
STUDIES ON THE TO XIC ITY  OF, AND ANTICOAGULANT RESPONSE TO, 
ORAL W ARFARIN ADMINISTRATION IN  WARFARIN-RESISTANT 
AND SUSCEPTIBLE MOUSE STRAINS
3.1. INTRODUCTION
From around 1950 a 'golden era' of rodent control, based on the use of 
anticoagulant rodenticides, was experienced in many countries, particularly in 
Western Europe, where it lasted for almost ten years. However, resistance to 
the anticoagulant rodenticide, warfarin, was first reported in the rat in 1960 
(Boyle, 1960), and in the mouse only a year later (Dodsworth, 1961). Subsequent 
to the finding that infestations of the house mouse (Mus Musculus) had become 
increasingly difficult to control in the late 1950's, even after continuous warfarin 
treatment. These reports had far-reaching effects due to the fact that not only 
were rodenticide-resistant rats and mice responsible for great economic losses, 
they also represented a potential threat to public health in many parts of the 
world. It  is therefore important that the mechanisms of warfarin resistance in 
both rats and mice be uncovered in order that new rodenticides, effective  
against warfarin-resistant animals, may be developed and once again we may 
return to a 'golden era' of rodent control.
The efficacy of the anticoagulant rodenticides in both warfarin- 
susceptible and warfarin-resistant animals depends on the interaction of several 
factors. All coumarin anticoagulant rodenticides act to alter the metabolism of 
vitamin K in a manner which blocks the synthesis of the vitamin K-dependent
blood clotting factors II, VII, IX  and X. Vitamin K shuttles between its 
hydroquinone form and a biologically inactive metabolite, vitamin K 2,3-epoxide, 
in the endoplasmic reticulum of the liver (Bell, 1978); this reaction being 
concurrent with and necessary for the synthesis of vitamin K-dependent clotting 
factors. Warfarin acts to inhibit the conversion of vitamin K 2,3-epoxide to the 
quinone form of the vitamin. Recycling of the hydroquinone form of vitamin K 
from it ’s quinone forms a cycle known as the vitamin K cycle (Figure 1.1.) (Fasco 
and Principe, 1982). Interference with any part of the cycle leads to decreased 
clotting factor synthesis and a tendency towards anticoagulation.
A more complex warfarin resistance mechanism has been suggested in 
the house mouse, compared with that of the rat (Lund, 1972; Greaves, 1971). 
Whereas the response of warfarin-susceptible rats to anticoagulation with 
rodenticides did not vary much, a greater interindividual variation in the 
response of house mice to the same compounds was found (Lund, 1972; Rowe and 
Redfern, 1968). In addition, a sex difference in susceptibility to warfarin was 
found to exist in mice. Females were more tolerant than males, and male mice 
became more susceptible to warfarin poisoning with increasing age. The 
response to anticoagulant administration in females was independent of their 
age. A further complication in assessing anticoagulant action is that warfarin is 
a racemic mixture. In the rat, a single oral dose of S(-) warfarin was found to be 
3.5-6.6 times more potent than the same dose of the corresponding R(+) 
enantiomer (Eble, et al 1966). Similarly, in man S(-) warfarin was shown to be 3- 
4 times more potent than R(+) warfarin (Sellers and Koch-Weser, 1973). Similar 
data in the house mouse has not been documented. These great differences in 
warfarin susceptibility made it very difficult to compare the responses of 
warfarin treatment in warfarin-susceptible and warfarin-resistant mice. The
fact that many animals which were warfarin-resistant in the wild, succumbed to 
warfarin fairly readily in the laboratory, also showed that warfarin resistance 
was not a well-defined pharmacological factor and indicated clearly that 
environmental factors were also involved (Greaves, 1971). At this stage, a 
standard international test for warfarin resistance in the house mouse was not 
available due to the inter-individual and sex differences discussed, and the fact 
that strain differences in warfarin susceptibility in mice which were not 
warfarin-resistant had also been documented (Lush and Arnold, 1975). In the 
United Kingdom mice were generally considered resistant to warfarin if  they 
survived a 21-day feeding tria l with 0.025 or 0.005% (w/w) warfarin bait (Rowe 
and Redfern, 1964).
Warfarin resistance in the house mouse was thought to be controlled by a 
number of genes (Rowe and Redfern, 1964). The identification of a major gene 
on chromosome 7, which was dominant in females, and under the influence of 
modifiers in the male (Wallace and MacSwiney, 1976) represented a major step 
forward, allowing the development of laboratory strains of warfarin-resistant 
and warfarin-susceptible mice which were biochemically similar apart from their 
resistance to warfarin. Thus, a strain of warfarin-resistant mouse has been bred 
(HC - homozygous Cambridge) which has the warfarin-resistance gene from a 
wild colony of warfarin-resistant mice trapped at the Plant Breeding Institute 
(PBI) introduced into an LAC-grey strain (see Section 2.1.1 for breeding details). 
The new strain allows direct biochemical and biological comparison between 
warfarin-resistant and warfarin-susceptible animals.
EXPERIMENTAL OBJECTIVES
To obtain dose-response curves for racemic warfarin in warfarin- 
resistant (HC) and warfarin-susceptible (LAC-grey) mice, in order to 
obtain an index of warfarin-resistance between the strains, in addition to 
monitoring their anticoagulant response to warfarin administration.
To determine the stereospecific hypoprothrombinaemic response of each 
mouse strain (warfarin-resistant and warfarin-susceptible) to R(+) and S (-) 
warfarin, administered individually at two dose levels.
To repeat the 21-day feeding tria l with 0.025% warfarin, used as a test 
for warfarin-resistance, to show the differential toxicities of warfarin in 
warfarin-susceptible (LAC-grey) and warfarin-resistant (HC) mice. This 
experiment was undertaken once the results of the dose-response studies 
were analysed, in an effort to obtain an index of warfarin-resistance 
between the two strains.
3.3. EXPERIMENTAL DESIGN
For all experiments warfarin-resistant (HC) and warfarin-susceptible 
(LAC-grey) male and female mice were used. The genetic background to the 
mouse strains used is discussed in Section 2.1.1. In toxicity studies, racemic 
warfarin or separate warfarin enantiomers were administered orally each day for 
four days at the doses indicated in Section 2.1.2 and toxicity and blood clotting 
times were determined as previously described (Section 2.1.2.). Similarly, the 
21-day feeding trial with 0.025% racemic warfarin was carried out as outlined in 
Section 2.1.2.
The doses of racemic warfarin used in this study were based in the case 
of LAC-grey warfarin-susceptible mice on doses of warfarin required to kill 
normal wild warfarin-susceptible mice. Doses of racemic warfarin for 
administration to HC warfarin-resistant mice were calculated from blood 
clotting data determined after dosing PBl-warfarin-resistant mice with various 
warfarin concentrations (Ayres, P., unpublished data, personal communication). 
The decision to include doses of 4 and 8 mg/kg/day was taken after the results of 
the other studies had been analysed (see Section 3.5.1.).
The doses used for administration of separate warfarin enantiomers were 
calculated from the toxicity data of racemic warfarin (Section 3.4.1.) using doses 
which corresponded approximately to the dose of racemic warfarin needed to kill 
50% of the mice of each strain. These doses were 16mg/kg/day for LAC-grey  
mice and 50mg/kg/day for HC mice. Enantiomers were also administered at 
these doses, in an effort to maintain the same levels of free warfarin available 
for liver uptake and therefore anticoagulant action as those when racemic 
warfarin was administered.
3.4. RESULTS
3.4.1. The Hypoprothrombinaemic Response of Warfarin-Susceptible and
Warfarin-Resistant Mice to Racemic Warfarin Administration 
Toxicity Data
The total number of deaths in each dose group for male and female mice 
of both warfarin-susceptible (LAC-grey) and warfarin-resistant (HC) mice is 
shown in Table 3.1. Initially considering LAC-grey mice, the toxicity data shows 
that females and males responded differently to each dose of racemic warfarin, 
and for neither sex were the dose-response curves of the expected sigmoidal 
character (Figure 3.1.). As the dose of warfarin was increased from 4 to 
32mg/kg/day (for 4 days) the toxicity of the compound in the male also increased 
from 1 to 7 deaths out of 10 mice in each group, as would be expected. 
However, at 64mg/kg/day, the toxicity decreased sharply, no deaths were 
reported, even after 21 days of monitoring. This phenomenon was unexpected, 
and therefore the experiment was repeated using two further groups of 1 0  mice, 
with the same results, so validating the initial finding at this dose. In the female 
warfarin-susceptible (LAC-grey) mice the deviation from expected sigmoidal 
dose-response kinetics was of a different kind. Starting with the lowest dose of 
warfarin (4mg/kg/day), and increasing the dose through 8 , 16, 32 and 
64mg/kg/day, the toxicity did not increase in a dose-dependent manner (Table 
3.1., Figure 3.1.) but was initially relatively high compared to data from the 
male; decreased and then increased to the original level at 16mg/kg/day, 
followed by a decrease at both 32 and 64mg/kg/day. In summary, for female 
LAC-grey mice, a relatively greater toxicity was found at the lower doses of 4, 8  
and 16mg/kg/day, compared with doses of 32 and 64mg/kg/day warfarin where 
little  toxicity was effected. Generally, male warfarin-susceptible LAC-grey
Table 3.1.
Toxicity o f Racemic Warfarin in Warfarin-Susceptible 
(LAC-grey) and Warfarin-Resistant (HC) Mice
LAC-Grey Mice (Warfarin-Susceptible)
Dose Number of Deaths
(mg/kg/day for 4 days) Male Female
4 1/10 4/10
8 2/10 2/10
16 5/10 4/10
32 7/10 1/10
64 0/10 1/10
16 S(-) 6/10 2/10
/
R(+) 3/10 1 / 1 0
HC Mice (Warfarin-Resistant)
Dose Number of Deaths
(mg/kg/day for 4 days) Male Female
4 0/10 0/10
8 1/10 0/10
25 2/10 0/10
50 4/10 0/10
1 0 0  6 / 1 0  0 / 1 0
200 3/10 0/10
400 8/10 0/10
800 - 6 / 1 0
50 S(-) 
R(+)
5/10
1/10
0/10
0/10
Resistant HC Mice
10 .
O *LAC
4 020
Dose of Warfarin (mg/kg for 4 days)
60
HC10
to
SZ4-)
<D 5
4 0 0  6 0 5
Dose of Warfarin (mg/kg for 4 days)
200
mice were less tolerant to the toxic effects of oral racemic warfarin  
administration than were their female counterparts.
Similarly, in the HC warfarin-resistant male mice, a non-sigmoidal dose- 
response curve was seen (Figure 3.1.) after racemic warfarin administration. 
The doses administered to the warfarin-resistant mice were much greater than 
those which caused greatest toxicity in the LAC-grey strain. The toxicity of 
racemic warfarin to the male HC mice increased gradually from 4mg/kg/day to 
lOOmg/kg/day, as would be expected, but at 200mg/kg/day the toxicity effect 
dropped, only to increase again at 400mg/kg/day. The three highest 
concentrations of warfarin were administered again to three groups of 1 0  mice 
and similar results were found. Clearly, with the male warfarin-resistant mice, 
higher doses of racemic warfarin could be tolerated before toxicity occurred, as 
compared with their warfarin-susceptible male counterparts. In female HC  
warfarin-resistant mice, warfarin doses of 4, 8 , 25, 50, 100, 200 and 
400mg/kg/day caused no deaths, although 6  out of 10 female mice died at 
800mg/kg/day. There was therefore a very marked difference in resistance to 
warfarin between these females and those of the warfarin-susceptible LAC-grey  
strain. Not only were female HC mice more resistant than female LAC-grey  
mice, they were also considerably more resistant with respect to warfarin  
toxicity than the male HC mice, even taking into account the fact that female 
warfarin-susceptible mice were more tolerant to warfarin than their respective 
males.
Blood Clotting Data A fter Racemic Warfarin Administration
Blood clotting data for both LAC-grey warfarin-susceptible and HC  
warfarin-resistant mice are expressed as prothrombin clotting time in seconds
(Table 3.2. and 3.3.). The percentage of normal clotting activity may be 
calculated for these values using standard curves constructed with various 
dilutions of normal blood (Figures 3.2. and 3.3.). These graphs were similar for 
all groups of mice, although males showed slightly longer clotting times than 
their female counterparts. Blood which had not clotted after 300 seconds was 
found to be uncoagulable and contained <6 % prothrombin clotting activity (PCA) 
for LAC-grey mice, and <10% for HC mice. The blood clotting times for both 
strains of mice are plotted versus the number of days after the first dose in 
Figures 3.4.-3.8. for LAC-grey mice and Figures 3.9.-3.16. for HC mice.
The data obtained for warfarin-susceptible LAC-grey mice have brought 
to light several interesting aspects of warfarin action with respect to 
differential responses to warfarin administration at various doses, and sex 
differences in anticoagulant response. A t all five doses studied in the LAC-grey 
warfarin-susceptible strain (4, 8 , 16, 32 and 64mg/kg/day), peak extension of 
clotting times was reached 2  days after the first dose, and at all but the 
4mg/kg/day dose was maintained at this level from 2-4 days after first dosing in 
both male and female mice. Sex differences were manifested in the time taken 
for blood clotting times to return to normal pre-dose levels at each of the five 
warfarin doses examined.
Comparing males and females at each dose it was found that at 
4mg/kg/day (Figure 3.4.) blood clotting times were increased in both sexes such 
that the peak was reached 2 days after the first dose of warfarin. These values 
subsequently declined to normal pre-dose levels 7 days after the first dose of 
anticoagulant, although a sharper rate of return was seen in females, compared 
with male LAC-grey mice. A t 8 mg/kg/day a greater anticoagulant response was
Bl
oo
d 
Cl
ot
tin
g 
Ti
m
es
 
(S
ec
on
ds
) 
fo
r 
W
ar
fa
rin
-S
us
ce
pt
ib
le
 
LA
C
-G
re
y 
M
ic
e
C M + I
ON
r-4 ^
.  CD
r-i O °  < 1+ I
00 i-H+ l °  CNJ+ I
o  
vo  ^
<f °
CM +  I
CM ^
A  °  
CM +  I
VO
coc_4->
CO
’c
E-a
<
JO
"£>co
4-U
CO
CM
A  co  
CM +1
CM ^
<f °
CM+ I >—1 + 1
A  ^  
ON O  
CM+ I
° 3
t—1+ I
LA ^  
•
A
ON 
LA Of 
vO °
LA 
CM ^
VO 
CM ^  
A  O
VO
00
IA
CM+I CM+i CM+1 CM+ l CM+I
LA
CO
>%
CO
Q
C''J VO ^ C M o O O □ CD O □ CD
csi • 
o  ^
o a o O o o O o
VO A A A A A A A A
CM +1 i—1+-1 A A A A A A A A
On vo  • • ^  A O a CD 00  .  A □ CD O
a A  • CD CD O c -  • CD 0 ° O OA A  ^ A A A r -  ^ A A A
CM +  I CM+l A A A ■—1+1 A CM+ 1 A A
00 CM • •
a •
CD CD O a CD O CD CD
I"- A O CD o CD CD CD a CD A  •
VO A A A A A A A A
CM CM +  l A A A A A A A A CM+ 1
V0 '“j CM• n ^  CD "1  A ^  A ^  00 °  A ■~i oo ^  A
A  2  
A  r-i
CSl •
o  ^
Lf\ •
o  ^
a
VO
r** •
v £  ^
ON • 
CM ^
-—I * 
ON ^
CM * 
00 03 5  CO
i—l +  i M + l CM+i i—1+ I CM +  i CM +l CM+l CM+ I CM+l CM+l
A  2 0 0  OJ A  ^ A  '“j A  2 00 A  2 VO ^
A  <1' A  ^ A  ^ CM N A  ^ VO ^ A  ^ A  A A  ^
O CM +  i CM+l CM +  l CM+ I CM +l CM+ I CM+ I CM+ 1 CM+l CM+ I
’b 0+ h cn- o t te «b < *
CM
IA
JD
COh-
JN
co
0) CO C^O 
>  TJ ‘ OJ w
_J  CTX)
0) <t
£ 01 ^ 
q J £ 00 VO CMA VO Ab
ov
e 
fig
ur
es
 
re
pr
es
en
t 
m
ea
n 
- 
st
an
da
rd
 
de
vi
at
io
n
VO
ON ^
i A  °  
r A +  I
>-H ^  ON O
VO ^  CM f A  VO ^  I A  ^
C^Q tA c D < N ° -H °  . 
CM +  I CM +  l CM +  I C M + l 1
VO 
VO ^
O 0  
LA +  I
o  cm  on
CO ^  CM ^  r A  ^  VO ^  
0 * 0 ^ 0 ^  □  q  o  
r A +  I CM l +  I A  +  I CM +  I I I
ON
CO
ON
CMLA
<F °
CM + I
1—• ^
I A  <=> 
C M + l
LA
CM
CM i—I
OCM ON
I A
VO °  
I A +  I 1
I A  O  
f A
CDVO
I A +  I C M + l C M + l C M + l < ± +  I
LA
r"«
o
pH CM•IS—
ON
i—1
I A  
CM R CM
<t
I A•
r-H O LA rH rA ° •1 ^ □CM +  l CM +  i C M +  1 1 CM +  I
VO 
A  R CD
1---1
vo ^ i—1
■—I
r A•
<t o L Jr A rH  a i 1—1 CDC M + l A CM +  1 1 I A +  I
rA
u.p 0
rH CM O ON ON 1---J LA r^ - rH ON ON•Is-
ON 1—1 o
CM CM CM CM c d R LA r H ^ LA N LA CM I A CM i—1 ON ^ IA rA
CO d vo d VO CO CO ° LA  ° CM O r A  ° rA P a d VO °
•
r A d LA d  °
•
. CO d
CM + I CM + I CM + I C M + I C M + l CM+ 1 CM+ I I A +  IC M + 1 r A + 1 CM + 1 CM +  i C M + I ■ CNI +  1
2  d
U ^  ^
I
4-)
0  vo 14JM• ■Nw 
0
°T LA 1
. £  0
tx w
5  5+ -  (A
tx NO VO CM —. ON i—1 i—I /—j i-H O  i» . CM >—I
Jo +? m <t v D f^ ^ r ^  . r A rv. f A n L A « O K C )  .  IA -k. IA  .  2^
v o p— ON rH rH i i iH O
c o
CM CO
v o
v o
rA
d
' •
CM
LA
r "
r A COo
I A  
■—1
I1" -•
O n rH
o  ^
LA  °
•
r A
VO
• r -  R
r H  1-1
< +  < f + 1 I A +  i '—1+ I r H + | L A +  1 < f +  1 CM + 1 r — f  i
ON NL-to a  LA  CM OS rH  
C M + IC M + I  C M + l L A + i  A
vo VO
rH lA
d i co' d
+ 1 1 A + 1
W <
a  CO S ^ v o C O ^ - H ^ d p r A ^ O j g r A ^ C M S  I A ° C M ^ A ^ S  V f l O  r—j d
UJ L_) I A  r H + 1  I A + 1  O N + I  0 N + i  C M + l L A + I  CM+ I 0 N + 1  A  I A  +  1 C M + l >—l + i  A  < f  +  I 1 C M + i 
v_^
W
0
P  m \  M 1 *H  hA CO lA  p n  On CO • r - j  CM — ON On CM CM C
. 5  i f ^ Q v l A  i V O ^ i i A . i —I m  On O  » >—I •  CM>\ I A  O  ^  VO O  - *  A  O  O
f—  < r * . * o * . * v o * . * o  CM * CM * O  .  * O  .  '  O  X j
_  < 3 - t A C M a r H r H r ^ a C M r^ < t r H r A  0 0  ^  l/V  ° f A  I A  °  I A  V O ^ ' I A  m
s '  CM i—I +  I < j" +  i i—1+ i v O + I  i—1 + I l A + i  A -  f—) + I  C M + f A + i  A  C O + i A  I A + 1  A  ■—«
. £  >*3 0*j u
o
I A VO r^ - On i—1 r H 1—1 rH LA LA i—i LA i—i•
vO
i—1 • VO rA CD CM CO VO CM ON r A I A ON i—i VO 1 On • O n LA•
r A LA i—I d LA d I A d d i— 1 I A d LA d d d
I I
r A <Jo d ON CD NO a
r H  r H + 1 V O +  i < T +  I lA +  i r— f  i I A + 1 < t + l r ^ +  i CM + IV O +  I ■ H +  1 < r + i
ON CM rH o r H ON ON r A rH LA r H CM
CM P "• LA IA CO LA CD LA -H CM• CM CM vo CM• ON I A CM >H CM r A I A•
LA O
•
LA d VO d LA d r A O CO d 1—1 a
•
CO d d P a d ON d d
0 CD
i j  0
■9 S ?  tx o  o  o  a
. C O O p o '  L A O  CD O  O  O
I—  □  C D  4 -  <3- CO CM L A r—I CM <J- CO
U fsT\ ^  1 • 1 > ’ » ' »  ’ > U '  L f \  ■ ’ 1 L f\  ■ » (—I U> NTV
■a ^ ^ o ^ o ^ o ^ n ^ o ^ o o ' o ^ o ^ o ^ o g n  g o  S  ^
g   + I  J  L A + I  A « + l    I  lV O + l ^ 4 + 1  T |  C M + l  >—1+ I 1 A  ^
i—i - -
CD
rH  CM I A
rH  ^  CO < t
o  c £  CO , a ;  o
+ 1 r— h i c m +  i
<b O f t )  of *b Of <b O f ' b ^ ' b  Of  ' b O f ' b o ^
• 0  0  t/5
f"N >  - a  >>
Ab
ov
e 
fig
ur
es
 
re
pr
es
en
t 
m
ea
n 
'
Percentage 
Clotting 
A
ctivity
Figure 
3.2. 
Standard 
Curve 
of 
Percentage 
Clotting 
A
ctivity 
Against 
B
lood
Percentage 
Clotting 
A
ctivity
Figure 
3.3. 
Standard 
Curve 
of 
Percentage 
Clotting 
A
ctivity 
Against 
B
lood
Days 
A
fter 
First 
Dose
Figure 
3.4. 
Blood 
Clotting 
Tim
es 
A
fter 
O
ral 
W
arfarin 
A
dm
inistration 
(4m
g/kg/day 
for 
4 
days) 
in 
LA
C
-G
rey 
W
arfarin-S
usceptible
Days 
A
fter 
First 
Dose
Figure 
3.5. 
Blood 
Clotting 
Tim
es 
A
fter 
O
ral 
W
arfarin 
A
dm
inistration 
(8m
g/kg/day 
for 
4 
days) 
in 
LA
C
-G
rey 
W
arfarin-S
usceptible
Days 
A
fter 
First 
Dose
Figure 
3.6. 
Blood 
Clotting 
Tim
es 
A
fter 
O
ral 
W
arfarin 
A
dm
inistration
Days 
A
fter 
First 
Dose
ro-
o
ou
o>
4^.
COr
y~i4
to
3lO
7TiQ
a.p
CD-
> ►
Q .
0)*<
CO
■to r>
ni
CDn
CD*<
Pn—h
P
□ 'I
COc
COnro■o
rr
5;
ro"
Figure 
3.7. 
Blood 
Clotting 
Tim
es 
A
fter 
O
ral 
W
arfarin 
A
dm
inistration
Days 
A
fter 
First 
Dose
Figure 
3.8. 
Blood 
Clotting 
Tim
es 
A
fter 
O
ral 
W
arfarin 
A
dm
inistration
evoked in both sexes than at 4mg/kg/day, as would be expected (Figure 3.4.). 
Normal blood clotting times were resumed 7 and 11 days after the first dose in 
females and males respectively, showing that LAC-grey males seem less tolerant 
to racemic warfarin than females at this dose. Similarly, there was a slight 
difference between females and males in their susceptibility to warfarin at a 
dose of 16mg/kg/day (Figure 3.6.) although this was not as large as that found at 
8 mg/kg/day and clotting factor levels had returned to their pre-dose values in 
males and females 8  and 7 days respectively after the first dose. An interesting 
feature of the anticoagulant response of the LAC-grey female at 16mg/kg/day 
was that the blood clotting times fell from a peak value 3 days after the first 
dose and then increased again on day 4, indicating that the effect of warfarin is 
cumulative when dosed chronically, as in this study. The profiles for blood 
clotting times at 32 and 64mg/kg/day (Figures 3.7. and 3.8.) were very similar 
for male mice, where blood clotting times decreased from their peak values 
after 4 days to return to normal levels 7 days after first dosing. Similarly, in 
females normal blood clotting times were seen 7 days after the first dose. At 
32mg/kg/day in the female, the clotting time decreased at day 3 and increased 
to a peak level at day 4, although the decrease was not as great as that seen at 
16mg/kg/day. A t 64mg/kg/day a similar phenomenon was observed in the female 
with a decrease in blood clotting time occurring 2  days after the first dose, and 
reaching a peak at 3 days after dosing.
In general, in the warfarin-susceptible LAC-grey mice sex differences in 
the response to warfarin were seen at low doses (4, 8  and 16mg/kg/day) (Figures
3.4., 3.5. and 3.6.) where the blood clotting times of females returned to normal 
much more quickly than did those of the male. However, at the higher doses of 
32 and 64mg/kg/day racemic warfarin (Figures 3.7. and 3.8.) the blood clotting
times for both males and females decreased to normal values at almost the same 
rate; those for males thereby returning to pre-dose levels more quickly than at 
the lower doses of warfarin.
In warfarin-resistant mice, the anticoagulant response of males was 
much greater with respect to increased clotting times than that seen for females 
at all doses administered (4, 8 , 25, 50, 100, 200, 400 or 800mg/kg/day for 4 days). 
It  was also apparent that the warfarin-resistant HC mice had a much lower 
hypoprothrombinaemic response to any particular dose of warfarin than the 
LAC-grey warfarin-susceptible animals. This is illustrated by comparing the 
response to warfarin doses of 4 and 8 mg/kg/day, and by the fact that the doses 
administered to HC mice were far greater than those given to LAC-grey mice, in 
order to cause a maximum elongation of blood clotting times.
In male HC warfarin-resistant mice (Table 3.3.) as the dose of racemic 
warfarin increased, a greater elongation of blood clotting times was seen, up to 
and including lOOmg/kg/day. The time taken to reach peak clotting times varied 
from 2-4 days, as can be seen from Figures 3.9.-3.13. for these doses, as did the 
time taken for normal pre-dose clotting times to return, ranging from 4 days at 
4mg/kg/day to 7 days at the other doses mentioned. This pattern of 
anticoagulation is as expected for increasing dose. A deviation from this pattern  
occurred however, at 2 0 0 mg/kg/day, where no overall increase in 
hypoprothrombinaemic response was observed, as compared with lOOmg/kg/day 
warfarin (Figures 3.14. and 3.13.). Slight differences were shown between the 
dose groups such that at the lower dose it took longer for the peak elongation of 
clotting times to be reached, but conversely, at 2 0 0 mg/kg/day although peak 
blood clotting times was reached more quickly, the anticoagulant response also
Days 
A
fter 
First 
Dose
UO
7CIQ
Cl
CO-
co
00-
Figure 
3.9. 
Blood 
Clotting 
Tim
es 
A
fter 
O
ral 
W
arfarin 
A
dm
inistration
Days 
A
fter 
First 
Dose
CD
UD
7TIQ
CL
•O
Q.
00-
Figure 
3.10. 
Blood 
Clotting 
Tim
es 
A
fter 
O
ral 
W
arfarin 
A
dm
inistration
Days 
A
fter 
First 
Dose
co-
II
* >  Si
Figure 
3.11. 
Blood 
C
lotting 
Tim
es 
A
fter 
O
ral 
W
arfarin 
A
dm
inistration 
(25m
g/kg/day 
for 
4 
days) in 
HC 
W
arfarin-R
esistant 
M
ice
Days 
A
fter 
First 
Dose
Figure 
3.12. 
Blood 
Clotting 
Tim
es 
A
fter 
O
ral 
W
arfarin 
A
dm
inistration
Days 
A
fter 
First 
Dose
co
oo
I D
00
CL
<0
+oo
Figure 
3.13. 
Blood 
Clotting 
Tim
es 
A
fter 
O
ral 
W
arfarin 
A
dm
inistration
Days 
A
fter 
First 
Dose
Figure 
3.14. 
Blood 
Clotting 
Tim
es 
A
fter 
O
ral 
W
arfarin 
A
dm
inistration
Days 
A
fter 
First 
Dose
10 -
co*
01 -
© -
-4 -
co.
co-
oo
UD
Q.
CL
HH
UQ
Cn
cd
D
UD
Days 
A
fter 
First 
Dose
<0 - 4 0
lQ
CLUs:
—+«o
Q .P
01
D
I
Figure 
3.16. 
Blood 
Clotting 
Tim
es 
A
fter 
O
ral 
W
arfarin 
A
dm
inistration
decreased more rapidly to normal levels. Although unexpected, the decrease in 
hypoprothrombinaemic response shown at 2 0 0 mg/kg/day correlated with a 
decrease in toxicity judged by mortality rates at this dose in the HC male (see 
Section 3.4.1 -Toxicity Data). At 400mg/kg/day in the male HC mice, a great 
increase in the anticoagulant effect of warfarin was shown (Figure 3.15.) 
compared to either 200 or lOOmg/kg/day; clotting times remaining elevated from 
2 - 1 0  days after dosing.
The blood clotting data obtained from these doses of racemic warfarin in 
the HC warfarin-resistant female was more complex, and as previously stated, 
evoked a lesser anticoagulant response at all doses than in the male HC mice. 
To this effect, the administration of 4mg/kg/day to the female HC mice, caused 
only a very slight increase in blood clotting time the first day after dosing, 
thereafter the levels returned to normal. A slightly greater response was seen 
after administration of 8 mg/kg/day (Figure 3.10.), the time taken for the peak 
hypoprothrombinaemic response was 4 days after first dosing indicating 
cumulative anticoagulation was effected. As the dose was increased to 
25mg/kg/day in the female, a response very similar to that found at 4mg/kg/day 
in the respect of the magnitude of the anticoagulant effect, although the peak 
response again occurred on day 4 after the first dose (Figure 3.11.). As the dose 
of racemic warfarin was increased to 50 and lOOmg/kg/day (Figures 3.12. and
3.13.) firstly an increase in the anticoagulation was caused by 50mg/kg/day, but 
a decrease in this level of response was evoked by the administration of 
lOOmg/kg/day to give a level approximately equivalent in order of magnitude to 
that observed after 4mg/kg/day racemic warfarin treatment. The same pattern 
of an increase in anticoagulation, followed by a decrease in this response, was 
followed as the two doses of 200 and 400mg/kg/day were administered (Figures
3.14. and 3.15.). The response to 200mg/kg/day was a little  less than that shown 
at 50mg/kg/day (Figure 3.12.) and that to 400mg/kg/day was almost the same as 
that shown at 8 mg/kg/day (Figure 3.10). These results seemed somewhat 
confusing, but considering Figures 3.9.-3.16. all the hypoprothrombinaemic 
variations discussed above are relatively small compared with the differences 
between male and female HC warfarin-resistant mice in this context. In 
addition, at none of these racemic warfarin doses in the female had maximal 
elongations of clotting times occurred (ie, incoagulable blood had not been 
affected). Only at a dose of 800mg/kg/day warfarin did the anticoagulant 
response reach maximum levels day 1  after the first dose, and began to decrease 
after day 2 to reach normal pre-dose levels 7 days after first dosing. It  is 
interesting to note that the response evoked by 800mg/kg/day warfarin in the 
female HC warfarin-resistant mice was of the same magnitude, although not as 
prolonged as that found after administration of 8 mg/kg/day to the female LA C- 
grey warfarin-susceptible mice.
The hypoprothrombinaemic response of warfarin-susceptible and 
warfarin-resistant mice to racemic warfarin administration was investigated as 
described elsewhere (Section 2.1.2.) and produced the results outlined above. 
Clearly many factors other than the presence or absence of the major gene for 
warfarin-resistance influenced the anticoagulant response of each group of mice 
to the doses of racemic warfarin administered. These factors will be discussed 
in Section 3.5.1.
2.4.3 The Stereospecific Hypoprothrombinaemic Response of Warfarin-
Susceptible and Warfarin-Resistant Mice to Administration of R(+) and
S(-) Enantiomers of Warfarin 
Toxicity Data
For LAC-grey warfarin-susceptible mice, toxicity could be regarded as 
stereospecific (Table 3.1.) since at 16mg/kg/day R(+) warfarin, 3 out of 10 male 
mice died, compared with 1 out of 10 female mice. At the same dose of S(-) 
warfarin, however, deaths of 6  and 2  out of 1 0  were obtained for male and 
female LAC-grey mice respectively, indicating the greater potency of the S(-) 
enantiomer.
Similarly, in the HC warfarin-resistant mice S(-) warfarin at 
50mg/kg/day was more potent than it's R(+) enantiomer, and caused 5 out of 10 
deaths in the male and no deaths in .the female. The toxicity of the R(+) 
enantiomer was such that 1  out of 1 0  males died, again no female deaths were 
recorded.
Blood Clotting Data After Administration of S(-) and R(+) Warfarin Enantiomers
Blood clotting data for both LAC-grey warfarin-susceptible and HC  
warfarin-resistant mice are expressed as prothrombin clotting time in seconds 
and summarised in Table 3.4. Figures 3.17 and 3.18. represent this data plotted 
against the number of days after the first dose.
In LAC-grey mice, 16mg/kg/day doses of either S(-) or R(+) warfarin  
enantiomers were administered to both males and females. The results (Figure 
3.17) showed that for each enantiomer of warfarin the hypoprothrombinaemic 
response of the male was greater than that of the female, and in addition that
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S(-) warfarin evoked a greater anticoagulant effect in both males and females 
than R(+) warfarin at the same dose.
A similar pattern with respect to the anticoagulant e ffect of the two 
warfarin enantiomers was found after treatment of male and female HC 
warfarin-resistant mice with 50mg/kg/day of each warfarin enantiomer (Figure 
3.18.). Again, the male HC mice were more sensitive to both enantiomers of 
warfarin, compared to females, although in the case of S(-) warfarin this 
difference in sensitivity between the sexes was much greater than that seen in 
the LAC-grey mice. S(-) warfarin caused a greater anticoagulant effect than 
R(+) warfarin in both males and female HC mice.
The significance of these findings, with respect to the toxicity and 
anticoagulant effects of racemic warfarin dosage, will be discussed in detail in 
Section 3.3.2.
3.4.3 Differential Toxicity of 0.023% (w/w) Racemic Warfarin to Warfarin-
Susceptible and Warfarin-Resistant Mouse Strains in a 21-Day Feeding
Trial 
Toxicity Data
Toxicity data for both male and female warfarin-susceptible LAC-grey 
and warfarin-resistant HC mice is summarised in Table 3.5. Means and standard 
deviations calculated for each group represent only mice which died during the 
course of the 21-day test. In addition, doses of warfarin shown for warfarin- 
resistant HC mice which survived represent the amount consumed within the 21- 
day test period. As can be seen from the results, warfarin-susceptible LAC-grey 
males and females were much more susceptible to the toxic action of warfarin
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than their resistant counterparts. Only 4 females and 5 male warfarin-resistant 
mice died, compared to all 10 male and female warfarin-susceptible mice. Those 
mice which did die, however, showed approximately equal mean lethal doses of 
warfarin for all groups of mice, ranging from 164.8-233.2mg/kg. Comparing 
male and female LAC-grey warfarin susceptible mice, the mean lethal dose of 
warfarin was similar in both sexes, although very slightly higher for the female. 
Similarly, the mean time of death was the same for each group of LAC-grey 
mice. Slight sex differences in susceptibility to warfarin were also noted in the 
warfarin-resistant HC strain of mice, such that more males than females 
succumbed to the lethal effects of the anticoagulant (4 females and 5 male 
deaths were caused). However, this difference in toxicity was not as great as 
would have been expected, considering the fact that in the previous studies (see 
Section 3.3.1., Table 3.1.) female warfarin-resistant mice showed a much greater 
tolerance to warfarin than did males in this strain. Furthermore, considering the 
fact that the surviving female HC mice consumed a mean dose of 797.5mg/kg 
over the period of 21 days, and that in previous toxicity studies (Table 3.1. and 
Section 3.3.1.) these females were able to tolerate 400mg/kg/day racemic 
warfarin dosed for 4 days with no discernable toxicity, the death of any female 
mice in the 21-day test would be considered unlikely. It  seemed strange, 
therefore, that the 4 female mice which did succumb to warfarin toxicity did so 
with a mean time to death of 6.3 days, a shorter period of time than that taken 
to cause death in warfarin-susceptible female mice (mean 9.4 days). Similarly, 
in the HC warfarin-resistant male, some deaths would be expected since it was 
previously shown that these mice were more susceptible to warfarin toxicity 
than their females, although they were less susceptible to warfarin than 
warfarin-susceptible LAC-grey males.
Again, it  appeared odd that three distinct groups, with different warfarin  
susceptibilities came to light in warfarin-resistant males during the 2 1 -day 
feeding tria l. These were those mice which survived the tria l and consumed a 
mean dose of 788.8mg/kg; those mice which died after consumption of a 
relatively large dose of warfarin; 309.7mg/kg (compared with LAC-grey 
warfarin-susceptible males) over a mean period of 1 2  days; and those mice which 
succumbed to warfarin toxicity after a very short period of time, 4.5 days, after 
consuming a mean dose of only 118.6mg/kg; less than the mean lethal dose for 
male LAC-grey mice. On further investigation, it was noted that the la tter  
group of HC males; those with extreme sensitivity to warfarin; and all 4 of the 
HC female mice which died during the feeding trial, were members of the same 
litte r. Further litters from the same parents were tested for warfarin-resistance 
using the warfarin/vitamin K epoxide test of Martin et al (1979) (see Section 
2.2.2. Animals) with the result that all were phenotyped as being w arfarin- 
resistant. However, when the same mice were monitored in a 21-day feeding 
trial, the number of deaths were comparable with those seen in w arfarin- 
susceptible mice. These phenomena will be discussed in detail in Section 3.5.
3.5. DISCUSSION
3.5.1. The Hypoprothrombinaemic Response of Warfarin-Susceptible and
Warfarin-Resistant Mice to Racemic Warfarin Administration
As stated in Section 3.3., the aim of this study was to establish an index 
of resistance between warfarin-susceptible (LAC-grey) and warfarin-resistant 
(HC) mouse strains. From the results obtained, however, it  became clear that 
since none of the toxicity data (Table 3.1.) followed the expected sigmoidal dose- 
response curve character (Figure 3.1.), LD^g values for each of the strains and 
sexes could not be calculated. In addition, the blood clotting data did not show 
the expected increase in hypoprothrombinaemic response with increasing dose, so 
that ED^g values could not be estimated from this data for warfarin-susceptible 
or warfarin-resistant mouse strains. The difference in resistance to warfarin  
anticoagulation between the LAC-grey and HC mouse strains has not been 
quantified, although qualitative comparisons can be made from these results. 
Several interesting characteristics have emerged from this study, relating to the 
nature of both interstrain and sex differences in the response to oral racemic 
warfarin administration.
Sex differences in warfarin susceptible and warfarin-resistant mouse 
strains will be discussed, with reference to their anticoagulant response and 
toxicity, followed by the strain differences between LAC-grey and HC mice in 
each sex, in order to explain the non-sigmoidal dose-response curves (Figure 3.1.) 
and the blood clotting data (Figures 3.2.-3.17.) obtained in this study.
In general from toxicity and blood clotting data it was found that male 
LAC-grey warfarin-susceptible mice were more sensitive to warfarin
administration than females of the same strain, especially at low doses (Figures 
3.4.-3.6.). This sex difference has been documented elsewhere (Rowe and 
Redfern, 1968; Greaves, 1971) in wild and laboratory-bred warfarin-susceptible 
mice, and is due to a true sex difference under hormonal control (Rowe and 
Redfern, 1967; Roll, 1966). A similar effect has been reported in rats (PytirSlS, 
1968), modified by two sex-dependent differences; higher plasma levels of 
prothrombin complex clotting factors, and a faster restoration of these levels 
after administration of warfarin in females compared with males and also a 
slower rate of warfarin metabolism in females than in males.
In addition to differences between the sexes in the 
hypoprothrombinaemic response to different warfarin doses, unexpected changes 
in this response were observed within each sex of the LAC-grey warfarin- 
susceptible mice. In particular, the male LAC-grey mice showed peak clotting 
time extensions and more prolonged anticoagulant action at a dose of 
8 mg/kg/day, than at any of the higher doses, where blood clotting times returned 
to normal more quickly as the dose of warfarin administered was increased 
(Figures 3.4.-3.8.). These findings suggested that some mechanism was in 
operation at the higher warfarin doses, which affected a change in the plasma 
protein binding, hepatic uptake, metabolism or excretion of warfarin, or a 
combination of these factors, such that the free warfarin concentration available 
for anticoagulant action was decreased. A decreased hepatic uptake with 
increasing dose has been reported in the rat (Takada and Levy, 1979) after 
intravenous administration of single doses of 0.1-lm g/kg warfarin. These doses 
are much smaller than those administered chronically by oral intubation in the 
present study. Extrapolation between species must always be made with caution, 
especially in this case, where such large strain differences between LAC-grey
and HC mice have been observed. The same authors have also reported that 
warfarin pharmacokinetics in the rat, again in the dose range of 0 .1 -lm g/kg were 
dose-dependent, the apparent volume of distribution, Vd , intrinsic clearance, 
C1int> anc* tota* clearance> C ly all decreased with increasing dose (Takada and 
Levy, 1980). This is of interest with respect to the decrease in 
hypoprothrombinaemia with increasing dose of warfarin found in LAC-grey male 
mice, since the Cl-^-j- value at a particular dose may be regarded as a general 
indication of the drug-metabolising capacity of the animal at that dose. From 
the results of Takada and Levy (1980), it would therefore seem that a decreased 
warfarin-metabolising ability was seen with increasing dose in the rat. This 
finding is contrary to the decreased anticoagulant effect seen here in LAC-grey 
mice, which could theoretically be explained by an increase in the rate of 
warfarin metabolism on increasing oral dosage from 8  to 64mg/kg/day for 4 days. 
Other workers have reported induced tolerance to the effect of warfarin in mice 
after multiple dosing (Rowe and Redfern, 1968), which was attributed to 
increased activity of warfarin-metabolising enzymes. In addition, other studies 
have shown several coumarin compounds -coumarin, 4-hydroxycoumarin, 7- 
hydroxycoumarin, acenocoumarol, bishydroxycoumarin, phenprocoumon and 
warfarin, to be inducers of the warfarin-metabolising cytochrome P-450 
enzymes, when administered at a dose of lOmg/kg intraperitoneally, daily for 5 
days in mice. The largest enzyme-inducing effect was observed with warfarin 
(Ritschel and Lee, 1977). Similarly, warfarin was reported to cause induction of 
liver cytochrome P-450 enzymes in a warfarin-susceptible mouse strain (Kling, 
Legrum and Netter, 1985), primarily inducing a cytochrome P-450 similar to that 
found after phenobarbitone pretreatment. It  therefore seems probable that at 
the higher doses of warfarin administered in my study (32 and 64mg/kg/day for 4 
days) enzyme induction of cytochrome P-450s occurred, so causing the decreased
anticoagulation described previously (Figures 3.7. and 3.8.). A similar 
mechanism may have been operating in the LAC-grey female also, since warfarin 
doses of 32 and 64mg/kg/day caused a decrease in toxicity (Table 3.1., Figure
3.1.) accompanied by no increase in hypoprothrombinaemic response (Figures 3.7. 
and 3.8.) compared to a dose of 16mg/kg/day.
Although reports of increased warfarin elimination have been published 
(Renowden, et al 1985; Yacobi, Slattery and Levy, 1980), these studies note the 
effects of a second compound on warfarin excretion, in the above cases, 
cholestyramine and phenobarbitone, respectively, and not the effects of 
increasing warfarin dose on this variable, as would explain my results. Thus, it 
may be suggested that the most likely explanation for the dose-dependent 
differences in toxicity and hypoprothrombinaemic response seen in both male and 
female LAC-grey mice was that induction of cytochrome P-450 levels by 
warfarin caused a decrease in the compound's efficacy as an anticoagulant. 
Further studies undertaken to investigate this probability are discussed in 
Section 5.4.1.
Having discussed both sex and dose-dependent variations in anti­
coagulant effect to oral racemic warfarin treatment in male and female 
warfarin-susceptible LAC-grey mice, the same responses must be explained for 
warfarin-resistant HC mice, and finally the comparative toxicities and blood 
clotting times between the two strains will be discussed.
A remarkable sex difference in the response of warfarin treatm ent was 
noted at all doses administered. Warfarin-resistant HC males were much less 
tolerant than their female counterparts with respect to toxicity and
anticoagulant response (Table 3.1., Figures 3.9.-3.16.). Although warfarin-
susceptible LAC-grey mice showed sex differences in that females were also
more tolerant to warfarin than males in this strain, the magnitude of the effect
was not as great as that in the HC strain. Thus, some other factor in addition to
the sex differences under hormonal control reported by Rowe and Redfern (1967)
may have been operating in the warfarin-resistant HC females. The vast
difference in male and female response to anticoagulation in the HC strain may
be explained by the fact that the major warfarin-resistance gene, present on
chromosome 7 in these mice, is fully dominant in the female, but it's partial
dominance in the male is under the control of modifiers other than sex (Wallace
and MacSwiney, 1976). The greater resistance of the female HC mice was 
effect
therefore a directjof the biochemical expression of a fully dominant warfarin- 
resistance gene, whereas in the male, having a greater susceptibility in general 
to warfarin than the female, and in addition lacking the full penetrance of the 
warfarin-resistance gene, led to a greater anticoagulant susceptibility, and so a 
large sex difference in toxicity and hypoprothrombinaemic response was 
observed.
The dose-dependent anticoagulant response of both male and female HC  
mice were, like the LAC-grey, difficult to interpret, since increasing the dose 
did not cause the gradually increased toxicity and elongated blood clotting times 
expected. In the male HC mice, hypoprothrombinaemic responses (Figures 3.9.-
3.16.) were almost as would be envisaged for such a study, with the exception of 
the response at 2 0 0 mg/kg/day, where no increase in response was observed 
compared to that evoked by half the dose (Figures 3.14. and 3.13.). This 
phenomenon was exemplified also in the fact that toxicity decreased at this dose 
level in the male (Table 3.1.). However, as the dose was increased to
300mg/kg/day, hypoprothrombinaemia and toxicity both increased. Since doses 
of 100, 200 and 400mg/kg/day warfarin were repeated in three further groups of 
1 0  mice with similar results, it  must be concluded that the decreased effect at 
2 0 0 mg/kg/day was a dose-specific phenomenon, and perhaps at this dose some 
aspect of warfarin metabolism or pharmacokinetics was affected such that 
hypoprothrombinaemic action of the anticoagulant was reduced.
Regarding dose-dependent changes in the toxicity of the HC female, it  
was clear that large doses could be tolerated without m ortality up to and 
including a dose of 400mg/kg/day (Table 3.1.). The blood clotting data obtained 
from these non-lethal doses did vary; in some cases quite markedly (Figures 3.9.-
3.16.). As the dose of warfarin was increased, there seemed to be a fluctuation 
in blood clotting times which increased and then decreased as the warfarin dose 
was progressively doubled, so that at 400mg/kg/day almost the same level of 
anticoagulation was in effect as that seen at 8 mg/kg/day, a quite remarkable 
finding, considering this represented a 50-fold difference in dose. Only at the 
dose of 800mg/kg/day was a maximal elongation of clotting times observed, 
resulting in incoagulable blood and a toxicity of 6  deaths out of 10. Perhaps the 
fluctuations observed at the lower warfarin doses represented inter-individual 
and dose-dependent variations which were observed because these doses were 
non-lethal. A relatively large inter-individual variation in
hypoprothrombinaemia would be expected since both LAC-grey and HC mice are 
outbred strains (Greaves and Ayres, in preparation).
Since high doses of racemic warfarin may cause induction of cytochrome 
P-450 to produce decreased toxicity in both males and females of the LAC-grey 
strain, this raised the question that if these high doses did cause cytochrome P-
450 induction in the LAC-grey strain, were the low toxicity levels in the HC  
strain due to the fact that relatively higher doses of warfarin had been 
administered? (Table 3.1.). In order to resolve this possibility, doses of 4 and 
8 mg/kg/day were also administered to HC warfarin-resistant mice and showed no 
toxicity in the female and only 1  death out of 1 0  at 8 mg/kg/day in the male. 
This led to the conclusion that the biochemical expression of the warfarin- 
resistance gene was responsible for the lack of toxicity in the HC strain, and not 
an increased tolerance due to cytochrome P-450 induction, as was seen in the 
LAC-grey strain.
It  must also be pointed out that the above sex and dose-dependent 
differences in anticoagulant action were observed subsequent to the 
administration of racemic warfarin to both LAC-grey and HC mice. The 
contribution of the R(+) and S(-) warfarin enantiomers may have been different 
in the males and females or at varying warfarin doses, thereby producing the 
differential effects observed. Although the ideal situation would allow the 
effects of one enantiomer to be assessed in the presence of it's epitope, 
unfortunately, the effects of separate warfarin enantiomers on blood clotting 
activity must be studied independently. The relative potencies of R(+) and S(-) 
warfarin enantiomers as anticoagulants are shown in Table 3.1. and Figures 3.17. 
and 3.18. in both male and female, warfarin-susceptible LAC-grey and warfarin- 
resistant HC mice, and discussed in Section 3.5.2..
Finally, with respect to the hypoprothrombinaemic response of warfarin- 
susceptible and warfarin-resistant mice to oral warfarin administration, inter- 
strain differences between LAC-grey and HC mice will be discussed. Toxicity 
data showed very clearly that the female warfarin-resistant mice were much less
sensitive to the anticoagulant action of warfarin than the warfarin-susceptible 
females. Even accounting for the decrease in toxicity, probably due to 
cytochrome P-450 induction, at the higher doses of warfarin in the LAC-grey 
female, a marked difference in toxicity was seen between the strains, the HC  
female showing no mortality until a dose of 800mg/kg/day warfarin. These 
results were also confirmed when blood clotting data from the two strains was 
compared. In all cases where no mortality was shown, the blood clotting times 
of the HC female were not maximally elongated and were shorter than at 
4mg/kg/day in the LAC-grey females, quite a remarkable finding since even at 
400mg/kg/day in the HC female the response of warfarin administration was 
smaller than that at 4mg/kg/day in the LAC-grey, a difference in dose of 100- 
fold. The clearly-defined differences in the hypoprothrombinaemic response to 
racemic warfarin between the two strains is due, in the female, to the full 
dominance of the warfarin-resistance gene, War, in the HC warfarin-resistant 
female mice, the biochemical expression of which has either pharmacokinetic or 
pharmacodynamic implications to cause genetically-incurred warfarin resistance.
The interstrain differences in toxicity and anticoagulant response to 
racemic warfarin administration between males of LAC-grey and HC strains 
were less marked than those discussed for females. However, the HC warfarin- 
resistant male was more tolerant to the toxic effect of warfarin than it's 
warfarin-susceptible counterpart, as can be seen from the fact that the HC male 
was able to tolerate higher doses of racemic warfarin than the LAC-grey male 
(Table 3.1.) and with hypoprothrombinaemic responses which were less marked 
than in the LAC-grey male. Clearly the difference between males of the two 
strains was less marked than that between females, and this was due to the fact 
that although the warfarin-resistant HC male possess the major warfarin-
resistant gene, War, it's biochemical expression is only partially dominant in the 
male (Wallace and MacSwiney, 1976), whereas in the female HC mouse, the same 
gene is fully dominant. Therefore the lower toxicity and anticoagulant effect in 
the male compared to female HC mice is due to the differences in penetrance of 
the warfarin-resistant gene, resulting in a reduced inter-strain difference 
between males compared with females.
Although from this study a direct comparison between warfarin- 
susceptible and warfarin-resistant mouse strains cannot be made in the form of 
an index of resistance, the oral administration of racemic warfarin to males and 
females of both strains has revealed a large amount of information relating to 
sex, dose and strain differences in the anticoagulant action of racemic warfarin 
which was of great importance when considering changes in the absorption, 
distribution, metabolism and excretion of warfarin in further studies.
3.5.2 The Stereospecific Hypoprothrombinaemic Response of Warfarin-
Susceptible and Warfarin-Resistant Mice to Administration of R(h-) or
S(-) Warfarin Enantiomers
Many synthetic drugs and pesticides exhibit chirality, ie, they are 
optical isomers (enantiomers) and are marketed as racemic mixtures (Testa, 1979 
and 1982). Enantiomers interact differentially with living systems, which are 
themselves chiral, leading to the expectation that optical isomers will produce 
distinct pharmacodynamic and pharmacokinetic responses, wherein one 
enantiomer contains most, if  not all, of the biological activity of the racemate. 
Warfarin is a typical example of this; the drug is marketed both for clinical and 
rodenticidal use as a racemic mixture, each of the optical isomers having 
differential hypoprothrombinaemic and toxicological responses in both man and
rat (Eble et al 1966; Breckenridge and Orme, 1972; Hewick and McEwen, 1973). 
In both species S(-) warfarin was the more potent enantiomer, being 3.5-6 . 6  
times more potent than R(+) warfarin in the rat (Eble, et al 1966; Breckenridge 
and Orme, 1972) and 3.8 times more potent that it's R(+) isomer in man 
(Breckenridge, et al 1973). Although man and the rat showed similar 
enantioselectivity with respect to anticoagulant potency, species differences in 
the action of the optical isomers have been shown in pharmacokinetic studies 
(Breckenridge, et al 1973; Hewick and McEwen, 1973) and will be discussed in 
detail in Chapter 5 of this thesis.
In the present study, warfarin enantiomers were dosed orally as 
previously described, with the result that in both male and female, warfarin- 
susceptible LAC-grey and warfarin-resistant HC mice the S(-) enantiomer was 
observed to be more potent than R(+) warfarin in evoking a 
hypoprothrombinaemic response (Section 3.4.2., Table 3.1. and Figures 3.17. and 
3.18.). In all cases, the anticoagulant response of male mice was greater than 
their respective females after administration of either R(+) or S(-) warfarin. 
Clearly, in all the species discussed, and in both warfarin-susceptible and 
warfarin-resistant mice S(-) warfarin has a greater potency due to 
stereoselective interaction with the enzymes vitamin K reductase and vitamin K 
epoxide reductase, the sites of warfarin action in the liver as reported by Fasco 
and Principe (1982) for the rat. How the stereoselective action of warfarin to 
cause hypoprothrombinaemia correlates with stereospecific absorption, 
metabolism, plasma protein binding and excretion will be discussed with 
reference to warfarin-resistance in further chapters of this thesis.
3.5.3. Differential Toxicity of 0.025% Racemic Warfarin to Warfarin-
Susceptible and Warfarin-Resistant Mouse Strains in a 21-Day Feeding
Trial
Since dosing warfarin-susceptible LAC-grey and warfarin-resistant HC 
mice with different doses of racemic warfarin did not allow the direct 
calculation of LD^g or ED^g values due to various sex and dose-dependent 
phenomena (see Sections 3.3.1. and 3.5.1.) the 21-day feeding tria l with 0.025% 
warfarin was undertaken in order to compare the results from the above strains 
with those obtained by previous workers in wild and laboratory-bred warfarin- 
susceptible and warfarin-resistant mouse strains (Rowe and Redfern, 1967; 
Greaves, 1971). In these studies wild warfarin-resistant mice were able to 
survive a test lasting 2 1  days during which time their only source of food was
0.025% warfarin (Rowe and Redfern, 1964), whereas warfarin-susceptible mice 
succumbed to the toxic actions of the anticoagulant within the 2 1 -day trial 
period (Bentley and Larthe, 1959). Thus the ability to survive for 21 days on a 
standard warfarin bait in the laboratory appeared to denote a capacity to 
withstand treatment with the anticoagulant indefinitely in the field. The results 
obtained from this standard test using LAC-grey and HC mice did show a greater 
susceptibility of the former strain to warfarin toxicity than the HC mice which 
possessed the major warfarin-resistant gene, War. However, as described in 
Section 3.3.3., various anomalies seemed to have occurred in both male and 
female toxicity levels in the HC mice, attributed to the fact that those 
warfarin-resistant mice which succumbed to warfarin toxicity were all from the 
same litte r, and therefore had the same parents. Comparing the mean lethal 
doses and days to death of mice in this litte r (Table 3.5.), these doses appeared 
very similar to the values for warfarin-susceptible mice, which lead to the 
conclusion that perhaps this litte r  was not warfarin-resistant. I f  this were the
case, the parents would be expected to be either both homozygous warfarin- 
susceptible animals, or heterozygous for warfarin-resistance, such that both 
homozygous-susceptible and heterozygous warfarin-resistant progeny were 
produced, which were all sensitive to the toxic effects of 0.025% (w/w) warfarin 
in a 2 1 -day feeding trial.
Further progeny from the same parents were tested for warfarin- 
resistance, using the warfarin/vitamin K epoxide test of Martin et al (1979) 
developed for rats, with the result that their blood coagulation activities showed 
them to be either homozygous or heterozygous for warfarin resistance, ie, they 
were not homozygous warfarin-susceptibles. The second phase of the test for 
warfarin-resistance genotype involves feeding a vitamin K-free diet for 4 days 
after which time blood clotting activities were used to show clear differences 
between animals homozygous or heterozygous for warfarin-resistance. However, 
this test was developed for the determination of the warfarin-resistance 
genotypes of rats, based on the fact that alterations in the enzyme vitamin K 
epoxide reductase occurred in the resistant rat such that these animals were able 
to utilise vitamin K epoxide in the presence of warfarin to form vitamin K 
hydroquinone needed for the synthesis of the vitamin K-dependent blood clotting 
factors (Bell, 1978) (Figure 3.1.). In addition, warfarin-resistant rats required a 
dietary supplement of vitamin K in order to maintain normal blood clotting 
function (Greaves and Ayres, 1973) so that the vitamin K-free diet would affect 
those rats homozygous for warfarin resistance more than heterozygous animals 
with respect to their blood clotting times. However, warfarin-resistant mice do 
not need a dietary supplement of vitamin K, therefore development of vitamin K 
deficiency in the second stage of this test does not occur in either warfarin- 
susceptible or warfarin-resistant mice, since they cannot be made vitamin K - 
deficient. Therefore, it may be speculated that those warfarin-resistant HC
mice which did not survive the 2 1 -day feeding tria l were a mixture of both 
homozygous susceptible and heterozygous resistant animals. These mice were 
classified as such by the test of Martin et al (1979) for warfarin-resistance in 
rats. Further clarity may be gained by using the results of the 0.025% warfarin 
feeding tria l, from which the litte r in question would have been classified as non- 
resistant, which confirms the findings of the test by Martin et al (1979).
Having said this, how can it be possible that mice considered 
heterozygous for the autosomal dominant warfarin-resistant gene, War, by the 
above tests, succumbed to warfarin anticoagulation when fed on 0.025% warfarin 
for 2 1  days, also considering the fact that other mice (both male and female) 
which were also warfarin-resistant but from different litters survived the 2 1 -day 
test and were judged warfarin-resistant according to the test of Martin et al 
(1979). Clearly, in this particular warfarin-sensitive litte r, some factor was 
lacking which was present in other warfarin-resistant mice undergoing the 2 1 - 
day test, such that their susceptibility to warfarin was increased and they were 
not truely warfarin-resistant. A hypothesis is proposed to explain this important 
finding:-
In the normal warfarin-resistant mice, ie, those females which survived 
the 2 1 -day tria l, and males not from the litte r indicated, it  is proposed that a 
multigene system is in operation to confer warfarin-resistance to these mice. 
Perhaps some change in either the pharmacodynamic or pharmacokinetic 
parameters of warfarin’s anticoagulant action takes place in normal warfarin- 
resistant mice, this change being coded for by a gene which is not War, the major 
warfarin-resistance gene. However, the second gene may be very close to the 
War gene on chromosome 7 in mice, such that in all cases of transfer of the
warfarin-resistance gene from PBI mice to HC mice, the second gene was also
coded for in the HC mice. The true major gene for warfarin-resistance in the
house mouse is also proposed to code for some biochemical change in the
pharmacodynamics or pharmacokinetics of warfarin’s action. However, the
biochemical mechanism coded for by the two genes must be different, so that
heterozygotes for War which lacked the second proposed gene, were unable to
survive the 21-day, 0.025% warfarin feeding tria l, whereas homozygous warfarin-
resistant mice co-expressed the second gene and therefore did not succumb to
the toxic effects of warfarin. The second gene may have some effect on the
metabolism of vitamin K, and so confer a greater tolerance to warfarin
administration. This suggestion is supported in part by the fact that in the rat,
2warfarin-resistance, coded for by the single dominant autosomal gene Rw in
linkage group 1 (Greaves and Ayres, 1967) is expressed biochemically as an
alteration in vitamin K metabolism (Hermondson et al 1969). The major gene
for warfarin-resistance in the house mouse, War, is present in linkage group 1
(chromosome 7) and as such, shares certain loci with group 1 in the rat (Wallace
and MacSwiney, 1976). The warfarin-resistance genes may be analogous in the
two species. It  therefore seems quite possible that the second gene proposed
may code for an altered vitamin K metabolism in the house mouse, is present
also in linkage group 1 (chromosome 7) and it may be this gene which is 
2
analogous with Rw in the rat, and not War, as previously thought.
In summary, a mechanism of warfarin-resistance is proposed such that 
the major warfarin-resistance gene and a second gene on chromosome 7 of HC  
mice have biochemical expression which confer changes in pharmacodynamic or 
pharmacokinetic factors of warfarin anticoagulant action. For example, the 
second gene may code for an altered vitamin K metabolism in warfarin-resistant
HC mice, and may be present on the same chromosome as War (chromosome 7) in 
these mice. The possession of the vitamin K gene is not thought to confer 
resistance, although these animals may pass the first part of the test of Martin 
et al (1979) for warfarin-resistance due to possible vitamin K metabolism 
changes. However, on the 21-day feeding tria l those mice not in possession of 
the second gene may succumb to the toxic effects of the anticoagulant. The 
feeding tria l therefore seems more selective for the detection of warfarin- 
resistance in house mice on the basis of overall toxic effects of warfarin, and not 
altered vitamin K metabolism alone, which is measured by the test of Martin et 
al (1979). It therefore seems that although in most cases the HC mice possess 
both the proposed gene and War. In some cases, as seen here, only one gene is 
present which gives anomalous results. The test of Martin et al (1979) was 
developed for use in warfarin-resistance genotype determination in rats and 
obviously is not as accurate in the house mouse, since it is proposed that the 
major warfarin-resistance gene, War, does not biochemically code for altered 
vitamin K metabolism, measured by the above test.
Clearly, many factors contribute to the anticoagulant effect evoked by 
warfarin in any particular species. In this study, which investigated the toxicity  
of, and anticoagulant response to, oral warfarin administration in warfarin- 
resistant and warfarin-susceptible mouse strains, many of these factors emerged. 
Within each of the two strains, sex, dose and enantiomeric differences in 
anticoagulant action were shown. In addition, different responses in warfarin- 
susceptible LAC-grey and warfarin-resistant HC mice were evoked after oral 
administration of racemic warfarin, exemplifying the inter-strain variations of 
hypoprothrombinaemia.
CHAPTER 4
PLASMA CONCENTRATION-TIME PROFILES OF R(+) AND S(-) WARFARIN 
ENANTIOMERS AFTER INTRAVENOUS AND ORAL ADMINISTRATION OF RACEMIC 
ANTICOAGULANT TO WARFARIN-SUSCEPTIBLE AND WARFARIN-RESISTANT MICE
4.1. INTRODUCTION
Having shown that the response to warfarin anticoagulation was 
different in warfarin-susceptible and warfarin-resistant mouse strains (Chapter 
3), due to the presence of the major warfarin-resistance gene, War, on 
chromosome 7 in the HC mouse strain, a logical progression of enquiry leads us 
to ask how War confers warfarin-resistance to HC mice, ie, what is (are) the 
biochemical consequence(s) of the expression of this gene?
Few studies designed to investigate the biochemical mechanism of 
warfarin-resistance have been reported in the house mouse. However, the 
expression of the warfarin-resistance gene, War, may affect the anticoagulant 
action of warfarin through pharmacodynamic and pharmacokinetic mechanisms. 
Examples of the former would include alterations in the bioavailability or 
metabolism of vitamin K, synthesis of vitamin K-dependent clotting factors, or 
direct actions on haemostasis. Pharmacokinetic mechanisms altered in warfarin- 
resistant mice may include absorption, distribution or plasma protein binding, 
warfarin metabolism by cytochrome P-450 and other drug-metabolising enzymes, 
or excretion. Genetically-determined warfarin-resistance has been quite 
extensively studied in the rat, as well as in man, as discussed in detail in Chapter 
1, Section 1.3. The biochemical mechanisms in the rat and human, by which
warfarin-resistance is genetically conferred is thought to involve an altered 
vitamin K epoxide reductase enzyme, which is relatively unaffected by high 
levels of warfarin. In the normal warfarin-susceptible rat, human and mouse, 
warfarin acts to inhibit the enzyme, vitamin K epoxide reductase, so that 
recycling of vitamin K, necessary for the synthesis of blood clotting factors, 
cannot occur. I t  is this inhibition which leads to anticoagulation in all animals, 
except those which possess an altered vitamin K epoxide reductase enzyme.
The first reports of hereditary warfarin-resistance in mice showed three
interesting findings (Rowe and Redfern, 1968). Firstly, some animals,
particularly females, were found to be inherently resistant to large doses of
warfarin; others gave a large initial response which declined to near normal after
daily administration of the compound over 1 0  days, suggesting induced tolerance,
while the third category of mice, whose blood plasma became and remained
uncoagulable, nevertheless showed no tendency to bleed. It  therefore appeared
that in addition to being genetically complex, warfarin-resistance in the house
mouse was also physiologically complicated. Further studies showed that the
biochemical manifestation of the warfarin-resistance gene, War, in the mouse
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was unlikely to be the same as that found for Rw in the rat. In addition, it was 
postulated that rather than being due to a pharmacodynamic mechanism such as 
the altered vitamin K metabolism seen in warfarin-resistant rats, warfarin- 
resistance in the house mouse may be due to an alteration in warfarin 
metabolism, and therefore a pharmacokinetic mechanism (Wood and Conney, 
1974).
The pharmacokinetics of warfarin have been documented in the rat and 
especially in man. However, no such data is available for either warfarin-
susceptible or warfarin-resistant mice. Initially, considering the situation in the 
human, it has been documented that the rate of warfarin elimination varied 
considerably amongst warfarin-sensitive individuals, with half-lives varying 
between 20 and 50 hours (Breckenridge and Orme, 1973b; O'Reilly et al 1963). 
However, warfarin contains an asymmetrical carbon atom and therefore exists as 
two distinct enantiomers. The contribution of the R(+) and S(-) enantiomers of 
warfarin to the overall half-lives of racemic warfarin has been investigated by 
various groups of workers.
In man, the rat and the mouse, S(-) warfarin is a more potent 
anticoagulant than R(+) warfarin (Breckenridge and Orme, 1972; Yacobi and 
Levy, 1974) (Chapter 3, Figures 3.17. and 3.18.). However, while the S(-) 
enantiomer is cleared more rapidly than R(+) warfarin in man, the reverse is the 
case in the rat. In the human, the half-lives of the enantiomers of warfarin vary 
between individuals:- R(+) warfarin, from 37-46 hours, and S(-) warfarin, from 
21-33 hours (Breckenridge et al 1974; Hewick and McEwen, 1973; Lewis et al 
1974). Similar values in the warfarin-susceptible Sprague-Dawley rat being 7.6 
hours for R(+) warfarin, and 11.0 hours for S(-) warfarin. In both humans and 
rats, several studies have been undertaken where the half-lives of R(+) and S(-) 
or racemic warfarin have been investigated in warfarin-resistant individuals. 
These studies showed that no significant difference in half-life  values could be 
found, compared v/ith results obtained in warfarin-sensitive individuals (Hewick, 
1972; Townsend et al 1975; O'Reilly, 1970; Alving et al 1985). Therefore, 
warfarin-resistance in man and the rat seem only to produce a pharmacodynamic 
effect to cause an alteration in vitamin K metabolism, as no pharmacokinetic 
differences between warfarin-susceptible and warfarin-resistant humans or rats 
were found.
The background of warfarin-resistance in the house mouse, however, is 
different from that of either the rat or man. In conjunction, the fact that 
warfarin-resistant mice did not have a greater requirement for vitamin K than 
did normal mice, and that their warfarin-metabolising ability seemed to be 
correlated with warfarin-susceptibility, pointed towards a pharmacokinetic, 
rather than a pharmacodynamic event, resulting from the biochemical expression 
of the warfarin-resistance gene. The most logical line of study at this stage was 
to examine the pharmacokinetic parameters, in particular, the metabolism of 
warfarin enantiomers of both warfarin-resistant and warfarin-susceptible mouse 
strains, in order to determine whether the pharmacokinetics correlated with the 
differences in toxicity already shown between the two strains of mice (Chapter
4.2. EXPERIMENTAL OBJECTIVES
1. To determine plasma concentration time profiles of R(+) and S(-) 
warfarin enantiomers after intravenous and oral administration of 
racemic warfarin to warfarin-susceptible and warfarin-resistant mouse 
strains.
2. Using the above profiles to determine pharmacokinetic parameters such
as plasma half-life  ( t i ) ,  apparent volume of distribution (Vd ), plasma
aPP
clearance (Cl ) and bioavailability (F) for both warfarin enantiomers, in 
P
order that any differences between warfarin-susceptible and warfarin- 
resistant mouse strains may be highlighted.
4.3. EXPERIMENTAL DESIGN
For all experiments, both male and female warfarin-susceptible and 
warfarin-resistant mice were used. A single dose of 16mg/kg racemic warfarin 
was administered either intravenously or orally, blood samples being taken at 
various time-points up to 5 hours after administration, as described in Section
2.1.3.
The dose of 16mg/kg was chosen based on results from toxicity studies 
described in Chapter 3, where dosing 16mg/kg/day warfarin for 4 days produced 
maximum separation of anticoagulant effect between the two strains of mouse, 
without complications such as increased tolerance to the anticoagulant 
occurring, as was suspected at higher warfarin doses in LAC-grey mice.
The two different routes of administration were studied in order to 
compare the bioavailability of warfarin enantiomers in each strain and sex o f 
mice.
The levels of both warfarin enantiomers in liver were also determined to 
compare the time course of hepatic warfarin uptake in warfarin-susceptible and 
warfarin-resistant mouse strains.
4.4. RESULTS
4.4.1. Intravenous Administration of 16mg/kq Racemic Warfarin : Plasma
Concentration Time Profiles of R(+) and S(-) Warfarin Enantiomers
The plasma time course profiles of the warfarin enantiomers are shown 
in Figures 4.1.-4.4. for both male and female warfarin-susceptible and warfarin- 
resistant mouse strains, represented by solid lines for intravenous 
administration. Pharmacokinetic parameters calculated from these results are 
shown in Table 4.1.
It  is obvious from Figures 4.1.-4.4. that in all strains and both sexes the 
plasma clearance (Clp) of R(+) warfarin was significantly greater than that of 
S(-) warfarin, the more potent enantiomer with respect to anticoagulation 
action (p<0.001 in all cases). Consulting Table 4.1. the most striking 
differences in pharmacokinetic parameters were seen for the S(-) enantiomer of 
warfarin in the warfarin-resistant HC mice, where there were significant 
(p<0.001) decreases in the plasma half-life ( t j )  and area under the curve (AUC) 
compared to the warfarin-susceptible LAC-grey females. These differences 
were also reflected by significant increases in both plasma clearance (Cl ) and 
elimination rate constant (Kej.m) values again in the HC female. No 
differences were seen in warfarin-resistant females compared with their 
warfarin-susceptible counterparts in plasma concentration at time 0  minutes 
(CpQ), or apparent volume of distribution (Vdgpp) values. Similarly, no 
significant changes in the pharmacokinetics of S(-) warfarin were seen 
comparing warfarin-susceptible and warfarin-resistant male mice. In addition, 
warfarin-susceptible LAC-grey female mice behaved in a very similar manner 
to both LAC-grey and HC male mice in terms of the pharmacokinetics of S(-) 
warfarin.
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Figure 4.1. Plasma Concentration-Time Profiles of R(+) and S(-) Warfarin
A fter Intravenous and Oral Administration of 16mg/l<g Racemic
Warfarin to LAC-Grey Male Mice
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Figure 4.2. Plasma Concentration-Time Profiles of R(+) and S(-) Warfarin
A fter Intravenous and Oral Administration of 16mg/kg Racemic
Warfarin to LAC-Grey Female Mice
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Figure 4.4. Plasma Concentration-Time Profiles of R(+) and S(-) Warfarin
A fte r Intravenous and Oral Administration of 16mg/kg Racemic
Warfarin to HC Female Mice
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Pharmacokinetic Parameters Calculated A fter Administration of 16mg/kq 
Racemic Warfarin by Either Intravenous or Oral Routes
INTRAVENOUS
S(-) Warfarin R(+) Warfarin
LAC LAC HC HC LAC LAC HC HC
Cp
(pg%nl)
17.94
-1.06
20.97
±1 . 0 0
17.02
±0.93
17.52
±0.91
20.97
±0.97
17.52
±1 . 0 2
17.57
±0.98
17.29
t i  (h) 
(elim)
12.53
±0.70
14.75
±0.79
12.45
±0.67
* * *
0.91
±0.04
0.186
±0 . 0 2
0.243
±0.03
0 . 2 2 2
±0 . 0 2
0.224
±0 . 0 2
Abs t j  
(h)
- - - - - - - -
K ' elim
(hr"1 )
0.044 0.046 0.056
* * *
0.763 3.72 2.85 2.64 3.08
±0 . 0 0 1 ±0 . 0 0 1 ±0 . 0 0 1 ±0.03 ±0.016 ±0.16 ±0.13 ±0 . 1 0
Vd
(1) aPp
Clp
0.017
±0.007
0.94
0.014
±0.007
0.65
0.018
±0 . 0 0 2
1 . 0
0.017
±0.006
* * *
12.95
0.014
±0 . 0 0 1
52.1
0.017
±0 . 0 0 1
48.5
0.017
±0 . 0 0 1
53.1
0.017
±0 . 0 0 1
52.6
(ml/hr) ±0 . 0 2 ±0 . 0 2 ±0.04 ±0.63 ±1.46 ±1.30 ±1.49 ±1.03
AUC 265.5
±9.83
282.4
±1 0 . 0 1
282.7
±8.79
* * *
22.41
±1.03
5.64
±0 . 2 1
6.15
±0.16
6.71
±0.18
5.62
±0 . 2 0
F
(%)
ORAL
S(-) Warfarin R(+) Warfarin
LAC LAC HC HC LAC LAC HC HC
Cp
(pg%nl)
17.06
±0.90
16.74
±0.89
21.73
±1.03
17.46
±1 . 0 0
6.71
±0.26
6.76
±0.29
18.8
±0.98
1 2 . 8 8
±0.92
t i ( h )
(elim)
Abs t i  
(h)
11.50
±0.63
0.54
±0 . 0 2
11.75
±0.64
0.54
±0 . 0 2
1.28
±0.63
* * *
0 . 2 0
±0 . 0 1
* * *
0.90
±0.03
0.46
±0 . 0 2
1.18
±0.19
0.39
±0 . 0 2
0.96
±0.06
0.33
±0 . 0 2
0 . 8 6
±0.05
* * *
0 . 1 0
±0 . 0 1
0.98
±0 . 1 0
0.32
±0 . 0 2
^elinn
(hr"1)
0.046 0.040 0.081 0f f l 1.59 2.40 1.96 2.49
±0 . 0 0 2 ±0 . 0 0 1 ±0.003 ±0 . 0 2 0 ±0.13 ±0 . 1 0 ±0.09 ±0.14
Vd
(1) apP
0.018
±0 . 0 0 2
0.018
±0.006
0.014
±0.004
0.017
±0 . 0 0 1
0.045
±0.006
0.045
±0.007
0.016
±0 . 0 0 1
0.024
±0 . 0 0 1
C1P
1.08 1.06 0 . 8 6
* * *
13.1 26.4 32.5 31.7 26.9
(ml/hr) ±0.03 ±0 . 0 2 ±0 . 0 2 ±0.71 ±1.34 ±1 . 1 2 ±1.09 ±0.89
AUC 223.8
±8.26
229.1
±7.11
204.4
±7.03
* * *
21.69
±1 . 0 1
5.29
±0.19
5.79
±0 . 2 1
6.24
±0.23
5.26
±0.26
F
(%)
84.3
±2.9
81.1
±3.3
72.3
±3.1
96.8
±4.6
93.8
±3.5
94.1
±3.1
93.0
±4.06
93.6
±4.9
Cp0  - Plasma concentration at time 0 minutes
t i  (elim) - H a lf-life  of elimination. Abs t j  - Absorption half-life  
K iim - Elimination rate constant *  P<0.01
aDD ~ Apparent volume of distribution * *  p<0.005
Clp -  Plasma clearance * * *  P < 0 *0 0
AUC - Area under the plasma concentration-time profiles 
F -  Bioavailability
The pharmacokinetic parameters of R(+) warfarin calculated following 
intravenous administration of 16mg/kg racemic anticoagulant were significantly 
different (p<0.001) from those of S(-) warfarin, with the exception of the CpQ 
and V d ^p  values in all strains and sexes investigated. In addition, all the 
parameters calculated from the plasma concentration time profiles of R(+) 
warfarin were approximately equal, irrespective of sex or strain (Table 4.1.).
In summary, in addition to the stereoselective plasma clearance seen 
after intravenous racemic warfarin administration, in both sexes and both 
strains, warfarin pharmacokinetics were altered in warfarin-resistant females; 
also in a stereospecific manner, such that S(-) warfarin was cleared from plasma 
at a faster rate than in the LAC-grey female, and males of both strains of 
mouse.
Hepatic Uptake of Warfarin Enantiomers
The liver levels of warfarin enantiomers after intravenous dosing are 
shown in Figures 4.5.-4.8. by the solid lines. For both male and female, 
warfarin-susceptible and warfarin-resistant animals, levels of S(-) warfarin were 
significantly greater (p<0.001) than those of R(+) warfarin after the 1 hour tim e- 
point, correlating with the stereospecific plasma data described above. A 
remarkable difference in the hepatic concentration of S(-) warfarin was seen 
comparing LAC-grey males and females with their warfarin-resistant 
counterparts. Firstly, considering the LAC-grey male, S(-) warfarin increased up 
to 1  hour after warfarin administration, thereafter declining to steady-state 
levels between 2 and 5 hours (Figure 4.5.). However, in the HC male, levels of 
S(-) warfarin continued to increase up to 4 hours after dosing, peak 
concentrations were almost 3 times those of LAC-grey livers. A similar
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situation was seen in the female mice, the peak levels of hepatic S(-) warfarin in 
the HC being approximately 1.5 times those of the LAC-grey. However, whereas 
in the male, peak levels were achieved more quickly in the LAC-grey mice, the 
reverse is true for females. Rapid hepatic uptake of S(-) warfarin was reflected  
by a maximum value 1 hour after dosing in the warfarin-resistant HC, compared 
with 2.5 hours in the LAC-grey female. The magnitude of the strain difference 
in liver S(-) warfarin levels was greater for males than females; LAC-grey 
females showed increased, and HC females decreased levels compared with the 
values of their respective males.
As previously stated, hepatic concentrations of S(-) warfarin were much 
greater than corresponding R(+) warfarin concentrations within each sex and 
strain. However, no interstrain differences in the levels of R(+) warfarin were 
seen for male mice (Figures 4.5. and 4.7.) following intravenous administration of 
racemic warfarin, the hepatic concentration of R(+) warfarin remained relatively 
constant over the time period studied. The female HC and LAC-grey mice 
showed a comparable response; only at 15 minutes after dosing was a significant 
(p<0.01) increase in R(+) warfarin seen in the HC female liver. A fter this tim e- 
point the same levels of the enantiomer were present in both strains throughout 
the period studied. In general, warfarin-resistant mice were found to have 
increased levels of hepatic S(-) warfarin compared with the warfarin-susceptible 
mouse strain.
4.4.2. Oral Administration of 16mg/kg Racemic Warfarin : Plasma
Concentration Time Profiles of R(+) and S(-) Warfarin Enantiomers
Plasma levels of R(+) and S(-) warfarin after oral administration are 
shown in Figures 4.1.-4.4. (discontinuous lines), and pharmacokinetic parameters
calculated from these profiles are summarised in Table 4.1. Again, as was seen 
after intravenous administration of racemic warfarin, in all cases the plasma 
clearance of R(+) warfarin was significantly greater (p<0.01) than that of S(-) 
warfarin once absorption had taken place, irrespective of the strain or sex of the 
mice.
Considering S(-) warfarin first of all in the LAC-grey mice, maximum 
plasma levels were reached 1 hour after the oral dose, compared with 15 minutes 
for the HC male. The same value for LAC-grey and HC females was found to be 
1 hour in both strains. The plasma elimination of S(-) warfarin was slightly 
quicker in the warfarin-resistant HC male, compared with the LAC-grey male, 
reflected by a significantly increased elimination rate constant (Table
4.1.) (p<0.01), although the plasma clearance was not significantly changed. All 
other pharmacokinetic parameters calculated for S(-) warfarin did not show 
strain differences in male mice. In female mice after oral racemic warfarin 
administration, however, stereospecific strain differences were seen similar to 
those observed after intravenous warfarin (Section 4.4.1.). Although the peak 
plasma concentration of S(-) warfarin in both warfarin-susceptible and warfarin- 
resistant mice occurred at the same time, as reflected by similar absorption 
half-lives (Abs t^ -  Table 4.1.), the plasma clearance (Clp), t j ,  K 0 j.m anci AUC  
of the HC female were significantly different (p<0.001) from those of the LAC- 
grey female, S(-) warfarin being eliminated from plasma at a faster rate in the 
warfarin-resistant animals. Comparing male LAC-grey and HC mice, it  can be 
seen that after administration of racemic warfarin the pharmacokinetics of the 
R(+) enantiomer did not show strain differences, apart from the fact that the 
absorption half-life  (Abs t j )  of the HC mice was significantly greater (p<0.001) 
than their warfarin-susceptible counterparts (Table 4.1.). Other than this one
parameter the pharmacokinetics of R(+) warfarin for males and females of each 
strain were essentially the same.
In general, all pharmacokinetic parameters were similar within each sex 
and strain after intravenous injection, compared to oral administration of 
racemic warfarin (Table 4.1.). Bioavailability (F) calculations comparing area 
under the curve (AUC) values after oral and intravenous administration routes 
showed levels approaching 1 0 0 % in all cases, which indicated that 
gastrointestinal absorption of almost all the racemic warfarin was effected in 
both male and female warfarin-susceptible LAC-grey and warfarin-resistant HC  
mouse strains.
Hepatic Uptake of Warfarin Enantiomers
The liver levels of warfarin enantiomers after oral dosing are shown in 
Figures 4.5.-4.8. represented by the discontinuous lines. For both male and 
female warfarin-susceptible LAC-grey and warfarin-resistant HC mice, levels of 
S(—) warfarin were significantly greater (p<0.001) than those of R(+) warfarin  
after the 2 hour time point, with the exception of LAC-grey females, where the 
level of significance was p<0.01 at time points of 2 and 4 hours only. Comparing 
interstrain variations in liver concentrations of S(-) warfarin in males, it  has 
been shown (Figures 4.5. and 4.7.) that in the HC warfarin-resistant male, 
significantly larger amounts of this enantiomer accumulated until a maximum 
level was reached 4 hours after intravenous dosing; a maximum at 3 hours after 
administration of warfarin was reached in the LAC-grey male mice, but the 
magnitude of this peak level was 4 times smaller than that seen in the HC mice. 
Similarly, comparing LAC-grey with HC females, a very significant difference in 
liver levels of S(-) warfarin was seen; the peak concentration in the HC being 5
times that in the LAC-grey female. This large difference was partly due to the 
fact that the liver levels of S(-) warfarin in the warfarin-susceptible LAC-grey 
mice were lower than those seen after intravenous administration of the 
anticoagulant (Figure 4.6.).
No significant differences between the two strains of mice were found the levels 
of hepatic R(+) warfarin, the concentrations of this enantiomer remained 
relatively constant in each sex and strain over the time period studied. With the 
exception of the LAC-grey female S(-) warfarin time course profile where 
decreased levels were seen, all other sexes and strains showed very similar liver 
concentrations of both R(+) and S(-) warfarin to those found after intravenous 
administration of the same dose of racemic warfarin.
4.5. DISCUSSION
As indicated earlier, previous studies which investigated warfarin-
resistance in the house mouse pointed towards a difference in the
pharmacokinetics or metabolism of warfarin in these mice, so conferring
warfarin-resistance (Lush and Arnold, 1975; Lush, 1976; Wood and Conney, 1974).
The plasma concentration time profiles of warfarin enantiomers after
intravenous and also oral administration of racemic anticoagulant were
investigated in LAC-grey warfarin-susceptible and HC warfarin-resistant mouse
strains. These in vivo experiments were carried out in order that the overall
physiological effect of warfarin was seen, and therefore changes in plasma
clearance (Cl ), apparent volume of distribution (Vd ), half-life ( t i ) ,  or p r r  app
bioavailability (F) would reflect accurately the toxicological situation when both 
warfarin-resistant and warfarin-susceptible mice are subjected to warfarin  
baiting in the field.
One of the most striking observations resulting from this study was the 
fact that after both intravenous and oral dosing, and in both sexes and strains of 
mouse, the R(+) warfarin enantiomer was cleared from the plasma at a 
significantly faster rate (p<0.001) than the S(-) enantiomer. Thus, the more 
potent anticoagulant S(-) warfarin (in it's free form, not bound to plasma protein) 
was available for uptake by the liver, and therefore available to exert a 
hypoprothrombinaemic action, for a longer duration of time than was it's 
epitope, the less potent R(+) warfarin enantiomer. Stereoselective plasma 
clearance of warfarin has been documented by other workers, both in the rat and 
in man. Rodenticidal and therapeutic formulations of warfarin contain equal 
quantities of the R(+) and S(-) enantiomers and in the rat and man, as well as the
mouse, S(-) warfarin is a more potent anticoagulant than R(+) warfarin (Yacobi 
and Levy, 1974; Breckenridge and Orme, 1972; Breckenridge et al 1974). 
However, while the S(-) enantiomer is cleared more rapidly in man (Breckenridge 
et al 1974; Hewick and McEwen, 1973), the reverse is the case in the rat 
(Breckenridge and Orme, 1972; Yacobi and Levy, 1974) and the mouse (Section
4.4.1. and above). The two enantiomers of warfarin in the rat were also shown to 
differ in their regioselective metabolism, ie, they were detoxified by different 
metabolic routes (Lewis et al, 1974), a phenomenon discussed in detail later in 
this thesis (Chapter 5, Section 3.5.). Thus, when racemic warfarin was 
administered, animals were, in effect, receiving two separate rodenticides, those 
being the R(+) and S(-) enantiomers of warfarin. Measurements of racemic 
compounds in biological fluids have in many cases been based on techniques 
unable to differentiate between enantiomers. Since the initial 50:50 
enantiomeric ratio of racemates may rapidly change (as shown in Figures 4.1.-
4.4.), the value of plasma levels and pharmacokinetic parameters obtained with 
racemates is highly questionable. The case for stereospecific analysis of a 
mixture of enantiomers has been discussed in detail only recently (Walle and 
Walle, 1986). Chromatographic separation of enantiomers is possible if a 
diastereoisomeric relationship is established between them, either through the 
use of chiral solvents (Gilon et al 1980; Ta'uhi et al 1981) or derivatization with a 
suitable chiral reagent. The la tter technique was used in this study, based on the 
method of Banfield and Rowland (1983) (see Section 2.1.3.).
Before more detailed discussion of pharmacokinetic differences between 
warfarin-susceptible and warfarin-resistant mice, bioavailabiity of the 
anticoagulant will be evaluated in the two mouse strains. Since warfarin was 
administered orally for all toxicity experiments (Chapter 3) where HC mice were
shown less susceptible to warfarin anticoagulation than LAC-grey mice, the 
possibility that the warfarin-resistance gene, War, was expressed biochemically 
to cause a reduction in the absorption of one, or both, enantiomers of warfarin 
could not be ruled out. A fter comparison of the area under the plasma 
concentration time curves following intravenous and oral dosing, the 
bioavailability (F) of the R(+) and S(-) warfarin enantiomers in both sexes and 
strains of mice ranged from 81-97% with no significant differences occurring 
between the strains (Table 4.1.). Thus, the absorption of warfarin was almost 
complete, although the time of maximum plasma levels was variable (Figures
4.1.-4.4.). These results are in agreement with warfarin absorption studies 
published elsewhere for the rat and man (Julkunen et al 1971; O'Reilly et al 
1963), which showed that warfarin was also well absorbed. However, the 
extremely rapid absorption of warfarin from the gastrointestinal tract of all 
three species seems contradictory to the generally accepted theory that drugs of 
medium molecular size (warfarin molecular weight = 308) are absorbed from the 
gastrointestinal tract mainly in undissociated form by passive diffusion. Findings 
by Julkunen et al (1971) have shown that absorption of warfarin also occurred in 
dissociated form in the gastrointestinal tract, so explaining the rapid absorption 
of the anticoagulant. In effect, these studies have shown that the biochemical 
expression of the warfarin-resistance gene, War, in HC mice was not manifest as 
a decreased absorption of warfarin from the gastrointestinal tract.
A lowering in the amount of warfarin (either R(+) or S(-) enantiomers) 
reaching the plasma, and therefore the amount available to cause a 
hypoprothrombinaemic response, assuming the same degree of plasma-protein 
binding in the two strains, is not responsible for warfarin-resistance in either 
male or female warfarin-resistant HC mice.
In addition to the intrastrain stereoselectivity in plasma clearance of 
warfarin discussed earlier in this Section, the plasma concentration time profiles 
after both intravenous and oral administration of racemic warfarin brought to 
light stereospecific interstrain differences between females of the LAC-grey and 
HC strains (Figures 4.2. and 4.4.). The variation was manifest as a significantly 
decreased plasma half-life  ( t j )  and area under the curve (AUC) with subsequent 
increases in elimination rate constant (Kejjm) and plasma clearance (Clp) 
(p<0.001) (Table 4.1.) in the warfarin-resistant HC female. This finding was 
particularly significant with respect to warfarin-resistance, since the S(-) 
warfarin enantiomer is the more potent, and so an increase in it's plasma 
clearance of 2 0 -fold accompanied by a 16-fold decrease in the plasma half-life , 
compared with warfarin-susceptible females meant that the more potent 
enantiomer was available to effect an anticoagulant response in the liver for a 
much shorter period of time in warfarin-resistant animals. This effect, coupled 
with the fact that there was no difference in the pharmacokinetics of R(+) 
warfarin between the two strains meant that at 16mg/kg racemic warfarin, a 
small hypoprothrombinaemic response would be expected in the HC w arfarin- 
resistant females compared with LAC-grey warfarin-susceptible females, purely 
on the basis of their S(-) warfarin plasma elimination kinetics. Whether this 
phenomenon exhibits itself as a manifestation of the biochemical expression of 
the major warfarin-resistant gene, War, is subject to debate. Clearly, as stated 
above, the increased clearance of S(-) warfarin in HC females contributed to 
their lack of susceptibility to anticoagulation. However, since the same effect 
was not witnessed in the warfarin-resistant HC male (Table 4.1.) which also 
expressed War, does this mean that the increased female plasma clearance was 
purely a sex-dependent difference? Here the difficulties in answering this 
question begin to multiply such that three postulates may be made: it  was shown
that the susceptibilities of male and female HC mice to warfarin were different 
in that males were more sensitive to anticoagulation than females (Chapter 3).
1. I f  we account for the expression of War resulting in a change in some other 
factor than plasma clearance, to the same extent in males and females, 
and in addition, warfarin tolerance was enhanced in females as a sex- 
dependent difference, as shown in this Chapter, this would seem a most 
likely explanation of the data so far exhibited. However, there are various 
anomalies in this argument, the explanations of which lead to the finding 
that perhaps this significant increase in plasma S(-) warfarin clearance was 
due to the expression of the warfarin-resistance gene, War. Firstly, since 
LAC-grey and HC mice were bred specifically to be biochemically similar 
apart from the presence of the War gene, it would be expected that if  the 
above argument were true, and a sex difference was in operation, this 
should be apparent in the LAC-grey female also, which was not the case 
(Table 4.1.). Also the fact that the warfarin-resistance gene was fully 
dominant in females but under the influence of modifiers other than sex in 
the male (Wallace and MacSwiney, 1976) was not accounted for in the first 
postulate, therefore a second theory will be put forward to explain the dataI
(Section 4.4.1.).
2. The expression of the major warfarin-resistance gene, War, in HC mice 
resulted in biochemical pleiotropism taking place, that is that the single 
gene, War, produced more than one primary action when expressed. This 
phenomenon occurs relatively frequently, a quite recent case was reported 
by Geissler et al (1981). In the case of War, the expression of the gene may 
have produced an alteration in some, as yet unknown, event to cause 
increased resistance to warfarin, and at the same time have caused the
variation in S(-) enantiomer clearance in females only because the same 
effect in males was suppressed by modifiers. This would explain why the 
LAC-grey female showed comparative warfarin pharmacokinetics with 
both LAC-grey and HC male mice.
The third postulate is merely an observational point, and consolidates the
theory put forward in Case 2 above. The breeding programme of HC
warfarin-resistant mice included the addition of several 'marker1 genes
such as frizzy (fr), pink-eyed dilution (p), chichilla (Cc^) and shaker- 1  (sh-1 )
on chromosome 7, by crossing a male homozygous for these genes with the
original warfarin-susceptible wild-derived strain (Wallace and MacSwiney,
1976). In the final warfarin-resistant, wild-derived PBI strain, the
arrangement of these genes on chromosome 7 was proposed as War - -  fr  -  - 
chsh-1 - - c - -p, War clearly being close to frizzy, a position for the 
former inside the fr  -  -sh-1 segment could not be ruled out (Wallace and 
MacSwiney, 1976). The exact gene sequence of segments between these 
marker genes is not known, and therefore the expression of one of these 
genes may have resulted in the changes in S(-) warfarin elimination 
(perhaps by an altered isoenzyme of warfarin-metabolising cytochrome P- 
450) seen in HC females independently of the expression of War. This 
would account for the lower S(-) warfarin plasma clearance of both male 
and female LAC-grey mice. However, both male and female warfarin- 
resistant mice express this gene sequence; only the female showed a 
variation in S(-) warfarin plasma elimination. It  would therefore seem that 
the most likely explanation for this data (Table 4.1. Figures 4.1.-4.4.) is 
that the expression of War as part of a pleiotropic effect, caused a 
stereospecific change in warfarin pharmacokinetics in female mice, while 
the same effect was modified in the male.
The data presented here is at variance with that from similar studies 
undertaken with warfarin-resistant rats and humans, which all showed that 
warfarin pharmacokinetics were unaltered in human warfarin-resistant kindreds 
(O'Reilly, 1970; Holt and Freytes, 1983; Alving et al, 1985), although quantitation 
of separate R(+) and S(-) enantiomers was not undertaken. Similarly, in 
warfarin-resistant rats, workers showed that whether using racemic (Townsend 
et al, 1975) or enantiomeric (Hewick, 1972) warfarin, pharmacokinetics of 
warfarin remained unaltered in resistance, leading to the conclusion that 
warfarin-resistance was due to some other factor than altered pharmacokinetics 
of warfarin. The fact that the apparent volume of distribution remained 
approximately the same in all strains and sexes after intravenous administration 
(Table 4.1.) indicated that the change seen in S(-) warfarin plasma elimination 
was not due to re-distribution of the enantiomer, but more probably an increased 
metabolism or excretion. These two possibilities will be investigated; data is 
presented in Chapters 5 and 6 , respectively.
In addition to the enantioselective plasma elimination kinetics of R(+) 
and S(—) warfarin, shown in Table 4.1. and Figures 4.1.-4.4. also stereoselectivity 
was shown in hepatic concentrations of warfarin enantiomers over the time 
period studied (Figures 4.5.-4.8.) where S(-) warfarin was present in significantly 
higher amounts than R(+) warfarin (p<0.001), except in the LAC-grey female 
after oral dosing, where the level of significance was lower (p<0.01). These 
results correlate with the plasma data in the same strains and sexes, where R(+) 
warfarin is eliminated at a faster rate from the plasma, presumably due to 
stereoselective warfarin metabolism by cytochrome P-450 in the liver. A major 
interstrain difference was seen in both males and females of the warfarin- 
resistant HC mice, which exhibited gradually increasing amounts of S(-) warfarin
over the time periods of 0.5-4 hours in the male and 0.25-1 hour in the female, 
these values were significantly greater (p<0.001) than those of LAC-grey animals 
(Figures 4.7. and 4.8.). Thus, it would seem that there was no distinct 
correlation between plasma clearance and hepatic warfarin content, although the 
decline in S(-) warfarin content of the liver after 1 hour in the HC female 
correlates with an increased plasma clearance of the same enantiomer in these 
mice. An increased hepatic uptake of the more potent S(-) warfarin enantiomer 
would be expected to cause an increased hypoprothrombinaemic response since 
the liver is the primary site of warfarin action. However, studies undertaken in 
the rat by Levy e t al (1978) showed similar results in warfarin-susceptible 
animals; these authors suggested that hepatic uptake may involve warfarin 
exchange with hepatic tissue not related to the biotransformation of the drug. 
Further studies of hepatic warfarin uptake (Coveil et al, 1983) showed that 
hepatic tissue did serve as a storage depot for warfarin in the body in much the 
same way as warfarin’s binding to albumin (Brodie, 1964; O’Reilly, 1967). This 
would account for the fact that although S(-) warfarin was clearly distributed 
differently in LAC-grey and HC mice, their apparent volume of distributions 
were the same (Table 4.1.), since highly bound S(-) warfarin in the liver would 
produce the same effect as being bound to albumin. Covell et al (1983) 
concluded that in the rat at least two different hepatic tissues exchanged 
warfarin with plasma, one exhibited Michaelis-Menton saturation kinetics, while 
the second showed linear exchange kinetics with free plasma warfarin. I f  a 
similar system were operating in mice, lower S(-) warfarin concentrations in 
livers of the LAC-grey strain may be due to the first class of hepatic tissue 
being saturated at the dose of 16mg/kg, leaving more of the enantiomer 
available for anticoagulant action. However, the same hepatic tissue in the 
warfarin-resistant HC mice may have a higher threshold saturation level, causing
the accumulation of S(-) warfarin as shown for both males and females in Figures
4.4. and 4.5. Warfarin’s association with this class of tissue in rats did not lead 
directly to the elimination of the drug, but acted as a depot, such that this 
proportion of the dose of warfarin was not available for anticoagulant action. In 
this manner, the lack of correlation between plasma warfarin clearance and 
hepatic warfarin content within each sex and strain, and also between warfarin- 
susceptible LAC-grey and warfarin-resistant HC animals is explained on the 
basis of differential classes of hepatic warfarin binding tissues. However, the 
increased hepatic uptake in HC females was not responsible for the increased 
plasma elimination of S(-) warfarin.
Clearly, further studies must be undertaken to elucidate other effect(s) 
of the biochemical expression of War, and the exact nature of the hepatic 
binding of warfarin in the two mouse strains, although the data presented in this 
Chapter provide a significant step forward towards the understanding of 
warfarin-resistance in the house mouse and show that speculation by various 
authors (Lush and Arnold, 1975; Lush, 1976) that warfarin-resistance mechanisms 
in the rat and house mouse were different was well-founded.
CHAPTER 5
IN  VITRO' HEPATIC MICROSOMAL METABOLISM OF R(+) AND S(-) W ARFARIN  
ENANTIOMERS IN  UNTREATED-, WARFARIN-, PHENOBARBITONE-, AND 3 -  
NAPHTHOFLAVONE-PRETREATED WARFARIN-SUSCEPTIBLE LAC-GREY  
AND WARFARIN-RESISTANT HC MICE
5.1. INTRODUCTION
Cytochrome P-450, the terminal oxidase of the mixed-function oxidase 
system, has been implicated in alterations in the hypoprothrombinaemic response 
of warfarin-susceptible LAC-grey mice with increased dose (Chapter 3, Section
3.5.1.), and as a possible explanation for increased warfarin tolerance in 
anticoagulant-resistant HC female mice (Chapter 4, Section 4.5.). To further 
examine these possibilities the in vitro hepatic microsomal metabolism of 
separate R(+) and S(-) warfarin enantiomers was studied in untreated warfarin- 
susceptible and warfarin-resistant mouse strains. This was done in order to 
determine whether any inherent differences between the strains could be 
observed (Methods described in Section 2.2.1.).
In an attempt to show whether increased warfarin dose levels produced 
lower toxicity in LAC-grey mice (Table 3.1.) because of increased warfarin  
metabolism after cytochrome P-450 induction, pretreatment of mice with 4 or 
64mg/kg/day (for 3 days) racemic warfarin was carried out, after which 
microsomal warfarin metabolism was studied. Similarly, in studies designed to 
probe the homogeneity of cytochromes P-450 in the male and female w arfarin- 
susceptible and warfarin-resistant mice, animals were dosed with known 
cytochrome P-450 inducers: phenobarbitone, 8 -naphthoflavone and clofibrate,
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prior to hepatic microsomal metabolic studies with R(+) and S(-) warfarin being 
carried out.
The family of enzymes, collectively known as cytochromes P-450, is 
widely acknowledged to be of critical importance in the Phase 1 metabolism of 
drugs (Conney, 1967), endogenous compounds, such as steroids (Gustafsson et al
1983) and pesticides (Levi and Hogson, 1985). Most of these compounds are so 
hydrophobic that they would persist in the organism indefinately if  it were not 
for Phase I and Phase II drug-metabolising enzymes (Goldstein et al 1974). 
During Phase I metabolism, polar groups (such as alcohols) are introduced into 
the parent molecule, thereby presenting Phase II conjugating enzymes with a 
suitable substrate. The Phase II enzymes use the polar metabolite group as a site 
for attaching other very water-soluble moieties such as glucuronide, sulphate or 
glycine. Phase I products, and especially the Phase II conjugates, are sufficiently 
polar to be easily excreted by the organism. Cytochrome P-450 monooxygenases 
are Phase I metabolising enzymes which insert one atom of atmospheric oxygen 
into their substrates (Mason et al 1955), and require the integrity of an electron 
flow between the cofactor, nicotinamide adenine dinucleotide phosphate 
(NADPH), and the oxygenated form of cytochrome P-450 (Nebert, 1979). 
Approximately three quarters of the cytochrome P-450 reductase molecule is 
believed to protrude from the surface of the lipid layer of cellular membranes 
(Vermilion and Coon, 1978) whereas cytochrome P-450 molecules are thought to 
be embedded deeply in the membrane in heterogeneous clusters (Matsuura et al 
1978). In 1964, there was evidence for only one form of cytochrome P-450. Two 
years later, there was spectral evidence for at least two forms (Omura and Sato, 
1964; Imai and Sato, 1966). To date, there is strong experimental evidence that 
the cytochrome P-450s constitute a super-family which consists of at least five
gene families: phenobarbitone (PB)-inducible, 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD)-inducible, pregnenolone 16 a-carbonitrile (PCN)-inducible, P-450gcc 
gene(s) responsible for cholesterol side-chain cleavage and the gene(s) encoding 
steroid C-21-hydroxylation. The PB, TCDD and PCN family names imply only 
that it's members show sequence homology to one or more genes that are 
inducible by PB, TCDD and PCN respectively (Nebert, 1985). I t  has been 
established that inducers of cytochrome P-450 bring about de novo synthesis of 
specific cytochrome P-450 species, resulting from the induction of specific 
messenger RNA species and genes are activated at the level of transcription 
(Morvine et al 1983; Atchison and Aclesnik, 1983). It  was proposed that heme is 
a general regulator of cytochrome P-450 at the level of transcription, whereas 
the drug, or it's metabolite, would impart the specificity needed for the 
induction of a particular species (Ravishankar and Padmanaban, 1985). I t  must 
be remembered that several forms of cytochrome P-450 have been purified to 
apparent homogeneity (Koop and Coon, 1979; Agosin et al 1979; Negeshi and 
Nebert, 1979), which are constitutive, ie, they are present in uninduced animals. 
Endogenous forms of cytochrome P-450 such as these may carry out more 
specific metabolic reactions than induced forms of cytochrome P-450, because 
many biosynthetic and catabolic processes of steroids and biogenic amines are 
critical to important life  functions. The ability of constitutive forms of 
cytochrome P-450 to metabolise xenobiotics may therefore be important for 
survival in a chemically adverse environment. Such an environment is seen in 
the field when rodents are subjected to warfarin poisoning. It  would be of 
advantage to these animals if endogenous cytochrome P-450 could metabolise to 
some extent, this toxic chemical suddenly added to their environment, until 
induced forms of cytochrome P-450 are capable of metabolising this compound 
more effectively.
Sex and age differences in the levels of constitutive forms of 
cytochromes P-450 have been documented, such that much of the sex difference 
in hepatic drug metabolism can be attributed to the anabolic activity of 
androgens to promote the biosynthesis of select isoenzymes of cytochrome P-450 
(Kato and Kamataki, 1982; Rambaugh et al 1984). Conversely, oestrogen 
treatment has been shown to reduce the specific content of hepatic cytochrome 
P-450 in rats and inhibit microsomal monooxygenase activity (El Defrawy et al
1974). In addition, a complete disappearance of a sex difference in some 
monooxygenase activities has been reported in old age, whereas the activities 
were more than several-fold higher in young males than in young females. It  has 
been proposed that these age-associated alterations in relative abundance of 
multiple species of cytochrome P-450 in male rat liver microsomes were the 
major cause of alterations in monooxygenase activity (Fujita et al 1985). In 
addition to age and sex differences in drug metabolism, multiple genetic 
polymorphisms of oxidative metabolism in humans have been shown to contribute 
to wide inter-individual variations observed in drug elimination kinetics and in 
the response to the pharmacological and toxic effects of therapeutic agents (Idle 
and Smith, 1979; Eichelbaum, 1982). The genetic polymorphism of debrisoquine 
4-hydroxylation is the most extensively studied inherited deficiency of oxidative 
drug metabolism. Investigations have shown that the formation of a major 
urinary metabolite is under the control of a single autosomal genetic locus, and 
that deficiency of debrisoquine hydroxylation is an autosomal recessive tra it 
(Price-Evans et al 1980). Different hepatic cytochrome P-450s are involved in 
normal and debrisoquine hydroxylation deficient people (Distlerath et al 1985). 
I t  therefore does not seem unreasonable to speculate that genetically-conferred 
warfarin-resistance in the house mouse may also be due to the presence of 
different cytochrome P-450 form(s) or variations in the concentration of specific
constitutive isoenzymes, so causing the increased stereospecific plasma 
elimination of S(-) warfarin in warfarin-resistant females (Chapter 4, Section
4.4.).
Numerous reports have indicated that identification of the specific 
warfarin metabolites formed in microsomal incubations may be useful diagnostic 
aids for the assessment of functional cytochrome P-450 isozyme contributions to 
observed microsomal activities, since the relative formation of R(+) and S(-) 
metabolites is altered differentially in hepatic microsomes by inducing agents 
(Kaminsky et al 1979; Porter et al 1981; Guengerich et al 1982). In this way, 
warfarin has been used to probe the heterogeneity of cytochrome P-450 in 
human, rat and mouse microsomal preparations (Kaminsky et al 1984; Heimark 
and Trager, 1985; Kaminsky et al 1984). In microsomes prepared from human 
liver, warfarin is metabolised in vitro to dehydrowarfarin and 4’-, 6 -, 7-, 8 - and 
10-hydroxywarfarin by cytochrome P-450 (Figure 5.1.) and the additional fact 
that warfarin metabolism is stereoselective has been used as the basis for 
evaluating similarities between cytochrome P-450 isozyme compositions. The 
same metabolites of warfarin have been detected subsequent to in vitro 
microsomal metabolism incubations with warfarin in rats, rabbits and mice. The 
mechanism of warfarin hydroxylation by cytochrome P-450 was thought to 
involve the direct epoxidation of the aromatic ring by an oxygen atom to yield an 
arene oxide which was subsequently rearranged to a phenol (Tomaszewski et al
1975). However, more recently Bush and Trager (1982) have shown that, 
contrary to expectation, the formation of the 7-hydroxy metabolite which 
corresponded to meta hydroxylation appeared to be distinct from pathways which 
lead to the 6 -and 8 -(ortho and para) hydroxywarfarins. Meta-hydroxylation of 
warfarin was thought to proceed by an addition rearrangement pathway via a
tetrahedral intermediate which was subsequently rearranged to the phenol. 
Speculation as to the preferred solution conformation of warfarin in the lipid 
environment of the active site of cytochrome P-450 was evaluated by Heimark 
and Trager (1984) since warfarin exists in solution in a tautomeric equilibrium of 
an open side-chain keto form (Figures 5.2.), a) and a diastereomeric pair of ring- 
closed hemiketals, b) on the basis of the above results, the hemiketal was 
proposed as the preferred conformation at the active site of cytochrome P-450.
Thus knowing the possible sites of cytochrome P-450-catalysed 
hydroxylation of warfarin, and the mechanisms whereby these metabolites may 
be formed, the differential stereo- and regio-selective warfarin metabolism may 
be examined. The differences between species, strains and organs of 
differentially-induced cytochrome P-450s may be discussed in detail, 
exemplifying the heterogeneity of cytochrome P-450 isoenzymes.
Although there are reports that human liver cytochrome P-450 has been 
partially purified in several laboratories (Beaune et al 1979; Erickson and 
Bbsterling, 1981; Kamataki et al 1979; Kitada and Kamataki, 1979), it was only 
with the quite recent purification of 6  different cytochrome P-450 isozymes 
from the livers of 4 organ donors (Wang et al 1983) that the multiplicity of 
human cytochrome P-450 was confirmed at the biochemical level. These 6  
isoenzymes probably do not represent the total pool of human liver cytochrome 
P-450s and the extent of the multiplicity of this pool is unknown. The 
metabolism of warfarin by human hepatic microsomes showed stereoselectivity 
in that 41-  and 7-hydroxywarfarin productions were significantly greater for the 
S(-) warfarin enantiomer. A purified human liver isozyme which yielded 6 R- 
hydroxywarfarin was arbitrarily named P-450^, while 7S-hydroxywarfarin was
also produced by this isozyme as well as by P-450g. The 6 R- and 75-
hydroxywarfarin metabolites were the major products of R(+) and S(-) warfarin 
metabolism in the majority of the liver microsomal preparations investigated, 
indicating that P-450y and P-450g occurred in all microsomal preparations. 
Kaminsky et al (1984) also showed that P-450,. yielded lOR-hydroxywarfarin and 
4’S-hydroxywarfarin as major and minor metabolites respectively. P-4502 and P- 
450^ also primarily formed lOR-hydroxywarfarin but at least 2-fold slower 
formation rates and did not yield 4'S-hydroxywarfarin. In general, the majority 
of human microsomal preparations investigated showed similarity in cytochrome 
P-450 isozyme compositions, based on the metabolism of warfarin. Thus, 
knowledge of the hepatic cytochrome P-450 isozyme composition, and of relative  
isozyme concentrations of an individual, would provide a valuable predictor of 
the potential responses of that individual to therapeutic drugs, chemical
carcinogens and environmental pollutants.
In the rat similar studies have shown regio- and stereoselective
differences in warfarin metabolism by different cytochrome P-450 forms, but in 
addition, differential inducibility has allowed further insight into the variability 
of the cytochrome P-450 isozyme compositions. Marked differences have been 
shown by Kaminsky, Fasco and Guengerich (1979 and 1980) between liver 
microsomes from uninduced, phenobarbitone-induced and 3-methylcholanthrene- 
induced rats. Thus, the former appeared particular active in 7-hydroxylating 
R(+) warfarin, while the latter were even more active in 8 -hydroxylating R(+) 
warfarin. One form of cytochrome P-450 isolated from liver microsomes of 
untreated rats (UT-A) appeared highly selective for the 6 -, 7- and 41- positions 
for which stereoselectivity was low, and for the 9- position with high
stereoselectivity. Cytochrome P-450-UT-C displayed comparable selectivities
but was universally less active than the UT-A  form. Various forms of 
cytochrome P-450 have also been isolated from liver microsomes of 
phenobarbitone, 3-methylcholanthrene, 3-naphthoflavone (BNF) and 
pregnenolone 16-a-carbonitrile (PCN) treated rats, and impressively large 
functional differences have been uncovered. The major warfarin metabolites 
associated with these purified cytochrome P-450 isozymes were:- P-450pg_g, R- 
4'-hydroxywarfarin; P-450g^p._g, R -6 -, R -8 -  and S-6 -hydroxywarfarin; P-450pg_
C, S-7-hydroxywarfarin; and P ^ O p E /p c N -E ’ R_1 0 “hydroxywarfarin (Guengerich 
et al 1982). The same authors have also compared different forms of liver, 
kidney and lung microsomal cytochrome P-450 by stereoselective and 
regioselective warfarin metabolism, concluding that warfarin was a poor 
substrate for cytochrome P-450 of control rat kidney and lung microsomes 
compared with the liver, phenobarbitone pretreatment induced different forms 
of cytochrome P-450 in liver, kidney and lung, and that 3-methylcholanthrene 
induced forms of cytochrome P-450 in all 3 tissues which were the same. These 
studies emphasised the complexity of the problem of dealing with multiple forms 
of membrane-bound cytochrome P-450 and showed that almost every liver 
microsomal monooxygenase activity towards a particular compound appeared to 
be distinctly different from each of the others and most likely represented the 
aggregated activity from numerous forms of cytochrome P-450.
In general, more research effort has been directed towards an 
understanding of the genetic aspects of cytochrome P-450 induction in mouse 
liver, rather than the purification and characterization of the isoenzymes 
present. Assessment of the cytochrome P-450 isozyme contents of DBA/2 (D2) 
and C57BL/6 (B6 ) mice untreated and treated with phenobarbitone (PB), 
pregnenolone 16-a-carbonitrile (PCN) or 3-naphthoflavone (BNF) has been
mainly based on comparisons with data obtained from rats, relating to the 
regioselectivity and stereoselectivity of warfarin metabolism (Kaminsky et al
1984). Untreated D2 or B6  mice had similar hepatic compositions of cytochrome 
P-450 isozymes to one another, both strains contained an isozyme very similar to 
rat P-450 UT-A. Phenobarbitone or pregnenolone 16-a-carbonitrile induction of 
the two strains yielded isozymes which were the same, or very similar, to rat P- 
4 5 0 ^ _ ^ , P-450pg_g, P-45C)pg_£ and P"^0pB/pQsj_^ isozymes. The stereo-and 
regioselectivity in the metabolism of warfarin by those isozymes have been 
shown previously. Mouse strains D2 and B6  had similar isozyme compositions 
when treated with phenobarbitone or pregnenolone 16-a-carbonitrile, but 
isozymes induced by phenobarbitone differed from those induced by pregnenolone 
16-a-carbonitrile. 8 -Naphthoflavone treatment of the D2 mice was without 
effect, but the B6  mice produced an isozyme(s) which was different from rat P- 
450bnf b> the major 8 -naphthoflavone induced isozyme in rat liver.
In summary, warfarin appears to be a substrate for almost all of the 
cytochrome P-450 isozymes isolated and purified up to the present time from  
human, rat or mouse liver, and yields specific multiple metabolite patterns. 
Thus, with a single substrate many of the species, strain and organ differences of 
cytochrome P-450s can be investigated. This eliminates the problems of 
assessing data derived with multiple substrates having varying solubilities and 
physicochemical characteristics and allows such direct comparisons between 
species as those outlined above. In the present study warfarin metabolism, as 
well as acting as a probe for multiple cytochrome P-450 forms after induction 
with phenobarbitone, 8 -naphthoflavone and clofibrate, will serve as a measure of 
the inherent detoxification capacities of both warfarin-susceptible LAC-grey and 
warfarin-resistant HC mice. In addition, the efficacy of warfarin as an inducer 
of cytochrome P-450 forms will be studied in order to correlate toxicity data 
with hepatic warfarin cytochrome P-450 levels.
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EXPERIMENTAL OBJECTIVES
To determine whether, on repeated dosing of relatively high doses of 
warfarin (64mg/kg/day for 3 days), induction of cytochrome P-450 occurs 
in LAC-grey mice, so explaining their lowered susceptibilities to 
warfarin at high warfarin doses observed in Chapter 3.
To probe the heterogeneity of cytochrome P-450 forms present in both 
male and female warfarin-susceptible and warfarin-resistant mouse 
strains by pretreatment with the cytochrome P-450 inducers 
phenobarbitone, 3 -naphthoflavone and clofibrate.
5.3. EXPERIMENTAL DESIGN
The doses of 4 and 64mg/kg/day were chosen since in the LAC-grey 
mice, toxicity levels decreased at the higher dose compared with the lower dose 
in studies designed to investigate the hypoprothrombinaemic response to 
warfarin (Chapter 3).
The cytochrome P-450 inducers, phenobarbitone, 3-naphthoflavone and 
clofibrate were chosen because they have been shown to differentially induce 
isozymes of cytochrome P-450 in various species, strains and organs.
In all cases, hepatic microsomal metabolism studies were carried out 
using separate R(+) and S(-) enantiomers of warfarin added to the incubation 
mixture.
Statistical analyses were carried out comparing each treatm ent with 
untreated hepatic microsomal metabolism rates of the same sex and strain of 
mice.
5.4. RESULTS
5.4.1. Studies on the Hepatic Microsomal Metabolism of Warfarin Enantiomers
A fter Pretreatment of Warfarin-Susceptible and Warfarin-Resistant 
Mice with 4 or 64mg/kg/day Racemic Warfarin, Phenobarbitone, 3- 
Naphthoflavone or Clofibrate
The overall cytochrome P-450 concentrations in hepatic microsomal 
preparations from pools of 10 male and female, warfarin-susceptible LAC-grey  
or warfarin-resistant HC mice untreated, or treated with phenobarbitone (PB), 
3-naphthoflavone (BNF) or clofibrate (CF) are presented in Table 5.1. While PB 
and BNF increased the overall cytochrome P-450 contents to similar extents in 
the 2 strains and sexes of mouse, CF administration showed no increase in the 
enzyme concentration in either strain. Similarly 64mg/kg racemic warfarin 
increased the specific contents of microsomes from all strains and sexes of mice 
to the same extent, whereas 4mg/kg racemic warfarin increased the 
concentration of cytochrome P-450 differentially in the males and females of 
the two strains, although all levels were greater than those of untreated mice. 
Overall cytochrome P-450 concentrations in untreated, saline, corn-oil or acacia 
gum-treated animals were the same as were their metabolic profiles after  
incubation with S(-) or R(+) warfarin, thus data for only untreated mice is 
presented here.
Untreated Mice
For untreated mice, the hepatic microsomal regio- and 
stereoselectivities will be discussed with reference to the differences between 
the 2 strains, by comparing male warfarin-susceptible LAC-grey mice with male 
warfarin-resistant HC mice, and the same for females. Also metabolism of
warfarin within each strain will be discussed, comparing males with females of 
each strain separately (Figure 5.3.)
Hepatic microsomal preparations from both mouse strains and sexes 
exhibited the same overall stereoselectivities for R(+) warfarin, with this 
enantiomer being favoured by approximately 9-fold in male mice (Figure 5.3.). 
All 4 groups of mice showed different Tegioselectivities for R(+) warfarin, such 
that 6 -  and 7-hydroxywarfarin in the HC female, 6 -hydroxywarfarin in the HC 
male and LAC-grey female, and 7-hydroxywarfarin in the LAC-grey male were 
the major metabolites. Metabolites of S(-) warfarin were not detected in 
experiments using preparations from female mice of both strains, whereas in the 
microsomes of males of the 2 strains 4’, 7- and 8 -hydroxywarfarins were formed. 
The overall rate of metabolism of R(+) and S(-) warfarin, based on protein and 
cytochrome P-450 concentrations was 2.5-2.6 fold higher for microsomes from 
males and females of the HC than the LAC-grey mice. These figures are 
exemplified by significant increases in 4', 6 - and 8 -hydroxy warfarin in the male 
and significant increases in 6 -, 7- and 8 -hydroxywarfarin in female HC mice 
compared with their warfarin-susceptible LAC-grey counterparts (Figure 5.3.). 
The male and female HC warfarin-resistant mice therefore had the capacity for 
a significantly greater (p<0.001 and p<0.01 respectively) rate of microsomal R(+) 
warfarin metabolism than did LAC-grey warfarin-susceptible mice. In addition 
to this strain difference, male warfarin-resistant and warfarin-susceptible mice 
showed overall rates of metabolism which were 2 -fold higher than those of their 
female counterparts showing that a sex difference in hepatic microsomal 
metabolism also occurred in untreated mice.
Figure 5.3. Hepatic Microsomal Metabolism of Warfarin in Untreated Mice
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Table 5.1.
Specific Contents for Microsomal Preparations From Warfarin-Susceptible and 
Warfarin-Resistant Mice O ther Untreated or Treated with Warfarin, 
Phenobarbitone, g-Naphthoflavone or Clofibrate
Specific Content (nmoles Cytochrome P-450/mg Protein)
LAC LAC HC HC Absorption
0 * 0  0 * 0
» "** Maximum (nm)
Untreated 0.36 0.28 0.33 0.32 (450.0)
4mg/kg Warfarin 0.48 0.76 0.69 0.47 (450.0)
64mg/kg Warfarin 0.65 0.56 0.58 0.60 (450.1)
Phenobarbitone 0.92 1.44 0.90 1.23 (450.1)
6 -Naphthoflavone 0.92 1.09 1.09 1.01 (448.0)
Clofibrate 0.38 0.37 0.38 0.34 (451.9)
Warfarin-Treated Mice (4mg/kg/day)
Hepatic microsomal preparations from male and female mice of both 
strains exhibited the same overall stereoselectivity for R(+) warfarin metabolism 
with this enantiomer being favoured by approximately 9-11 fold (Figure 5.4.). 
The regioselectivities for R(+) warfarin were slightly different for the 2 strains 
and sexes such that in the microsomes of the HC male and LAC-grey female, 4'- 
hydroxywarfarin was the major metabolite, whilst 6 -hydroxy- and 7- 
hydroxywarfarin were the major metabolites of HC female and LAC-grey male 
microsomal preparations respectively. Compared with untreated mice of the 
same strain and sex, a remarkable increase (p<0.001) in the rate of both R(+) and 
S(—) warfarin metabolism was seen for the HC male mice (Figure 5.3.), no 
significant change was noted in the HC female after 4mg/kg/day racemic 
warfarin treatment. However, in LAC-grey mice small changes (p<0.01) in the 
formation of 6 - and 8 -hydroxy R(+) warfarin and 4*-hydroxy R(+) warfarin were 
seen in males and females respectively, as compared with untreated microsomal 
preparations.
Warfarin-Treated Mice (64mg/kg/day)
Hepatic microsomal preparations from all sexes and strains of mice 
again showed the same overall stereoselectivies for R(+) warfarin metabolism 
(Figure 5.5.) with this enantiomer being favoured by approximately 10-fold. The 
regioselectivities for R(+) warfarin metabolism were similar within each strain; 
4'-hydroxywarfarin being the major metabolite of microsomes from HC mice, 
and 6 -hydroxywarfarin being the major metabolite in microsomal incubations of 
LAC-grey mice. Significant increases (either p<0.001 or p<0.005) in the rates of 
formation of hepatic microsomal 4'- 6 -, 7-, and 8 -hydroxy R(+) warfarin of both 
male and female LAC-grey mice were seen, coupled with significant (p<0.001)
increases in the production of 41-  and 7-hydroxy S(-) warfarin metabolites in 
preparations from the LAC-grey male. HC mice showed significant changes in 
41-, 6 - and 8 -hydroxy R(+) warfarin production from microsomal preparations, 
being increases of the HC female and decreases of the HC male, compared with 
untreated mice. The female HC mice microsomal metabolism rates of 41- and 7- 
hydroxy S(-) warfarin were increased from non-detectable levels in untreated 
mice.
Phenobarbitone-Treated Mice
In all sexes and strains of mice, the overall stereoselectivity for R(+) 
warfarin hepatic microsomal metabolism was approximately 7-11 fold greater 
than that for S(-) warfarin (Figure 5.6.). The regioselectivities were very similar 
for males and females of the HC strains, which showed significant (p<0.001) 
increases in 4'-hydroxy R(+) warfarin as the major metabolite and smaller 
increases in 8 -hydroxy R(+) warfarin in female and 7- and 8 -hydroxy R(+) 
warfarin in male HC mice. In addition S(-) warfarin metabolism was increased 
for 41- and 7-hydroxywarfarin in HC females, whilst remaining unchanged in 
males. For LAC-grey mice the regioselectivity was slightly different between 
the sexes after phenobarbitone treatment. Significant (p<0.001) increases in 4’-, 
6 -, 7- and 8 -hydroxy R(+) warfarin were seen in both males and females, the 
levels of each metabolite being the same in females, whilst the rate of 4'- 
hydroxy metabolite production was approximately twice that of the other 
metabolites in the male. The production of all 4 metabolites of warfarin  
previously mentioned was increased in female LAC-grey mice from non- 
detectable levels in untreated animals. An increase (p<0.005) in 4'-hydroxy S(-) 
warfarin was shown for LAC-grey males (Figure 5.6.).
g-Naphthoflavone-Treated Mice
Hepatic microsomal preparations from both strains and sexes of mice 
exhibited the same overall stereoselectivity for R(+) warfarin with this 
enantiomer being favoured by approximately 8 -fold. Only in HC male 
microsomal preparations were S(-) warfarin metabolites (6 - and 7- 
hydroxywarfarin) produced, the levels being non-detectable in the other 3 groups 
of mice. The regioselectivity of males and females of both strains of mice were 
very similar with 6 -  and 7-hydroxy R(+) warfarin being produced in 
approximately equal amounts. $-Naphthoflavone treatment led to significant 
(p<0.001) decreases in the production of 41, 6 - and 7-hydroxy R(+) warfarin in 
both male and female HC hepatic microsomes (Figure 5.7.) as well as significant 
decreases in 7- and 8 -hydroxy R(+) warfarin in LAC-grey females, and in 4'- and 
6 -hydroxy R(+) warfarin in LAC-grey males.
Clofibrate-Treated Mice
Again, hepatic microsomal preparations from both strains and sexes were 
stereoselective for the R(+) enantiomer of warfarin (approximately 3-fold). The 
regioselectivities of males and females within the same strain were similar 
(Figure 5.8.). 6 -Hydroxy R(+) warfarin was the major metabolite in HC mice, 
and 7- and 8 -hydroxy R(+) warfarin were produced as major metabolites by LA C - 
grey preparations. Clofibrate treatment produced significant decreases in the 
production of 7-hydroxy R(+) warfarin and 7-and 8 -hydroxy R(+) warfarin in 
female and male LAC-grey microsomal preparations respectively. Similarly, in 
HC mice significant decreases in the microsomal production of 4'-hydroxy R(+) 
warfarin from females and 4'-, 6 - and 8 -hydroxy R(+) warfarin from males were 
seen (Figure 5.8.).
5.8. DISCUSSION
The data presented in this Chapter will be discussed with respect to 
three specific areas of investigation. These are as follows. Firstly, does 
increased warfarin metabolism as a result of cytochrome P-450 induction, 
account for decreased toxicity and anticoagulant action on repeated 
administration of high doses of warfarin in warfarin-susceptible LAC-grey mice? 
(Chapter 3, Section 3.5.). Secondly, can the increased plasma elimination of S(-) 
warfarin in HC warfarin-resistant female mice (Chapter 4, Section 4.4.) be 
attributed to an increased hepatic metabolism of the enantiomer by cytochrome 
P-450s in untreated mice?. Thirdly and finally, the data obtained from hepatic 
microsomal metabolism studies after treatment of mice with phenobarbitone, (3- 
naphthoflavone or clofibrate will be assessed with regard to evaluating the 
cytochrome P-450 isozyme compositions of the two mouse strains.
Addressing the first of these questions, the stereo- and regioselectivities 
of warfarin metabolism were investigated after the pretreatment of mice with 
either 4mg/kg/day or 64mg/kg/day racemic warfarin orally for 3 days. In Table
3.1. toxicity data in LAC-grey mice at these dose levels showed that in both 
males and females at the higher dose of 64mg/kg/day, less toxicity via 
anticoagulation was effected than at the lower dose of 4mg/kg/day it was 
proposed that this phenomenon may have been due to high doses of warfarin 
causing induction of cytochrome P-450 levels, allowing these mice to detoxify 
the warfarin at a faster rate, thereby reducing their susceptibility to 
hypoprothrombinaemia. Data obtained from hepatic microsomal incubations 
with warfarin enantiomers is presented in Figures 5.3.-5.5. Comparing untreated 
mice, and mice treated with 4 or 64mg/kg/day racemic warfarin in each of the
sexes and strains investigated (Figures 5.3.-5.5.), it became apparent that in 
LAC-grey mice, as the dose of warfarin increased, so did the rate of warfarin 
metabolite production in microsomal preparations from males and females. 
Increases in hepatic microsomal metabolism reached the level of significance 
such that p<0.01 at 4mg/kg/day warfarin; the same figure at 64mg/kg/day being 
p<0.001. Induction of cytochrome P-450 is therefore a likely event on repeated 
administration of warfarin, especially at high doses in the LAC-grey warfarin- 
susceptible mice. In HC warfarin-resistant mice, induction of hepatic 
microsomal warfarin metabolism was also seen after treatment of males and 
females with warfarin. Sex-dependent differences were noted, however, in that 
induction of metabolism at 4mg/kg/day was effected in males, whilst this dose 
had no observable effect in females. Similarly, after 64mg/kg pretreatment, 
hepatic microsomal preparations from HC females showed increased warfarin 
metabolic rates, but levels were decreased in those from males (Figures 5.3.- 
5.5.). In LAC-grey and HC mice, treatment with 4 or 64mg/kg/day induced 
cytochrome P-450 levels differentially. This statement is corroborated by the 
fact that the specific contents of the hepatic microsomal preparations prepared 
from these mice were increased compared with untreated mice (Table 5.1.). The 
enzyme-inducing effects of coumarin compounds in mice has been investigated 
previously by Ritschel and Li-Hwa Lee (1977). These authors showed in vivo that 
the sodium pentobarbitone sleeping time of mice was significantly reduced by 
several coumarin compounds: coumarin, 4-hydroxycoumarin, 7-hydroxycoumarin, 
acenocoumarol, phenprocoumon and warfarin. The largest enzyme-inducing 
effect was seen with warfarin at a dose of lOmg/kg administered 
intraperitoneally daily for 5 days. Further to the findings of this study, Kling et 
al (1982); Legrum et al (1984) and Kling et al (1985) have shown that warfarin 
was able to cause induction of the microsomal mixed-function oxidase system as
characterised by increased microsomal protein and cytochrome P-450 content as 
well as proliferation of endoplasmic reticulum and enzyme kinetic data. By 
comparing hepatic microsomal protein patterns by PAGE gel electrophoresis 
before and after partial purification, the above authors concluded that warfarin 
elicited phenobarbitone-like induction of the hepatic monooxygenases in mice at 
a daily dose of 120mg/kg warfarin administered intraperitoneally for 3 days. The 
data presented in this Chapter is not inconsistent with these reports in that the 
maxima of absorption of the reduced carbon monoxide spectra of hepatic 
microsomal preparations after warfarin pretreatment were found to be 450.0 and 
450.1nm at the 2 doses of 4 and 64mg/kg racemic warfarin for all sexes and 
strains of mice. A similar figure of 450.1nm was found after treatment of both 
HC and LAC-grey mice with phenobarbitone (Table 5.1.).
The fact that although after treatment with warfarin, hepatic 
microsomal preparations from male and female LAC-grey and HC mice showed 
the same stereoselectivities, regioselectivities in metabolism of warfarin were 
different in LAC-grey and HC mice, indicating that after warfarin treatment the 
cytochrome P-450 isozyme compositions of the 2 strains were not the same. In 
general, warfarin treatment increased the production of 4'-hydroxy R(+) and S(-) 
warfarin to the greatest extent in HC males and females compared with 
untreated mice. Conversely, in LAC-grey mice 6 -, 7- and 8 -hydroxy R(+) 
warfarin and 4'-hydroxy S(-) warfarin were preferentially increased after 
warfarin pretreatment. The similar regioselectivities shown by males and 
females within the same strain indicated that the hepatic cytochrome P-450 
isozyme complement within the same strain was similar in males and females. 
One explanation for the differences between the LAC-grey and HC strains 
relates to a phenomenon discussed in detail in Chapter 4, Section 4.5. where it
was indicated that the exact gene sequence of segments of chromosome 7 
between the warfarin-resistant gene and several marker genes in HC mice was 
unknown (Wallace and MacSwiney, 1976). It  is possible that differential 
cytochrome P-450 isozyme gene complements are present in this region of 
chromosome 7 and are responsible for the different regioselectivities in warfarin 
metabolism seen in LAC-grey and HC mouse strains. The omission of one gene 
coding for induction of a particular isozyme of cytochrome P-450 may be 
sufficient to cause the observed regioselective differences in warfarin 
metabolism. Chromosome 7 in the mouse has been reported to contain not only 
the major warfarin-resistance gene, War, but also the murine Coh locus, which 
controls the induction of liver microsomal coumarin 7-hydroxylase activity by 
phenobarbitone (Kaipainen et al 1984). Therefore, the phenomenon of a gene 
such as this being present in one strain of mice and not another, so causing 
differences in hepatic microsomal metabolism, is not uncommon.
In summary, warfarin has been shown to cause induction of microsomal 
cytochrome P-450s effective in the metabolism of warfarin in both LAC-grey 
and HC mouse strains. This increased metabolism possibly accounted for 
decreased toxicity levels observed at high warfarin doses in LAC-grey mice 
(Table 3.1.). It  is postulated that the 2 strains of mice, warfarin-susceptible and 
warfarin-resistant, have different hepatic microsomal complements of 
cytochrome P-450 isozymes, accounting for the different regioselectivity in 
warfarin metabolism seen in these mouse strains.
The second area of investigation undertaken in this study was to probe 
the hepatic microsomal metabolism of warfarin in both male and female 
warfarin-susceptible and warfarin-resistant mice in an attempt to correlate the
in vivo increased plasma elimination of S(-) warfarin in HC females (Chapter 4, 
Section 4.4.) with increased metabolism of this enantiomer by hepatic cytochome 
P-450s of untreated mice. In this respect, it can be seen that although the 
regioselectivity of warfarin metabolism was different in male and female 
warfarin-susceptible LAC-grey and warfarin-resistant HC mice, the 
stereoselectivity for R(+) warfarin was effective in all 4 groups of mice (Figure
5.3.). In females of both strains of mice, S(-) warfarin metabolites were not 
produced in quantities sufficient to be detected. It  must be concluded, 
therefore, that increased metabolism of S(-) warfarin by hepatic cytochrome P- 
450s was not responsible for the greater plasma elimination of this enantiomer 
shown in Chapter 4, Figure 4.3. An interesting trend, however, was shown in the 
hepatic microsomal metabolism of untreated mice. Both male and female HC  
warfarin-resistant mice showed significantly greater levels of R(+) warfarin 
metabolite production than their warfarin-susceptible counterparts (Figure 5.3.). 
Clearly, this factor would contribute in part to the fact that warfarin-resistant 
mice show decreased hypoprothrombinaemic responses to warfarin 
administration. Although R(+) warfarin produced a smaller anticoagulant action 
than it ’s epitope, it  still can effect hypoprothrombinaemia (Chapter 3, Section 
3.4.2.).
The lack of correlation of plasma elimination in vivo and warfarin 
metabolism in vitro of S(-) warfarin in the warfarin-resistant HC female may be 
explained in a variety of ways. For example, the hepatic microsomal metabolism 
patterns obtained in vitro may not accurately reflect the hepatic metabolism of 
warfarin in vivo. In addition, since microsomal warfarin incubations were 
carried out using separate R(+) and S(-) enantiomers of the compound, the effect 
of each enantiomer on the metabolism of the other could not be assessed. The in
vivo studies presented in Chapter 4 were undertaken using administration of 
racemic warfarin, and R(+) and S(-) enantiomers of warfarin were assayed in the 
same sample. Extrapolations from in vitro and in vivo situations must always be 
made with great care, much as extrapolation from one species or strain to 
another cannot necessarily be made with any particular degree of accuracy. 
However, taking these factors into consideration, if  an increased hepatic S(-) 
warfarin metabolism in HC females was occurring, it  would be expected that a 
2 0 -fold increase in plasma clearance, accompanied by a 16-fold decrease in half- 
life would have been expressed as a significant increase in S(-) warfarin 
metabolism, even if  this increase were not of the same order of magnitude as the 
observed plasma clearance. Therefore, it seems unlikely that increased hepatic 
microsomal S(-) warfarin metabolism was responsible for the greater plasma 
clearance of this enantiomer in HC female mice.
Since only hepatic microsomal metabolism was investigated, the 
possibility that extra microsomal (ie, mitochondrial or cytosolic), or extrahepatic 
warfarin metabolism may be responsible for the observed effect, cannot be 
ignored. The proposed pleiotropism in the biochemical expression of the major 
warfarin-resistance gene, War, may be manifest as a difference in kidney, lung 
or other organ metabolism of S(-) warfarin, in both male and female warfarin- 
resistant mice. It  is proposed, however, that the effect is modified in the male, 
so that increased plasma S(-) warfarin clearance is observed only in the female. 
Different forms of liver, kidney and lung microsomal cytochrome P-450 have 
been shown after phenobarbitone or 3-methylcholanthrene treatm ent in rats, as 
probed by immunological inhibition of the regio- and stereoselective metabolism 
of warfarin (Kaminsky et al 1979). Although in these studies, warfarin was a 
poor substrate for cytochrome P-450 of control rat kidney and lung microsomes
relative to rat liver microsomes, phenobarbitone treatment induced cytochrome 
P-450s which were essentially different in liver, lung and kidney microsomes. 
The cytochrome P-450 isozyme complements of kidney and lung microsomes 
prepared from warfarin-resistant HC mice may differ from those of LAC-grey 
mice such that the above effect on S(-) plasma warfarin clearance was observed.
An alternative explanation for this phenomenon is based on the 
knowledge that the plasma clearance of a compound does not necessarily reflect 
the metabolism of that compound. For example, decreased plasma protein 
binding or increased excretion may also produce an increase in plasma clearance 
values. Such may be the case for warfarin. Since in vivo pharmacokinetic 
parameters were determined from the plasma concentration time profiles of R(+) 
and S(—) enantiomers of the parent compound alone, only an increased excretion 
of unchanged or Phase II conjugated parent compound would be reflected in an 
increased plasma elimination such as that seen in the HC female. In other 
words, an increase in the excretion of metabolites, or conjugates of metabolites, 
of either warfarin enantiomer would have no effect on the measured plasma 
concentration time profiles exhibited in Figures 4.1.-4.4. Further studies will be 
discussed in Chapter 6 , where excretion data for R(+) and S(-) warfarin 
enantiomers in warfarin-susceptible LAC-grey and warfarin-resistant HC mice 
will be presented, and in Chapter 7, where plasma protein binding of warfarin
enantiomers in LAC-grey and HC mice is investigated.
«
Returning to the data presented in this Chapter, hepatic microsomal 
metabolism studies after treatment of mice with phenobarbitone, f3- 
naphthoflavone or clofibrate will be assessed with regard to evaluating the 
cytochrome P-450 isozyme compositions of warfarin-susceptible LAC-grey and
warfarin-resistant HC mice in order to identify any differences which may occur 
between the 2 strains (Section 5.4. and Figures 5.6.-5.8.).
The metabolism of warfarin has been used by several groups of workers 
in order to probe the complexities of cytochrome P-450 isozyme multiplicity 
(Kaminsky et al 1984; Heimark and Trager, 1985; Rettie et al 1985). Substrate 
stereo- and regioselectivities of microsomal-bound cytochrome P-450s in the 
metabolism of warfarin have been used to partially predict microsomal 
cytochrome P-450 compositions by comparison with regio- and 
stereospecificities of highly purified cytochrome P-450 isozymes. The excellent 
correlations between the rates of formation of warfarin metabolites in various 
microsomal preparations and the presence of the corresponding isozymes in the 
same preparations indicated that warfarin metabolism had potential for assessing 
part of the functional cytochrome P-450 isozyme composition of tissues. In 
contrast, many common catalytic assays used in studying cytochrome P-450- 
related activity were not reliable indicators of changes in concentrations of 
individual isozymes because of the lack of substrate specificity for catalysis by 
individual cytochrome P-450s. A functional characterization of cytochrome P- 
450 forms has thus been allowed using a tool the multiple aspects of structural 
selectivity in warfarin metabolism. In this way, the microsomal metabolism of 
warfarin in phenobarbitone-, 6 -naphthoflavone- and clofibrate-treated warfarin- 
susceptible and warfarin-resistant male and female mice will be discussed and 
the relevance of these findings related to warfarin microsomal metabolism in 
untreated mice.
Considering treatment of mice with phenobarbitone detailed analysis of 
the regio- and stereoselectivities is presented in Section 5.4. and Figure 5.6. The
most striking difference in metabolite production in warfarin-susceptible mice 
was a large increase in 4’-hydroxy R(+) warfarin in LAC-grey males which was 
not seen specifically in females, where all hydroxy metabolites were produced in 
equal quantities. The regioselectivity of S(-) warfarin metabolism was however 
similar in both sexes. A sex-dependence in microsomal cytochrome P-450 
induction by phenobarbitone therefore appeared to be in operation in LAC-grey 
mice. The same was not true for warfarin-resistant HC mice, where the regio- 
and stereospecificities were the same in males and females, but differed from 
either sex of the LAC-grey mice. A fter phenobarbitone treatment of rats, 
Kaminsky et al (1983) showed that purified isozymes of cytochrome P-450 were 
associated with major metabolites: P-450pg g, 4'-hydroxy R(+) warfarin, P- 
450pB q> 7-hydroxy S(-) warfarin and P-450pg ^  which did not metabolise 
warfarin to any great extent. Similar studies of microsomal warfarin 
metabolism in C57BL/6 (B6 ) and DBA/2 (D2) mice (Kaminsky et al 1984) using 
antibodies raised to the major inducible forms of rat cytochrome P-450 
isozymes, showed relatively higher formation rates of R(+) 10-, 7-, 4’-  and 6 - 
hydroxywarfarins catalysed by microsomes from phenobarbitone-treated mice 
were associated with the presence of cytochrome P-450 isozymes of P-450yy  
P-450pg g, P-4 5 Opg_0 , and £• Although the regioselectivities
were not the same in the strains of mouse used in the present study, one could 
speculate that in the warfarin-resistant mice after phenobarbitone-treatment, 
microsomal metabolism of warfarin which showed large increases in 4'- and 7- 
hydroxy R(+) and S(-) warfarin metabolite production may have been due to 
induction of cytochrome P-450 isozymes P-450pg g and P-450pg ^  respectively. 
In LAC-grey mice, different amounts of forms of cytochrome P-450s were 
responsible for warfarin metabolism after phenobarbitone treatment. In the 
female 41- 6 -, 7-and 8 -hydroxy R(+) and S(-) warfarin metabolites were increased
to the same extent as each other. Again, P-450pg g and P-450pg ^  may have 
been responsible for 4'-and 7-hydroxy R(+) warfarin, but 6 - and 8 -hydroxy R(+) 
warfarin are mainly produced by P -4 5 0 ^ p  g in the rat, although in mice 3 - 
naphthoflavone did not induce any cytochrome P-450 which was responsible for 
warfarin metabolism. Clearly phenobarbitone was able to induce a cytochrome 
P-450 similar to rat P - 4 5 0 g  in LAC-grey females and to a smaller extent in 
males, although in this sex, P-450pg g seemed to be the most active constituent 
of the microsomal preparation. Hepatic microsomal preparations from 
phenobarbitone-treated LAC-grey and HC mice exhibited similar regio- and 
stereoselectivity for warfarin metabolism with the exception of 6 - and 8 -hydroxy 
R(+) warfarin in LAC-grey mice. Thus, after phenobarbitone treatment the P- 
450 isozyme compositions of the 2 mouse strains were similar, with an additional 
isozyme thought to be present in LAC-grey hepatic microsomal preparations.
3-Naphthoflavone (3NF) treatment increased the overall cytochrome P- 
450 concentrations of the LAC-grey and HC mice, as shown by increased specific 
content values of microsomal preparations (Table 5.1.). Phenobarbitone 
treatment also showed the same effect, but the absorption maximum of the 
reduced carbon monoxide spectra after the 2  treatments were different, 
exhibiting values of 450.1nm and 448.0nm for phenobarbitone and $- 
naphthoflavone treatment respectively, indicating that the major isozymes of 
cytochrome P-450 induced by the 2 agents were different. Hepatic microsomal 
preparations from 8 -naphthoflavone-treated LAC-grey and HC mice (both males 
and females) exhibited similar regioselectivity and stereoselectivity for warfarin 
metabolism, thus indicating that after 8 -naphthoflavone treatment the 
cytochrome P-450 isozyme compositions of the 2 mouse strains were similar. 
Compared with untreated mice in all 4 groups studied, significant decreases in
the rate of R(+) warfarin metabolism were seen, indicating that the B- 
naphthoflavone inducible cytochrome P-450 isozymes did not metabolise 
warfarin. This contrasts sharply with the warfarin metabolism by microsomes 
from B-naphthoflavone treated rats, where 6 -  and 8 -hydroxy R(+) and 6 -hydroxy 
S(-) warfarin metabolites are rapidly formed specifically by P-450^jsjp g. 
However, Kaminsky et al (1984) showed that in B6  and D2 mice, treatment with 
B-naphthoflavone induced cytochrome P-450 isozymes which did not metabolise 
warfarin, in agreement with data presented here. Based on this data, it must be 
concluded that B-naphthoflavone induced rat and LAC-grey/HC mouse 
cytochrome P-450 isozymes are different.
Clofibrate (CF), like phenobarbitone, showed regioselectivity and 
stereoselectivity of warfarin metabolism that was different in the 2  strains of 
mouse studied. However, here the similarity in hepatic microsomal metabolism 
after treatment with these agents ends. Specific content values of microsomal 
preparations after clofibrate treatment were not increased over values obtained 
with untreated microsomes. Despite this fact, the absorption maxima of 
451.9nm showed that the major isozyme of cytochrome P-450 induced by this 
agent was different from untreated microsomes and preparations from 
phenobarbitone or B-naphthoflavone treated mice. C lofibrate-treated HC mice 
exhibited hepatic microsomal metabolite regio- and stereoselectivities which 
were very similar to that seen in untreated HC female mice (Figures 5.8. and
5.3.). Thus, the observed warfarin metabolism by microsomes from clofibrate- 
treated HC female mice must have been catalysed by other non-clofibrate 
inducible cytochrome P-450 isozymes since the metabolite profiles of clofibrate- 
treated and untreated HC female mice were similar. In the same way, untreated 
HC male mice must have non-clofibrate or B-naphthoflavone inducible
cytochrome P-450 isozymes, although the relative amounts/composition was 
different from that of HC females as judged by their different regioselective 
metabolite patterns (Figure 5.3.). Hepatic warfarin metabolism, after treatment 
of rats or mice with clofibrate, has not been reported until now, and so although 
highly purified cytochrome P-450 isozymes induced by this agent have been 
isolated (Tamburini et al 1984) the stereo- and regioselectivities of these 
isozymes for warfarin metabolism is not documented. However, the fact that 
clofibrate produced different metabolite patterns in LAC-grey and HC mice 
showed that the isozyme compositions in the two mouse strains was different 
after clofibrate treatment. In addition, the fact that clofibrate pretreatment 
decreased the levels of warfarin metabolites produced by hepatic microsomal 
preparations from all groups of mice, is consistent with data found in the rat. In 
the latter species, clofibrate induces cytochrome P-452 which does not readily 
metabolise drugs, but preferentially metabolises lauric acid (Tamburini et al 
1984).
With regard to warfarin-resistance, this study using selective inducers of 
specific cytochrome P-450 isozymes has indicated differences in the inducibility 
of these isozymes by phenobarbitone and clofibrate in LAC-grey and HC mice. 
Perhaps in the LAC-grey mice, the section of chromosome 7 which is different 
from that containing the major warfarin-resistance gene, War, and various 
marker genes, may contain a gene or genes coding for induction of different (or 
extra) cytochrome P-450 isozymes, so causing the different regioselectivities 
between the two strains after phenobarbitone and clofibrate treatments. 
Although this postulate is of interest with respect to the cytochrome P-450 
isozyme composition of hepatic microsomal preparations from warfarin- 
susceptible LAC-grey and warfarin-resistant HC mice, it is of no great 
significance in the explanation of the biochemical manifestation of War.
In untreated mice, 4 different regioselectivities of warfarin metabolism 
were observed for microsomal preparations of the 4 groups of mice examined 
(Figure 5.3.). In untreated mice, males and females of LAC-grey and HC mouse 
strains would appear to all have different cytochrome P-450 isozyme 
complements from one another, or different amounts of these isozymes. 
Whether this is a strain and sex difference or whether it is related to warfarin- 
resistance is not known at the present. Only by purifying the cytochrome P-450 
isozymes from these animals would this question be answered. Although this was 
a fascinating prospect, unfortunately, the subject area fell outside the scope of 
this thesis; which attempts to elucidate the biochemical manifestation(s) of the 
expression of the major gene, War, coding for warfarin-resistance in mice.
CHAPTER 6
U R IN AR Y AND FAECAL EXCRETION O f[ 1 4 c]-W A R FA R IN  IN  
WARFARIN-SUSCEPTIBLE LAC-GREY AND WARFARIN-RESISTANT HC MICE
6.1. INTRODUCTION
Excretion of drugs may occur via the urine, bile, faeces and/or 
respiratory gases. Warfarin and related compounds undergo extensive 
metabolism, as has been shown for mice in Chapter 5, thereby becoming more 
polar and more liable to be excreted, especially in the urine. Only very small 
amounts of warfarin have been reported to be excreted unchanged in the urine of 
humans, rats or rabbits (Koch-Weser and Sellers, 1971). This is due not only to 
the fact that warfarin is metabolised to a large degree, but also that the high 
degree of albumin binding protects the drug from glomerular filtration. 
Furthermore, any warfarin filtered is largely unionised in the normal urinary pH 
range, and is passively reabsorbed during concentration of the filtra te  in the 
renal tubules (Burns et al 1953). Warfarin metabolites are usually less highly 
protein bound and more water-soluble than the parent compound, therefore they 
are readily cleared by the kidney and their plasma concentrations are 
correspondingly low.
The biliary route of excretion plays a major role in the elimination of 
anions with molecular weights greater than 300. Warfarin, therefore, with a 
molecular weight of 308, may be excreted via the bile. Warfarin metabolites and 
glucuronide, sulphate, glycine or glutathione conjugates, have an increased 
molecular weight and as such, are more likely to be excreted in bile. Several 
studies have shown distinct and independent carrier-mediated active transport
processes for the sequestration of drugs into the bile (Smith, 1971). First, 
secretion of drugs into bile occurs against a high concentration gradient; 
bile/plasma concentration ratios of 50/1 are not unusual. Secondly, a limiting 
rate of drug secretion is reached which cannot be exceeded. Thirdly, various 
members of the same class of drug (anion, cation, non-ionised) compete, one 
depressing the biliary excretion of the other, but there is no competition 
between members of different classes. Drugs in the bile are passed to the 
intestine by means of these active transport processes. Passive diffusion of 
drugs from the plasma into the intestinal tract depends on factors such as the pH 
values of the plasma and intestinal contents, the pKa of the drug and the degrees 
of binding to plasma protein and to constituents of the intestinal contents. 
Warfarin, with a high degree of plasma protein binding and low pKa is not 
available for passive diffusion from the plasma to the intestine (Plaa, 1971).
Many studies of the metabolic products and the distribution of 4-
hydroxycoumarins have been reported. 4-Hydroxycoumarin itself was found to
be excreted as the glucuronide in both rabbits and dogs (Mead et al 1958;
Roseman et al 1954). Even earlier than this, Weiner et al (1950) showed that less
than 1 % of dicoumarol remained unchanged in human urine, and that the urine 
fi4 1
from rats given C -dicoumarol indicated the presence of 7 metabolites.
[14 "1None of the methylene-I CJ was expired as labelled CC^ in this study, a 
finding corroborated by Eisenhower et al (1952) and by Berg (1964) in the case of 
14C -warfarin.
Warfarin excretion in the rat was shown in the latter study to take place 
both in the urine (two-thirds of the dose) and in the faeces (one-third of the 
dose). The radioactivity excreted in urine was found to be unchanged warfarin
(6 .6 %), several hydroxylated warfarin derivatives, 4-hydroxy (21%), 6 -hydroxy- 
(15.4%), 7-hydroxy (35%) and 8 -hydroxy warfarin (8.9%) as well as a glucuronide 
conjugate of 7-hydroxy warfarin (3.9%). Chromatographic data indicated the 
presence of these metabolites in faeces, with 7-hydroxywarfarin as the major 
metabolite. However, the metabolites were present in different relative 
amounts from those found in urine, and were not quantitated. Losito and 
Rousseau (1972) identified the major biliary warfarin excretion product as 6 - 
hydroxywarfarin (19.6%) and other warfarin metabolites, with unchanged 
warfarin accounting for 8.5% of excreted radioactivity.
Similar findings to those seen above have been documented in the rat and 
guinea-pig (Coldwell et al 1974; Wong et al 1978), where warfarin and its 
metabolites were excreted into bile. In the case of the guinea-pig approximately 
43% of the warfarin was excreted via this route, although a vast majority 
eliminated by the bile undergoes enterohepatic circulation and is finally disposed 
of by the kidney. In man, it is not known if  biliary excretion of warfarin also 
occurs. The rat and guinea-pig appeared to be unsuitable animal models for 
extrapolation to the human because their molecular weight thresholds for biliary 
excretion are different from man (Williams, 1971). For this reason the biliary 
excretion of warfarin in the rabbit was investigated by Wong and Solomonraj 
(1980) because its threshold molecular weight for biliary excretion is more 
comparable to that in man. Findings from this study showed that the major 
urinary metabolites were warfarin alcohols (31%), 4-, 6 -, and 7-hydroxywarfarin 
constituting 11, 7 and 3.1% of the dose, and unchanged warfarin, 12%. Only 
6 .2 % of the administered radioactivity was excreted in the bile, glucuronide 
conjugates of warfarin and its hydroxylated metabolites making up the majority 
of this percentage. In the rabbit, the bile was only a minor excretory route for
warfarin and only polar and bulky conjugates of the drug were found to be 
eliminated by this pathway. Therefore, it  is to be expected that the human 
resembles more closely the rabbit than the rat or guinea-pig in the biliary 
elimination of warfarin.
In the results presented in this Chapter, urinary and faecal excretion of 
warfarin in warfarin-susceptible LAC-grey and warfarin-resistant HC mice will 
be documented.
EXPERIMENTAL OBJECTIVES
To discern whether an increased excretion of S(-) warfarin (or conjugate) 
was responsible for the increased plasma clearance of this enantiomer in 
warfarin-resistant females (Figure 4.4.).
To determine if an increased excretion rate of unchanged S(-) or R(+) 
warfarin was responsible for warfarin-resistance in HC mice, compared 
with their warfarin-susceptible LAC-grey counterparts.
To compare the pattern of urinary and faecal warfarin metabolite 
excretion with the microsomal warfarin metabolite profiles of warfarin- 
susceptible and warfarin-resistant mouse strains presented in Figure 5.3.
6.3. EXPERIMENTAL DESIGN
Urine and faeces samples were analysed from individual mice in the 
cases of total radioactivity determination and R(+) and S(-) warfarin and 
glucuronide/sulphates of these enantiomers. Pooled urine and faeces samples 
within each time period of collection were employed for the warfarin metabolite 
analyses, due to the small sample sizes available.
A ll results are presented as the percentage of the dose excreted in a 
cumulative fashion, over the 3 time periods, 0-6, 6-24 and 24-48 hours after 
dosing.
Statistical analysis using students unpaired t-test was effected, 
comparing LAC-grey and HC mice of the same sex, and males and females of the 
same strain.
not measured, since previous studies (Berg, 1964; Goding, 1969) showed no traces 
of either enantiomer of warfarin being excreted as labelled carbon dioxide.
The excretion of activity in the respiratory gases of the mice was
6.4. RESULTS
6.4.1. Total ~^C -Urinary and Faecal Excretion Rates in Warfarin-Susceptible
and Warfarin-Resistant Mice
Cumulative percentages of the dose as in urine and faeces from
warfarin-resistant and warfarin-susceptible male and female mice are shown in 
Figure 6.1. after intravenous administration of a single intravenous dose of 
16mg/kg racemic warfarin. Considering the excretion of warfarin in urine in the 
first case, it can be seen that the cumulative excretion profiles for warfarin- 
susceptible LAC-grey males and females were slightly different (Figure 6.1.)
excretion) than males, although this difference was not statistically significant. 
Warfarin-resistant HC males and females exhibited almost identical patterns of
statistically significant increased (p<0.005) rates 24 hours after dosing, compared 
with male and female LAC-grey mice. Between 25-27% and 37-38% of the dose 
was excreted in urine in LAC-grey warfarin-susceptible and HC warfarin- 
resistant mice respectively over the first 48 hours after warfarin administration.
greater interstrain variation between males and females than was seen from  
urinary excretion (Figure 6.1.). Excretion in LAC-grey warfarin-susceptible 
mice showed that males eliminated radioactivity at a faster rate than did 
females, so much so that after both 24 and 48 hours the levels were significantly 
different (p<0.001). The percentages of the dose excreted after 48 hours were 
48% and 10% for male and female LAC-grey mice respectively. Smaller sex 
differences in the excretion of radioactivity were noted in HC mice, although in
such that the female excreted slightly more warfarin (as measured
excretion over the 48 hour time period monitored, which were manifest as
The excretion of the 14,C label from racemic warfarin in faeces showed
„ ™ „ ,  excreted label . .  ,  t.e te , « .  did c e i . , ,  td .
reverse situation to that exhibited by LAC-grey mice. 24 and 48 hours after 
dosing, the cumulative excretion levels were significantly different (p<0.005) 
between the sexes in HC mice. Final percentages of the dose excreted in faeces 
were 47% and 59% for males and females respectively. Comparing LAC-grey 
and HC mice, Figure 6.1. shows that 24 and 48 hours after dosing there were 
significant differences in ^ c j  excretion between the strains. Female HC mice 
exhibited a significant (p<0 .0 0 1 ) increase in J^cjexcretion compared with female 
LAC-grey mice at both 24 and 48 hour time periods. Conversely, LAC-grey 
males showed significantly (p<0.005) increased excretion 24 hours after dosing 
only. A fter 48 hours LAC-grey and HC male cumulative excretion levels were 
very similar.
f l4  TTotal C -warfarin excretion in both urine and faeces is shown below 
for male and female warfarin-susceptible LAC-grey and warfarin-resistant HC 
mice, expressed as a percentage of the dose excreted in the 48 hours after 
warfarin administration:
LAC-grey Male 84.20%
LAC-grey Female 50.80%
HC Male 84.49%
HC Female 97.77%
Based on these figures, males of the two strains showed very similar 
total excretion of radioactivity, whereas HC female mice excreted almost twice
n 4 1as much C label as their LAC-grey counterparts.
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6.4.2. Excretion of R(+) and S(-) Warfarin Enantiomers and Conjugates in LA C-
grey and HC Mice
warfarin-susceptible LAC-grey and warfarin-resistant HC mice are shown in
Figures 6.2. and 6.3. respectively, over the 3 time periods of collection, 0-6, 6-24
and 24-48 hours. Enzyme hydrolysis products of 3-glucuronidase/aryl sulphatase
incubations, yielding unchanged drug are expressed on the same axes as R(+) and
S(-) unchanged warfarin in each of the groups of mice studied. A fairly complex
n 4  *i
pattern of excretion of C radioactivity emerged on analysis of separate 
enantiomers of unchanged warfarin, and conjugates of these enantiomers. Figure
6.2. shows the pattern of excretion of these compounds in the urine. Females of 
both warfarin-susceptible and warfarin-resistant mouse strains showed similar 
patterns of R(+) warfarin excretion, where more unchanged compound was 
excreted, compared with the conjugate of R(+) warfarin. In all other groups of 
mice, the reverse situation was noted in that more conjugated enantiomers (both 
R(+) and S(-) warfarin) than unchanged warfarin were excreted. The la tter was 
also true for S(-) warfarin excretion in females of both strains. In male and 
female HC and female LAC-grey mice, more S(-) warfarin was excreted in the 
48 hours after dosing than R(+) warfarin (Figure 6.2.). This was particularly 
noticeable in HC warfarin-resistant mice. In male LAC-grey mice, R(+) warfarin  
was excreted at about the same percentage of the dose as its epitope, the more 
potent anticoagulant S(-) warfarin. Comparing males and females of the same 
strain, it was noted that in LAC-grey mice the cumulative pattern of excretion 
of S(-) warfarin and conjugates of this enantiomer were very similar in the two 
sexes. Very small amounts, only 0.26 and 0.31% of the dose being excreted as 
these compounds after 48 hours of urine collection. The excretion of the R(+) 
enantiomer of warfarin differed slightly between males and females of the LA C -
Urinary and faecal excretion warfarin enantiomers in
grey strain, in that more conjugated enantiomer was excreted in the males, 
resulting in a slight but non-significant increase in R(+) warfarin excretion in this 
sex compared with S(-) warfarin. Similarly, in HC mice, males excreted more 
R(+) warfarin as both conjugated and unchanged compound than females, 
resulting in the total cumulative elimination of 0.66% and 0.24% of the dose for 
males and females, a difference which was significant (p<0.005). The pattern of 
S(-) warfarin excretion in the HC mice was very similar, with less unchanged 
enantiomer than conjugates in both sexes. However, male mice excreted a total 
of 2.22% of the dose compared with 1.36% in females, as S(-) warfarin and 
conjugates, a difference which was significant (p<0 .0 0 1 ).
The differential urinary excretion of R(+) and S(-) warfarin, either 
unchanged or as conjugates in LAC-grey and HC mouse strains exhibited 
interstrain differences (Figure 6.2.). Comparing males of the two strains, it 
could be seen that HC mice eliminated a significantly greater (p<0.001) 
proportion of the dose of -warfarin as both unchanged and conjugated R(+)
enantiomer and as the conjugated S(-) enantiomer, levels of unchanged S(-) 
warfarin being very similar in males of both strains of mice. It  must be stressed 
that the significant increase in S(-) warfarin conjugate excretion in male HC  
mice represented an increase from 0.26 to 2.2% of the warfarin dose. The 
hypoprothrombinaemic significance of this change will be discussed in detail in 
Section 6.3. Comparing female LAC-grey and HC mice, significant increases 
(p<0.01 and p<0.001) in the amount of unchanged R(+) and S(-) warfarin, and the 
amount of S(-) warfarin conjugates respectively, were seen in warfarin-resistant 
HC mice.
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In general, an overall increase in the urinary excretion of unchanged R(+) 
and S(-) warfarin and their conjugates was seen in both male and female 
warfarin-resistant HC mice in comparison with their warfarin-susceptible LA C- 
grey counterparts. However, these studies showed that although significantly 
different excretion patterns were shown between the two strains of mice, the 
increases accounted for only 2 % of the administered warfarin dose being 
maximally excreted as each warfarin enantiomer over the first 48 hours after 
dosing.
Faecal excretion of 14c -warfarin in the forms of R(+) or S(-) 
unchanged warfarin, or conjugates of these enantiomers is shown in Figure 6.2. 
I t  can be seen that relative to the urinary excretion of these compounds (Graph 
34) the faeces was a minor route of excretion. The faecal excretion pattern of 
LAC-grey and HC mice was very similar and also was almost the same as the 
pattern of urinary excretion of the enantiomers in LAC-grey mice (Figure 6.2.). 
No difference in the excretion patterns of unchanged warfarin enantiomers or 
conjugates were seen between the sexes or strains, although in all cases, slightly 
more S(-) enantiomer than R(+) enantiomer was excreted. The maximum faecal
excretion of 14c -warfarin as unchanged compound or conjugates was found to 
be approximately 0.25% of the administered dose for each warfarin enantiomer 
in the 48 hours after administration.
6.4.3. Excretion of Warfarin Metabolites and Their Conjugates in Urine and 
Faeces of LAC-Grey and HC Mice
The profiles of ^ 4 c ]  excretion of warfarin metabolites and their 
conjugates in urine and faeces of LAC-grey and HC mouse strains are presented 
in Figures 6.4. and 6.5. Unfortunately, current chromatographic techniques do
not permit separation of the metabolites of R(+) and S(-) enantiomers of warfarin 
after administration of racemic anticoagulant. However, since in vitro 
microsomal metabolism studies using separate warfarin enantiomers have been 
carried out (Chapter 5) results from excretion studies may be correlated with 
this data.
Initially, the urinary excretion of warfarin ' metabolites and their 
conjugates will be described in LAC-grey and HC mice, after which the 
excretion of these compounds in faeces will be presented. In each case, 
reference to sex and strain differences in the amounts of each metabolite of 
warfarin or metabolite conjugate will be made. Urinary excretion profiles of 
warfarin metabolites and their conjugated forms are presented in Figure 6.4.. 
The relative warfarin metabolite excretion patterns were similar in both male 
and female, warfarin-susceptible and warfarin-resistant mouse strains, the major 
urinary metabolite produced in all groups of mice being 4'-hydroxywarfarin and 
the glucuronide or sulphate conjugate of this metabolite; with the exception of 
the HC male where 7-hydroxywarfarin conjugates were excreted in the largest 
amounts in urine. In LAC-grey mice, significant sex differences in urinary 
metabolite excretion were not observed (Figure 6.4.) although in the female, 6 - 
hydroxywarfarin conjugates were produced in greater amounts than in the male. 
Considering HC mice, relatively larger sex variations in urinary metabolite 
excretion were exhibited. In the male, significantly greater amounts of 7- 
hydroxy and 8 -hydroxywarfarin were produced (p<0 .0 1 ) than the female. 
Conversely, the female of this strain exhibited excretion of 4'-hydroxywarfarin 
and conjugates of this metabolite which were greater than those of the male 
(p<0.001). In addition, females produced more 6 -hydroxywarfarin, but less 
conjugated metabolite than male HC mice. In summary, the major sex
difference in urinary warfarin metabolite excretion in the HC strain was the 
preferential excretion of 4’-hydroxywarfarin in females and 7-hydroxy warfarin in 
males.
Interstrain differences in the urinary excretion of radioactivity as 
warfarin metabolites were quite marked (Figure 6.4.). In males of the HC 
warfarin-resistant strain, significant increases (p<0.001) in 7-, and 8 - 
hydroxywarfarin excretion were seen, in addition to an increase in the 
elimination of 6 -hydroxywarfarin conjugates compared with LAC-grey males. 
Conversely, the LAC-grey males exhibited a greater cumulative percentage of 
4'-hydroxywarfarin excretion over the 48 hour time period studied. Comparing 
females of the two strains; it was shown that the urinary excretion of 6 -, and 7- 
hydroxywarfarin was increased (p<0 .0 0 1 ), in addition to an increase in 
elimination of both 4'-hydroxywarfarin and its glucuronide/sulphate conjugate in 
the warfarin-resistant HC strain, compared with warfarin-susceptible females. 
The total urinary excretion of warfarin as metabolites and conjugates in males 
and females of the two strains amounted to 19 and 24% respectively in LAC-grey 
mice and 30 and 40% of the administered dose respectively in HC mice, 
exemplifying the significant increases in urinary excretion of warfarin 
metabolites and their conjugates in warfarin-resistant mice, illustrated in Figure 
6.4.
Faecal excretion profiles of warfarin metabolites and their conjugated 
forms are presented in Figure 6.5.. In all sexes and strains with the exception of 
LAC-grey females; the major faecal excretion product was the conjugate of 4'- 
hydroxywarfarin. In LAC-grey females this was the 7-hydroxywarfarin conjugate 
(Figure 6.5.). However, major sex differences in the LAC-grey strain were
exhibited, as were interstrain differences in faecal metabolite excretion. 
Warfarin metabolite excretion in the faeces was significantly less (p<0.005) in 
female warfarin-susceptible mice than their male counterparts for all the 
metabolites and their conjugates. A similar sex difference was not exhibited in 
HC warfarin-resistant mice, where although male mice showed an increased 
faecal excretion of 7-hydroxywarfarin compared with females, the females 
exhibited an increased elimination of 6 -hydroxywarfarin and its conjugate, 
relative to male HC mice. In general terms it can be seen that more conjugated 
metabolite than metabolite itself was excreted in faeces in all 4 groups of mice 
studied, compared with urinary excretion patterns which showed the reverse 
trend (Figures 6.4. and 6.5.). Comparing faecal excretion of warfarin 
metabolites and conjugates, in both warfarin-susceptible and warfarin-resistant 
strains of mice, it could be seen that in males there were significant (p<0.005 
and p<0.001) increases in the amounts of 8 -hydroxy warfarin conjugates and 7- 
hydroxywarfarin metabolites in the HC strain compared with LAC-greys. 
However, the latter strain showed significant (p<0.001) increases in the faecal 
excretion of 6 -hydroxywarfarin, and conjugates of both 6 - and 41- 
hydroxywarfarin. D ifferential faecal excretion patterns were seen between 
males of the two strains. In female HC mice, the excretion of all metabolites 
and conjugates was significantly increased in comparison with LAC-grey 
females. This effect was contributed to by the fact that warfarin metabolite 
and conjugate excretion in the LAC-grey females was lower than that seen for 
the other 3 groups of mice studied. So, both sex and strain variations in the 
faecal excretion of warfarin metabolites and their conjugates have been 
described. Total faecal excretion values, expressed as a percentage of the 
administered dose for these metabolic products were as follows: 46% and 10% 
for LAC-grey and 35% and 53% for HC male and female mice respectively.
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These levels were greater than those seen for urinary metabolite and conjugate 
excretion in all but the LAC-grey female mice.
The overall excretion of radioactivity from an administered dose of 
16mg/kg racemic warfarin, labelled with *n position 4 has been presented,
with the contributions of unchanged R(+) and S(-) warfarin enantiomers, warfarin  
metabolites and conjugates of all these compounds to the excretion totals having 
been reported (Figures 6.1.-6.5.).
6.5. DISCUSSION
The results presented in this Chapter will be discussed with reference to 
several avenues of enquiry. These include accounting for the increased plasma 
clearance of S(-) warfarin observed in warfarin-resistant female mice, in the 
light of the experimental results obtained from in vitro hepatic microsomal 
studies (Figure 4.4. and Table 4.1.). In addition, the possibility that warfarin- 
resistance may be due to the major warfarin-resistance gene, War, exerting a 
biochemical manifestation to cause increased excretion of unchanged warfarin, 
thereby reducing warfarin's anticoagulant action in the HC mouse strain will be 
discussed. Finally, the correlations between the production of warfarin  
metabolites by in vitro hepatic microsomal preparations and the excretion of 
warfarin metabolites in urine and faeces will be discussed.
mice showed that in both strains, apart from the LAC-grey female, a greater 
percentage of the dose was excreted via the faeces, as compared with urine over 
the 48 hours after administration (Figure 6.1.). The decreased cumulative 
percentage of warfarin seen in the faeces of LAC-grey females was mainly due 
to their decreased excretion of warfarin metabolites and their conjugates via 
this route of elimination (Figure 6.5.). Drugs and metabolites which are found in 
urine are not available for reabsorption, however most of the drug or metabolite 
which is excreted in faeces (unless incompletely absorbed after oral dosing) 
arrives in the intestine after being actively transported from liver parenchymal 
cells via the bile cannaliculi and the common bile duct. From the intestine, the 
drug and metabolite may be excreted in faeces, or reabsorbed to return to the 
liver. This cycle is known as enterohepatic circulation. In the case of this study,
The overall excretion pattern warfarin in LAC-grey and HC
any unchanged warfarin in faeces must have been excreted via the bile, since the 
dose of racemic warfarin was administered intravenously via the tail-vein. The 
molecular weight of a compound has an influence on its biliary excretion. The 
higher the molecular weight, the more likely it is to be excreted via the bile. 
The threshold molecular weights for the excretion of anionic compounds, such as 
warfarin, varies with species, such that values for the rabbit, guinea-pig and rat 
are 475, 400 and 325 -  50 respectively. In the mouse therefore, with a biliary 
excretion molecular weight cut-off of 300, it  is not surprising that some warfarin 
(molecular weight = 308) and warfarin metabolites (molecular weight = 324) were
14C in faeces. Moreover,excreted preferentially in bile and appeared as 
conjugates of the parent drug and metabolites had molecular weights which were 
increased further, making them more likely to be excreted in bile. It  would 
appear that enterohepatic circulation of warfarin, metabolites and conjugates 
may have been in operation since both warfarin and warfarin metabolite 
conjugates appeared in the urine of these mice, presumably via reabsorption of 
these compounds from the intestine after their sequestration by the bile, and 
eventual excretion via the kidney. Therefore, the findings that warfarin was 
excreted in both urine and faeces; the la tter being the major route in all but 
LAC-grey female mice; is explained on the basis of an increased molecular 
weight on metabolism and conjugation having caused preferential biliary 
excretion of these compounds. This would also explain the finding that in the 
urine, relatively more warfarin metabolites than their conjugates were excreted, 
whereas the reverse situation was seen in faeces, more conjugated metabolite 
being excreted in most cases (Figures 6.4. and 6.5.).
The overall pattern of excretion of L' * c j  label from warfarin within 
each sex and strain of mouse, showed that quite extensive metabolism of the
anticoagulant took place, since very little  unchanged warfarin was excreted,
either in urine or faeces. A maximum excretion of 3.5% of the administered
dose was excreted as unchanged or conjugated warfarin. The pharmacological
significance of the excretion of unchanged warfarin will be discussed later in this
Section. The contribution of metabolism to the percentage of the dose excreted
may be illustrated by comparing the total metabolite excretion in either urine or
f i4  1faeces for each sex and strain of mouse. Thus, total excretion of C 
warfarin as metabolites or conjugates of metabolites, over 48 hours after dosing 
were:-
LAC-grey Male 65%
LAC-grey Female 34%
HC Male 65%
HC Female 93%
These data are in agreement with those found by other workers in the 
rat. Losito and Rousseau (1972) showed that male Sprague-Dawley rats excreted 
a total of 70% of the intravenously administered dose of 1.4mg/kg as warfarin 
metabolites in both urine and faeces in the first two days after dosing. 
Similarly, using male Holtzman rats, Barker et al (1969) had previously shown 
that 77% of the dose of lm g/kg was excreted as warfarin metabolites. However, 
these workers exhibited no data from female rats, and did not distinguish 
between metabolites of warfarin and their conjugates, therefore comparison 
between species cannot be carried out directly on the data obtained for female 
mice.
An increased plasma clearance of S(-) warfarin has been documented 
previously in warfarin-resistant HC female mice (Figure 4.4.). It  was proposed 
that this may have been due to an increased metabolic rate of this enantiomer in 
these mice. However, in vitro studies of the hepatic microsomal metabolism of 
warfarin enantiomers did not show a great difference in the metabolic rate of 
the S(—) warfarin enantiomer which would explain the observed in vivo effect in 
these mice (Figure 5.3.). Therefore, the excretion rates of the two unchanged 
enantiomers were investigated in male and female LAC-grey and HC mice in 
order to determine whether an incrased S(-) warfarin excretion in HC females 
could explain the increased plasma clearance of this enantiomer relative to the 
other three groups of mice being monitored. The half-life  of the S(-) enantiomer 
of warfarin in HC females was found to be 0.91 hours, compared with 12-14 
hours in the HC male and LAC-grey male and female (Table 4.1.). This meant 
that 12 hours (one half-life in HC males) after dosing compared with 8.51pg/ml 
plasma of S(-) warfarin in HC males and LAC-grey mice, there was only
0.0086pg/ml plasma of this enantiomer in HC females, a difference of almost 
1000-fold. This difference cannot be correlated with the difference in excretion 
of unchanged S(-) warfarin and its conjugates, whereby the HC males and 
females excreted 2.5 and 1.6% of the dose, compared with 0.5 and 0.4% of the 
administered warfarin in LAC-grey males and females. This constituted a 
difference of only 4-fold between HC females and LAC-grey animals, and such a 
small percentage of the dose excreted as unchanged S(-) warfarin over 48 hours, 
would seem unlikely to be responsible for the vastly increased tolerance to 
warfarin seen in the warfarin-resistant HC female (Table 3.1.), or the increased 
plasma clearance (Table 4.1.) of the same animals. An interesting finding with 
respect to this problem, was that the overall excretion of warfarin metabolites 
and their conjugates in the HC female was 93% of the dose in the 48 hours after
dosing, compared with 65% for males of both strains, and 34% for LAC-grey 
females. This would tend to suggest that warfarin metabolism was responsible 
for the increase in plasma clearance of S(-) warfarin in HC females. Even 
though the excretion studies could not distinguish between metabolites and 
conjugates of the two warfarin enantiomers, it was known from in vivo studies 
that the elimination half-lives of all groups of mice was the same with respect to 
R(+) warfarin, so that any changes in metabolite production would be more likely 
to result from S(-) warfarin metabolism. In vitro studies did not show any 
changes in S(-) warfarin metabolism by hepatic microsomal preparations from 
HC or LAC-grey females (Figure 5.3.). The data presented in this Chapter would 
seem to indicate extramicrosomal or extrahepatic metabolism of S(-) warfarin as 
being responsible for the above phenomenon, in view of the results obtained from 
in vivo studies (Figure 5.3.).
The second objective of this group of experiments was to discover 
whether the major warfarin resistance gene, War, exerted a biochemical 
manifestation causing increased excretion of unchanged warfarin in warfarin- 
resistant HC mice, thereby reducing their susceptibility to warfarin’s 
anticoagulant action in comparison with warfarin-susceptible LAC-grey mice. 
The urinary and faecal excretion of warfarin enantiomers and their conjugates in 
male and female LAC-grey and HC mice is shown in Figures 6.2. and 6.3. No 
difference was seen in the faecal excretion of either enantiomer between the 
two strains of mice, this route of excretion being minor, approximately 0.1 -0.3%  
of the dose of R(+) and S(-) warfarin being excreted in all 4 groups of animals 
(Figure 6.3.). Therefore, increased faecal excretion of the unchanged warfarin  
cannot be responsible for warfarin-resistance in the HC mice. Considering 
urinary excretion, however, HC mice did exhibit significantly increased
excretion of both the R(+) and S(-) warfarin enantiomers or their conjugates 
compared with LAC-grey mice (Figure 6.2.). The excretion of S(-) warfarin 
conjugates were greatly increased in both male and female HC mice, which 
would suggest that since the more potent warfarin enantiomer was excreted at 
an increased rate in warfarin-resistant mice, compared with their warfarin- 
susceptible counterparts, this effect may account for the biochemical expression 
of the major warfarin resistant gene, War. Although increased excretion of 
unchanged R(+) and especially S(-) warfarin must contribute to an increased 
tolerance to warfarin in the HC strain, the modest percentage of the 
administered dose excreted in this way (2.5% over 48 hours) would not account 
for the vast decrease in warfarin susceptibility observed in warfarin-resistant 
HC mice (Table 3.1.). Therefore, just as the differential potencies of R(+) and 
S(—) warfarin could not be explained by differences in their rates of excretion, 
neither can warfarin-resistance be explained on the basis of differential 
excretion of unchanged warfarin enantiomers between warfarin-resistant HC and 
warfarin-susceptible LAC-grey mice. In the same manner, other workers have 
shown that genetically-determined warfarin resistance was independent of 
warfarin excretion in both man and the rat (Alving et al 1985; Holt and Freytes, 
1983; Hermondson et al 1969). No reports have been documented to date which 
describe warfarin excretion in either warfarin-susceptible or warfarin-resistant 
mice.
Finally, the pattern of warfarin metabolite or conjugate excretion w ill 
be compared with the pattern of warfarin metabolites produced by hepatic 
microsomal preparations from untreated animals, in order to show any 
similarities or discrepancies between the profiles of warfarin-susceptible and 
warfarin-resistant mice. Although this involves comparing an in vitro response
of hepatic microsomal preparations from untreated mice to added warfarin, with 
an in vivo response to a single intravenous dose of racemic warfarin by each 
strain of mouse, a qualitative but not quantitative comparison will be made, so 
validating this assessment. The excretion of warfarin metabolites must mimic 
their production by in vivo metabolic processes, although the exact location of 
the warfarin-metabolising enzymes is not known. Hepatic microsomal
metabolism of warfarin offers one distinct organ site for the biotransformation 
of the anticoagulant, and so the contributions of the liver in the overall 
qualitative production of warfarin metabolites may be indicated. If  the urinary 
and faecal excretion patterns of warfarin metabolites and their conjugates are 
combined, it  can be seen that in the HC males and females by far the largest 
excretion products were 41- and 7-hydroxywarfarins. In LAC-grey mice, the 
largest excretion was of 4'-hydroxywarfarin (Figures 6.4. and 6.5.). These 
differences in metabolite profiles were not mimicked by in vitro hepatic 
microsomal preparations (Figure 4.4.) where the production of R(+) warfarin 
metabolites was different for the 4 groups of mice studied, and different from 
the profiles described above. This indicated that one of three things may have 
occurred in the whole animal to account for these discrepancies:
1. The hepatic microsomal metabolism system was not a good model for
hepatic metabolism of warfarin in vivo.
2. The effect of the presence of both warfarin enantiomers in the in vivo
situation caused differential metabolite patterns to be produced which 
were not mimicked in vitro because enantiomers of warfarin were 
incubated with microsomes individually.
3. Another site than the liver microsomes was responsible for the
production of warfarin metabolites, so causing the apparent 
discrepancies between the in vivo and in vitro metabolic responses.
In order to evaluate these possibilities, studies by other workers will be 
discussed. For example, considering the first possibility for explanation of these 
differences, the microsomal metabolism of warfarin has been used by various 
groups of scientists in order to probe cytochrome P-450 heterogeneity (Kaminsky 
et al 1984; Rettie et al 1985; Bush and Trager, 1984). In these studies, the 
metabolic rates of warfarin were correlated with cytochrome P-450 isozyme 
concentrations in microsomes, determined by immunochemical quantitation 
techniques. Comparisons of these rates with those obtained using purified 
isozymes showed that isolation from the microsomal membrane, purification, and 
subsequent reconstitution of cytochrome P-450 isozymes did not affect the 
substrate specificities of the isozymes. Furthermore, excellent correlations 
between the rates of formation of warfarin metabolites by microsomal 
preparations, and the in vivo production of urinary metabolites are being used at 
present to develop non-invasive assays to assess the profile of human liver 
cytochrome P-450 (Kaminsky et al 1984). Therefore the vast wealth of 
information derived from the hepatic microsomal metabolism of warfarin in 
humans, rabbits, rats and mice would suggest that this system was a good model 
for predicting in vivo hepatic metabolism profiles of warfarin.
This leaves two possibilities for explaining the results obtained, the first 
of which would again suggest that the metabolism of warfarin by liver 
microsomal preparations was not a good model for the in vivo situation. Since 
all the studies undertaken above described the stereoselectivity of warfarin  
metabolism after incubating with separate warfarin enantiomers, this possibility 
may also be regarded as improbable.
Evidence to corroborate the final possibility put forward has been 
documented by Kaminsky et al (1979). These workers have shown that 
comparison of different forms of liver, kidney and lung microsomal cytochrome 
P-450 by immunological inhibition of regio- and stereoselective metabolism of 
warfarin showed the presence of distinct forms of cytochrome P-450 in 
microsomes prepared from untreated and phenobarbitone or 3- 
methylcholanthrene-treated rat liver, kidney and lung. It  would seem quite 
probable that this may be the case in the mice used in this study. A warfarin- 
metabolising cytochrome P-450 isozyme(s) in an organ other than the liver or an 
extramicrosomal organelle may be responsible for the differing profiles of 
warfarin metabolite excretion, compared with in vitro hepatic microsomal 
metabolism.
CHAPTER 7
PLASMA PROTON BINDING OF R(+) AND S(-)WARFARIN IN  
WARFARIN-SUSCEPTIBLE LAC-GREY AND WARFARIN-RESISTANT HC MICE
7.1. INTRODUCTION
Plasma proteins are able to adsorb, or bind, compounds of diverse 
chemical structure, and as such, modify not only the passive diffusion of these 
agents into blood, but also fluctuations in the concentration of the transported 
molecules. Plasma protein-bound molecules may greatly exceed the availability 
of these molecules in a free state in the aqueous phase of the blood. Since the 
free concentration of drug usually controls the rate of exit from capillaries to 
the site of pharmacological activity, the protein-bound state affords a temporary 
protection from toxic material by allowing time for metabolising and excretory 
mechanisms to eliminate undesirable compounds. Thus, binding by plasma 
proteins provides a vital function which has been explored in a wide number of 
contexts. Perhaps the most frequently documented of these is the study of drugs 
causing plasma protein binding displacement, and evaluation of the clinical 
significance of this interaction mechanism. The simultaneous use of several 
therapeutic agents has become commonplace, and therefore some interaction  
between almost any two concommitantly-administered drugs must be expected. 
During the 30 years of their therapeutic use, coumarin anticoagulants have been 
found to interact with many other drugs (Koch-Weser and Seller, 1976b). Thus 
drug interactions with 4-hydroxycoumarin anticoagulants have been shown to be 
not only common, but usually therapeutically significant and often potentially 
serious. Coumarins are highly bound to plasma proteins, with approximately 97%
of warfarin bound to human serum albumin (O'Reilly et al 1963; O'Reilly, 1964; 
Aggeler and O'Reilly, 1966; O'Reilly, 1967). Because of this, warfarin is largely 
partitioned in the plasma compartment, although the free plasma concentration 
is quite low. A t the clinically common total warfarin concentration of 2.5mg/l, 
the free concentration is only 75pg/l (2.4 x lCf^M) and this concentration 
remains a fairly constant fraction of the total plasma concentration over a wide 
range of concentrations (Koch-Weser and Sellers, 1971). Drug interactions 
resulting from competition between warfarin and other drugs for the binding 
sites of serum albumin have been studied for many years (Henry and Wosilait, 
1975; Hull et al 1978; Wosilait, 1975; Wosilait, 1977a). Even so, the role of 
protein binding displacement in interactions with warfarin has probably been 
overestimated (Serlin and Breckenridge, 1983). While many drugs (usually highly 
protein-bound acidic compounds) can displace warfarin from albumin binding 
sites, this does not automatically produce an increased anticoagulant effect. In 
practice, protein binding displacement alone has not generally produced more 
than a transient rise in prothrombin clotting time. It  is notable that the drugs 
frequently quoted as producing significant interactions with warfarin by binding 
displacement also interact by other mechanisms which are probably of greater 
significance. For example, these include phenylbutazone (Lewis et al 1974) and 
Clofibrate (Bjornsson et al 1979).
Protein binding also influences the rapidity of onset and duration of the 
pharmacological effect. The 97% bound warfarin accurately parallels the 
extended biological half-life and the extent of the hypoprothrombinaemic effects 
of this compound. It  has been proposed that the high degree of non-electrostatic 
binding of warfarin to albumin and its non-polar character account for the 
sustained level of this drug in the plasma, the absence of urinary excretion, and
its small volume of distribution (O'Reilly, 1967). Sodium warfarin is bound solely 
to albumin of plasma proteins, has an ionizable acidic group of physiological pH 
and is hydrophobic, therefore hydrophobic binding, as well as hydrogen bonding, 
plays an important role in binding to albumin. The major source of the energy of 
binding is the coumarin nucleus itself; whereas the addition of the hydroxyl group 
at position 4, or substitution at position 3 (Figure 5.1.), necessary for 
anticoagulant action, contribute only a little  to the binding energy (O'Reilly,
1970). It  is now widely accepted that there are two major binding sites for 
warfarin on albumin (O'Reilly, 1970). However, recent reports (Larsen et al 
1984; Vander Giesen and Wilting, 1983) have suggested that the question of 
whether one or two high affinity sites for warfarin are present in human serum 
albumin should be regarded as an open one, since previous studies have relied 
purely on binding equilibrium measurements. These authors considered that 
stepwise binding constants provide a stoichiometric description of warfarin 
binding to human serum albumin which shows that the equilibrium mixture 
contains the stoichiometric complexes of warfarin and albumin 1:1, 2:1, 3:1 and 
4:1, besides free warfarin and unloaded albumin. Therefore, each stoichiometric 
complex was shown to consist of a mixture of several species of warfarin 
attached to different sites on the albumin molecule. In addition, a pH-dependent 
conformational change in bovine and human serum albumin around physiological 
pH has been noted (Van der Giesen and Wilting, 1984) whereby two 
conformational states of albumin are exhibited. The neutral (N) form occurrs 
mainly below neutral pH and the basic (B) form at higher pH. The 
conformational change between these two states is therefore called the neutral- 
to-base or N-B transition. Evidence has been produced to indicate that the 
kinetics of warfarin binding to albumin proceeded in two steps; a diffusion- 
controlled step, followed by a considerably slower step, during which the stable
warfarin-albumin complex was formed. Further studies are now underway to 
elucidate the precise role of the N-B transition in affecting the rate of 
metabolic processes, and also in the transport function of albumin. In this way, 
analysis of the binding mechanism of warfarin with plasma albumin may provide 
insight into its interaction with sites of biological activity.
Variations between species in plasma protein binding of drugs have been 
implicated as causes for the differences in pharmacological potency, drug 
distribution and elimination rates of various compounds (Koch-Weser and Sellers,
1971). There is considerable variation in the anticoagulant effect of warfarin 
among animal species. Sellers et al (1977) showed that although the human, rat 
and mouse are most sensitive to anticoagulant action by warfarin, with guinea- 
pigs, cats and dogs intermediate, and the rabbit, cow and chicken least affected, 
there is no apparent inverse relationship between the degree of albumin binding 
and anticoagulant sensitivity. Rat albumin bound more warfarin (97%) than 
human (96%) followed by sheep (95%), dog (93%) and finally, horse, whose 
albumin bound warfarin to a minimal extent. In fact, the species with the most 
extensive binding (human and rat) were most sensitive, suggesting that 
differences between the species in affinity at the site of action and not free 
warfarin concentration accounted for differences in response to anticoagulation.
O'Reilly (1970) had previously shown a 6 -fold lesser binding by canine, as 
compared with human albumin and suggested that this may explain why, in man 
with greater binding, phenylbutazone potentiated warfarin's anticoagulant 
action, but in dogs, with less binding, the enzyme-inducing effects of 
phenylbutazone predominated. The warfarin-phenylbutazone interaction has 
been studied further, (Lewis et al 1974) with the findings that warfarin
metabolism was altered in a stereoselective manner, such that S(-) warfarin 
plasma elimination was preferentially slowed, providing a mechanism for the 
augmentation of anticoagulation. Interference with plasma protein binding was 
suggested as a cause for this increased hypoprothrombinaemia. This study 
highlights the implications of chiral aspects of drug interactions. The 
discrimination of mirror-image stereoisomers by a protein surface is not so 
surprising, considering the facts that proteins consist of chiral amino-acid units, 
and are macromolecules possessing chiral secondary structures by forming 
cavities or helical sequences, thus providing chiral environments for small 
bioactive molecules such as warfarin. Plasma protein binding is therefore often 
manifest by differential binding strengths of the enantiomers, giving rise to 
different distribution between bound and free states for the optical antipodes if 
the drug is administered in the racemic form. The strong binding of warfarin to 
human serum albumin shows slight, though significant, stereoselectivity for the 
S(-) enantiomer (Simonyi et al 1986). The importance of considering the actions 
of racemates in terms of the contributions of their enantiomers has been 
stressed previously, since, as in the case of protein binding, there may be no 
major differences between the binding affinities of the enantiomers, but their 
interactions with other molecules may be highly enantiospecific.
The results presented in this Chapter encompass binding data of both 
R(+) and S(-) warfarin enantiomers to the plasma proteins of male and female 
warfarin-susceptible LAC-grey and warfarin-resistant HC mice.
EXPERIMENTAL OBJECTIVES
To show any differential plasma protein binding of warfarin enantiomers 
between warfarin-susceptible LAC-grey and warfarin-resistant HC mice, 
which may have pharmacological significance with respect to warfarin 
resistance.
To correlate the percentage of free warfarin enantiomers in vivo with 
warfarin pharmacokinetics in each sex and strain of mice.
To elucidate whether a decreased plasma protein binding of S(-) warfarin 
in female warfarin-resistant mice, may have been responsible for the 
increased in vivo plasma clearance of the enantiomer in this group of 
mice reported in Figure 4.4. and Table 4.1.
7.3. EXPERIMENTAL DESIGN
The concentrations of warfarin used for in vitro studies were calculated 
using the peak plasma concentrations of warfarin obtained after intravenous 
dosing of 16mg/kg warfarin reported in Chapter 4 (Figures 4.1.-4.4.) which 
corresponded to approximately 150pM racemic warfarin. In all cases the same 
amount of protein was present in each incubation mixture, and results presented 
represent the means of duplicate analyses from triplicate incubations.
In vivo studies were carried out after dosing mice intravenously with 
16mg/kg racemic warfarin and collecting plasma samples at various time points 
after administration. The free fraction of warfarin was determined after 
ultracentrifugation (Chapter 3, Section 3.3.) and total warfarin determined as 
described previously (Chapter 3, Section 3.3.).
All experiments were carried out at 37°C.
7.4. RESULTS
7.4.1. 'In Vitro1 Binding Studies
Binding of R(+) and S(-) enantiomers of warfarin was investigated in 
vitro, using 6  concentrations of racemic warfarin. The percentage of free R(+) 
and S(-) warfarin at these concentrations in male and female warfarin- 
susceptible and warfarin-resistant mice is presented in Table 7.1. Binding 
isotherms calculated from this data are exhibited in Figure 7.1. Bound and free 
equilibrium concentrations of R(+) warfarin in LAC-grey mice are plotted in 
Figure 7.1.a. showing bound warfarin relative to the concentration of albumin as 
a function c (free R(+) warfarin concentration on a logarithmic scale) and as a 
Scatchard plot (Figure 7.1.b.), bound/free versus bound R(+) warfarin. Very 
similar binding isotherms could be plotted for all sexes and strains of mice with 
respect to both R(+) and S(-) warfarin, therefore only a representative plot for 
both Figure 7.1.a. and 7.1.b. is presented. The former plot indicates that binding 
increased continuously with rising concentration of free warfarin, a level of 
saturation was not reached at the highest concentratins of warfarin applied. The 
Scatchard graph (Figure 7.1.a.) suggests a high affinity binding of two warfarin 
molecules and low affinity binding of two additional molecules and was almost 
identical for both R(+) and S(-) warfarin in LAC-grey and HC males and females. 
However, although such interpretations of the Scatchard plot have often been 
seen in the literature, a more detailed analysis is required in order to test this 
binding model, and will be discussed in Section 7.5. The main purpose of this 
study was not to probe the plasma protein binding sites with respect to their 
stoichiometric interactions with warfarin, but to discern whether the free and 
bound concentrations of the warfarin enantiomers showed strain differences 
between LAC-grey and HC mice.
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Warfarin Bound/mg Plasma Protein
The percentage of unbound R(+) and S(-) warfarin changed very little  
over the range of warfarin concentrations investigated in any sex or strain of 
mouse (Table 7.1.). For LAC-grey mice, approximately 4-5% in males and 3-5%  
in females of each warfarin enantiomer was in the free form in plasma. For both 
males and females, a slight, though statistically non-significant stereoselectivity 
in warfarin binding, was exhibited for the S(-) enantiomer. A similar pattern of 
binding was shown in warfarin-resistant HC mice. The percentage of each 
enantiomer o f warfarin in the free form was relatively constant over the range 
of concentrations studied. On average, the percentages of R(+) and S(-) warfarin  
in free form in HC males and females were 2.4, 2.0, 0.79 and 0.97% respectively, 
corresponding to 97.6, 98, 99.2 and 99.0% bound. An interesting feature was 
exhibited by the HC female mice; although slight stereoselectivity was shown in 
HC males, and LAC-grey males and females in binding S(-) warfarin, the reverse 
was true for HC females where slightly more R(+) warfarin was bound at all 
concentrations of warfarin studied.
Comparing the warfarin-susceptible LAC-grey and warfarin-resistant HC  
mouse strains, it can be seen that there was a significant (p<0.001) decrease in 
the percentage of free R(+) warfarin in warfarin-resistant, as compared with 
warfarin-susceptible males (Table 7.1.). Similarly, significant decreases were 
seen for the amount of free S(-) warfarin in male HC mice at the higher 
concentrations of warfarin studied. With respect to females of the two strains, 
again, warfarin-resistant HC mice bound both R(+) and S(-) warfarin to a 
significantly greater (p<0.001) degree at all 6 warfarin concentrations than did 
their warfarin-susceptible counterparts. The percentages of free warfarin in HC  
females was slightly lower than those for HC males although this difference was 
not statistically significant.
7.4.2. 'In Vivo1 Binding Studies
The percentage of each warfarin enantiomer in the free form is shown 
for male and female warfarin-susceptible and warfarin-resistant mice in Table
7.1. at 0, 3 and 6 hour time points after dosing. The percentages correspond 
quite well with those found in in vitro studies (Table 7.1.) described above. The 
percentage of each enantiomer of warfarin in unbound form remained fairly  
constant within each sex and strain over the 3 time periods studied. In LAC-grey 
warfarin-susceptible mice the average percentages of free R(+) and S(-) warfarin 
in the plasma of male and female mice were 3.5, 2.9, 3.05 and 2.3% respectively. 
The same figures for HC warfarin-resistant males and females were 2.4, 2.0,
0.48 and 0.56% respectively. Again, in LAC-grey males and females and in HC  
males, a slight stereoselective preferance for S(-) warfarin binding was observed, 
as judged by the smaller percentage of free warfarin compared with R(+) 
warfarin values. However, the reverse was true in HC females, where a smaller 
percentage of free R(+) warfarin was exhibited, indicating greater binding of this 
enantiomer to plasma proteins.
The warfarin-resistant HC females showed significantly smaller 
(p<0.001) percentages of both R(+) and S(-) warfarin in their unbound states 
compared with warfarin-susceptible LAC-grey mice at all 3 time points. 
Similarly, HC males exhibited free R(+) warfarin percentages at 0 and 6 hours 
which were significantly less (p<0.001) than those found for LAC-grey males. It  
is interesting to note that over the 6 hour time period, the percentage of free 
warfarin enantiomers remained fairly constant within each group of mice. 
Considering the fact that over this period the plasma concentrations of S(-), and 
especially R(+) warfarin, decreased to quite a large extent (Chapter 4, Figures
4.1.-4.4.).
The pharmacological implications of the observed differences in plasma 
protein binding will be discussed with respect to sex, interstrain and 
stereoselective differences, and the significance of these findings will be related 
to warfarin-resistance in mice.
7.5. DISCUSSION
The plasma protein binding of R(+) and S(-) warfarin enantiomers in 
warfarin-susceptible and warfarin-resistant mice is shown in Table 7.1. and 
Figure 7.1. These results were obtained using ultracentrifugation, but the 
majority of authors have documented percentages of warfarin binding obtained 
using equilibrium dialysis. An important consideration in evaluating binding 
procedures is the relative ability of each to assess differences in the percentage 
of unbound warfarin between individuals. A recent study has evaluated the 
protein binding of warfarin as determined by ultrafiltration and equilibrium 
dialysis (Mungall et al 1984) and demonstrated that equilibrium dialysis and 
ultracentrifugation were similar in their ability to discriminate warfarin binding 
differences between patients. Another area where errors may be made when 
comparing data derived from various sources is in the use of Scatchard plots. As 
indicated previously, (Section 7.4.1.) conclusions of the presence of a binding site 
cannot usually be made from a binding isotherm such as the Scatchard plot alone, 
unless supported by evidence from sources other than binding equilibrium studied 
(Klotz, 1982). Although Scatchard plots are useful as indicators of the number of 
binding sites present on albumin for a given bioactive molecule, they cannot 
indicate a definitive solution, such as the warfarin binding shown in Figure 7.1.b. 
may lead us to believe. Here, the results indicate two equally high affinity  
binding sites and two secondary sites for warfarin, in both LAC-grey and HC  
strains of mouse. However, Larsen et al (1984) have shown similar binding 
isotherms for warfarin to those presented here, but have extended their studies 
to show that co-operativity between the first two warfarin molecules to a 
moderate extent may explain their data. In this case binding of one warfarin  
molecule would increase the affinity for binding of the second, to a lim ited
extent, but complexes with only one bound warfarin may still exist 
independently. The mechanism was postulated to involve an allosteric change of 
one binding site on albumin induced through a conformational change by binding 
of warfarin to another site. Thus, it  is possible to describe multiple binding 
equilibria of warfarin to plasma proteins in stoichiometric terms, a possibility 
which is disregarded when Scatchard's equation alone is used. Therefore, the 
question of whether one or two high affinity sites for warfarin are present on 
plasma proteins should be regarded as debatable, until studies other than binding 
equilibrium measurements have been performed.
Taking these factors into account, it  can therefore be concluded that in 
male and female warfarin-susceptible LAC-grey and warfarin-resistant HC mice, 
the binding of R(+) and S(-) warfarin enantiomers to plasma protein was shown to 
involve either one or two high affinity sites, and two or more secondary sites 
(Figure 7.1.b.) Although a definitive solution with respect to binding sites and 
affinities of binding has not been obtained from the data presented in this 
Chapter, this was not the aim of the study. The major objective was to highlight 
any sex or strain differences in the binding of warfarin enantiomers to plasma 
proteins, and as such Scatchard plots adequately showed that the binding sites 
for R(+) and S(-) warfarin were the same in all strains and sexes of mice studied.
However, when considering the percentage of free R(+) and S(-) warfarin  
in the plasma, differences were seen between both the enantiomers of warfarin, 
and the strains of mouse. For example, in both sexes of LAC-grey warfarin- 
susceptible animals and in males of HC warfarin-resistant mice, a 
stereoselectivity for S(-) warfarin binding was shown both in vitro and in vivo. 
However, in HC females binding of the R(+) warfarin enantiomer was greater
than for it's epitope, again both in vitro and in vivo. In studies by other workers 
(Sellers, 1977; Koch-Weser and Seller, 1971; Koch-Weser and Sellers, 1976), the 
S(-) isomer of warfarin was documented to be more tightly bound to the albumin 
of humans and rats than R(+) warfarin. It  would therefore appear that the case 
of preferential R(+) warfarin binding in the warfarin-resistant female mouse was 
contrary not only to the situation in the other three groups of mice, but also in 
comparison with other species. In addition to this variation in stereoselectivity 
of binding, it could be seen that strain differences also occurred (Table 7.1.), 
such that males and females of the HC warfarin-resistant strain bound relatively 
more warfarin than their warfarin-susceptible counterparts. In vitro and in vivo 
studies showed that the binding of both R(+) and S(-) warfarin in HC females was 
significantly greater (p<0.001) than in LAC-grey females, at all concentrations 
of warfarin and time points after warfarin administration studied. However, a 
less marked effect was seen for HC males, where although significant increases 
(p<0.001) in binding of the R(+) warfarin enantiomer were exhibited, the 
differences in S(-) warfarin binding between HC and LAC-grey mice were not 
always significantly increased in the former strain (Table 7.1.). These strain 
differences are exemplified by the average percentages of bound R(+) and S(-) 
enantiomers of warfarin in each group of mice, both in vitro and in vivo 
warfarin.
R(+)% s(-)%
LAC-grey Male 95.5 96.9
Female 97.0 97.6
HC Male 97.6 98.0
Female 99.2 99.0
These percentages of binding in warfarin-susceptible LAC-grey mice are 
as expected in comparison with those documented by previous workers in various 
animal species (Seller et al, 1977; O'Reilly, 1970) where mouse and rat albumin 
bound more racemic warfarin (97%) than human albumin (96%) with sheep, dog 
and finally, horse albumin showing a decline in the extent of racemic warfarin 
binding. However, warfarin-resistant mice showed a greater percentage binding 
than those documented by other authors for warfarin-susceptible mice and also 
those of LAC-grey mice documented in this Chapter. The pharmacological 
significance of differences in both stereoselectivity and strain in the binding of 
warfarin to plasma proteins will be discussed with special relevance to in vivo 
pharmacokinetic data (Chapter 4) and warfarin-resistance. Firstly, the 
contribution of strain differences to these aforementioned factors will be 
discussed, followed by the differences in stereoselectivity.
Increased plasma protein binding of R(+) and S(-) warfarin by warfarin- 
resistant HC mice may be expected to result in a decreased concentration of 
free drug in the plasma available for equilibration with the sites of warfarin 
anticoagulant action in the liver when compared with the situation in LAC-grey 
mice. Thus, decreased hypoprothrombinaemia would result from any particular 
dose of warfarin (provided the warfarin binding sites on albumin were not 
saturated) as compared with warfarin-susceptible mice. This explanation would 
be consistent with the fact that increased plasma protein binding of warfarin  
enantiomers contributed to warfarin-resistance in these mice. The sex 
difference in warfarin binding may also be explained in terms of warfarin- 
resistance since female HC mice showed an even greater degree of warfarin  
binding than did males (Table 7.1.). The major warfarin resistance gene, War, 
has been shown to be dominant in female HC mice, but it's partial dominance in
male HC mice is under the control of modifiers other than sex (Wallace and 
MacSwiney, 1976). However there are various points of discussion pertaining to 
this hypothesis which should be debated before a conclusion is reached. It  is 
important to consider plasma-protein binding in conjunction with other in vivo 
and in vitro data presented for warfarin-susceptible and warfarin-resistant mice. 
Initially data will be proposed which seems to contradict the postulate, followed 
by data in agreement.
1. If  displacement of warfarin from it's plasma protein bound form by other 
drugs results only in a transient rise in prothrombin clotting time, as 
proposed by Serlin and Breckenridge (1983) why should an increase in the 
free percentage of warfarin in the plasma of LAC-grey mice, cause any 
more than a transient rise in the hypoprothrombinaemic effect of 
warfarin, compared with HC mice?
2. If  the differences in plasma protein binding between the mouse strains 
were due to the biochemical manifestation of War, large differences in 
hypoprothrombinaemia, such as those documented in Chapter 3, Section
3.4.1. are expected. With regard to this statement, Seller et al (1977) 
showed that in man, free warfarin concentration did not correlate with 
warfarin sensitivity on the basis of plasma protein binding 
measurements, and suggested that, in fact, greater 
hypoprothrombinaemia with a higher degree of plasma protein binding 
was effected, with albumin behaving as a reservoir for bound warfarin, 
leading to a slower elimination and a more prolonged inhibition of 
vitamin K-dependent clotting factor synthesis.
Evidence which would support the suggestion that plasma protein binding 
contributes to warfarin-resistance in HC mice include the following arguments:
The displacement of warfarin from plasma proteins by administration of 
another drug allows the distribution of warfarin to alter from one 
equilibrium state to a second such state, ie, warfarin is re-distributed 
and does not necessarily produce a greater effect at the site of 
anticoagulant action (Serlin and Breckenridge, 1983). Comparison of the 
effect of drug displacement does not parallel that of inherent 
differences in plasma protein binding, where a steady-state equilibrium 
between albumin and warfarin is reached which changes si owly while 
warfarin is gradually released as biotransformation lowers the 
concentration of the free drug. Therefore, the extent of plasma protein 
binding in this case, in conjunction with other in vivo events such as the 
warfarin-metabolising capacity of the liver and warfarin binding at 
inactive sites, plays a vital role in the achievement of a steady-state 
equilibrium of the anticoagulant after administration of a single dose. A 
higher degree of plasma protein binding would thus afford the warfarin- 
resistant mice some measure of protection against warfarin 
anticoagulation, as compared with warfarin-susceptible mice, with a 
smaller capacity for warfarin-binding.
In vivo pharmacokinetic data presented in Chapter 4 (Figures 4.5.-4.8.) 
showed that the hepatic uptake of the more potent S(-) warfarin  
enantiomer was greater in warfarin-resistant HC than warfarin- 
susceptible LAC-grey mice, and it was proposed that one class of hepatic 
tissue served as a storage depot for warfarin. In addition, warfarin- 
resistant females exhibited a greater plasma clearance rate than their 
warfarin-susceptible counterparts for the more potent anticoagulant, S(-) 
warfarin. Considering these two factors, it  would seem unlikely that the 
increased plasma protein binding of warfarin would result in a more 
prolonged inhibition of blood coagulation in HC mice, compared with 
warfarin-susceptible LAC-grey mice.
It  is therefore proposed that the strain differences in plasma protein 
binding exhibited by LAC-grey and HC mice (Table 7.1.) contribute to the fact 
that the HC mice, with greater binding, are more resistant to the anticoagulant 
action of warfarin, and that the increased binding may be a result of the 
biochemical expression of the major warfarin-resistance gene, War.
Having discussed the large interstrain differences in the plasma protein 
binding of warfarin, the observed stereoselectivity in binding within each strain 
and sex will be discussed. The contribution of the enantioselective binding will 
be related to the overall in vivo effect of warfarin as an anticoagulant agent. In 
all groups of mice studied, with the exception of HC females, the S(-) 
enantiomer of warfarin was most highly bound to plasma proteins (Table 7.1.) yet 
it was more potent an anticoagulant and less rapidly metabolised than the R(+) 
enantiomer. This suggests that differences in the potency of the two isomers 
are due primarily to differences in receptor site affinity, and not differences in 
albumin binding. The differences in binding of the two warfarin enantiomers was 
not statistically, but most probably, pharmacologically significant. When a drug 
is as highly protein-bound as warfarin, small alterations in the percentage of 
bound drug may cause relatively large fluctuations in the effective dose of that 
drug reaching the site of pharmacological action. Thus, a greater binding of S(-) 
warfarin, the more potent enantiomer acted to reduce the potential 
anticoagulation, since more of the least potent R(+) warfarin enantiomer was 
available to act at the site of action in the liver. The fact that HC warfarin- 
resistant females exhibited the converse stereoselectivity, showing more R(+) 
warfarin bound to albumin than S(-) warfarin for both in vitro and in vivo binding 
experiments, was interesting. The increased binding of the less potent R(+) 
enantiomer would, on first observation, seem to indicate that relatively more of
the S(-) enantiomer was free in plasma and therefore available for uptake to 
either the site of anticoagulant action or the site of proposed inactive warfarin 
binding in the liver. In addition, this would seem to be a cause of the increased 
plasma clearance of this enantiomer observed in HC females (Chapter 4, Figure
4.4.). However, on closer inspection, it can be seen that although a reversed 
stereoselectivity in warfarin binding was seen in HC females, these mice still 
exhibited a higher degree of S(-) warfarin binding than their LAC-grey 
counterparts. Since increased plasma clearance of S(-) warfarin was not seen in 
LAC-grey females, with higher free plasma levels of this enantiomer, plasma 
protein binding differences are unlikely to be responsible for increased S(-) 
warfarin plasma clearance in warfarin-resistant females.
Having discussed stereoselectivity and strain differences in warfarin 
plasma protein binding with respect to warfarin-resistance, the possibilities of 
how the increased binding of R(+) and S(-) warfarin in HC mice is effected will 
be evaulated. Since all plasma protein binding determinations were carried out 
under the same conditions with the same amount of protein in each sample 
incubation, the increased binding of warfarin exhibited by HC mice was not due 
to increased concentrations of plasma proteins in the plasma. There are various 
mechanisms by which increased plasma protein binding could be augmented. 
Firstly, an increased affinity for R(+) and S(-) warfarin enantiomers may have 
occurred via an alteration in the chiral secondary structure of the albumin 
molecule, by forming asymmetrical cavities of helical sequences which were not 
present in the albumin of LAC-grey mice. Secondly, binding of R(+) and S(-) 
warfarin to plasma proteins other than albumin may have occurred. Warfarin 
binding in humans, rats, mice and most other species has been reported to occur 
solely via the binding to plasma albumin (Simonyi et al 1986). However, the
other drugs also bind to different plasma proteins, the most common of these 
being a^-acid glycoprotein which binds $-adrenergic blockers and psychotropic 
agents amongst others (Piafsky, 1980). Thirdly and finally, the increased binding 
of both R(+) and S(-) warfarin in HC warfarin-resistant mice may be due to the 
fact that more of the albumin molecule is in the neutral (N) form, facilitating  
greater binding of the anionic warfarin molecule. At a pH of 7.8, albumin is in 
the basic (B) form and bound warfarin can be displaced by magnesium ions (Van 
der Giesen and Wilting, 1983). However, this warfarin-displacing effect cannot 
be observed when the protein is in the N configuration, such as is the case at 
physiological pH, used in the binding experiments presented in this Chapter. The 
N-B transition clearly alters the protein structure in some way, perhaps so that 
the binding sites of warfarin and Mg are further apart in the N, compared with 
the B form. It  would not seem improbable therefore, that a change in 
conformation, such as that seen during the N-B transition of albumin may have 
occurred in warfarin-resistant mice to cause increased warfarin binding. 
Clearly, further studies would have to be undertaken in order to elucidate the 
mechanism of the observed increase in warfarin plasma protein binding in 
warfarin-resistant mice.
In summary, an increased plasma protein binding of both R(+) and S(-) 
warfarin was exhibited by warfarin-resistant HC mice, compared with their 
warfarin-susceptible LAC-grey counterparts. It  is proposed that this strain 
difference may be a result of a pleiotriopic effect of the major warfarin- 
resistance gene, War. Previously, a sex-specific effect on the plasma clearance 
of S(—) warfarin was also attributed to the biochemical expression of these gene 
in the warfarin-resistant HC mice, with the same effect in the male being 
suppressed by modifiers. It  has been shown, however, that the increased plasma
elimination of S(-) warfarin in HC females was not due to its increased hepatic 
metabolism, excretion rate or decreased plasma protein binding. However, the 
major manifestation of the biochemical expression of the warfarin-resistance 
gene, War, in both male and female HC mice is proposed to cause an increased 
plasma protein binding of both R(+) and S(-) warfarin enantiomers, thereby 
reducing the hypoprothrombinaemic effect of the anticoagulant in warfarin- 
resistant mice.
CHAPTER 8
DISCUSSION
WARFARIN METABOLISM AND DISPOSITION IN  WARFARIN 
SUSCEPTIBLE LAC-GREY AND WARFARIN-RESISTANT HC MOUSE STRAINS
Before being able to discuss the hypotheses proposed in previous 
chapters, relating to the biochemical manifestation(s) of the major warfarin- 
resistance gene, War, in HC mice, the nature of the differences in 
hypoprothrombinaemic response to warfarin administration between LAC-grey 
and HC mouse strains must be exemplified. Thus, the sex-, dose- and strain- 
dependent differences seen after warfarin administration (Chapter 3) will be 
reviewed.
Initially, considering sex differences in each strain of mouse, it was 
found that both in LAC-grey and HC mice, male mice were more sensitive to the 
anticoagulant action of warfarin than their female counterparts, although the 
magnitude of this difference was greater between HC males and females 
(Figures 3.4.-3.16. and Table 3.1.). In both strains, this effect was due to a true 
sex difference under hormonal control, Rowe and Redfern (1967) having 
documented a similar phenomenon in wild and laboratory-bred warfarin- 
susceptible mice. The greater difference between the warfarin sensitivies of 
male and female warfarin-resistant HC mice compared with their warfarin- 
susceptible counterparts may be explained by the fact that the penetrance of the 
warfarin-resistance gene, War, is different in male and female HC mice. The 
gene is carried as an autosomal dominant tra it in females, but the same tra it in 
males is under the influence of modifiers and therefore is only partially dominant
(Wallace and MacSwiney, 1979), causing a lesser degree of warfarin-resistance in 
these mice. Secondly* a dose-dependence in the sensitivity of both warfarin- 
susceptible and warfarin-resistant mouse strains to orally-administered warfarin 
was documented (Figures 3.4.-3.16. and Table 3.1.). In LAC-grey warfarin- 
susceptible males and females, as the dose of racemic warfarin was increased 
from 4 to 64mg/kg/day the toxicity increased, as would be expected, until the 
dose level reached 32mg/kg/day in females and 64mg/kg/day in males where the 
number of animals which succumbed to warfarin’s action decreased. This, 
phenomenon was proposed to be caused by either a dose-dependent increase in 
hepatic uptake or by enzyme induction of warfarin-metabolising cytochrome P- 
430s at the higher doses of warfarin. The la tter possibility was investigated as 
shown by the results presented in Chapter 5 (Figures 5.3.-5.5.). Indeed, induction 
of cytochromes P-450s did occur at 64mg/kg/day, manifested by an increased 
production of warfarin metabolites by hepatic microsomal preparations from 
both male and female LAC-grey compared with preparations from untreated 
LAC-grey mice (Figures 3.3. and 3.3.). In addition, induction of the metabolism 
of warfarin was seen to a lesser extent in microsomal preparations from HC 
mice after administration of 64mg/kg/day racemic warfarin for 3 days. A third 
factor which was documented in Chapter 3 was that large differences were seen 
between the responses of both males and females of the HC strain to warfarin 
administration, compared with LAC-grey males and females. However, the 
difference between warfarin-susceptible and warfarin-resistant females was so 
great that the same clotting time response was evoked by 4mg/kg/day for 4 days 
in LAC-grey females as that seen for 400mg/kg/day for 4 days in HC females; a 
100-fold difference in response (Figures 3.4. and 3.15.). This difference was 
accounted for by the fact that the HC females possessed the warfarin-resistance 
gene, War, as an autosomal fully dominant tra it (Wallace and MacSwiney, 1979).
The difference between the hypoprothrombinaemic responses of males of the two 
strains was not as great. However, male HC warfarin-resistant mice were able 
to tolerate larger doses of warfarin whilst eliciting a smaller anticoagulant 
response compared with LAC-grey warfarin-susceptible mice (Figures 3.4.-3.16. 
and Table 3.1.). This phenomenon, again, was due to the fact that the warfarin- 
resistance gene, War, is only partially dominant in the HC male. Thus, the 
biochemical manifestation(s) of War were modified in the male in such a way as 
to cause a reduced sensitivity to warfarin hypoprothrombinaemia compared with 
LAC-grey males, but the magnitude of this strain difference was not as great as 
that seen between HC and LAC-grey females (Figures 3.4.-3.16.).
The above observations were made after administration of racemic 
warfarin. Therefore, the contributions of the separate R(+) and S(-) enantiomers 
of warfarin to these overall responses were investigated (Figures 3.17 and 3.18.) 
in both warfarin-resistant and warfarin-susceptible mice. In both strains and 
both sexes, the anticoagulant potency of the S(-) warfarin enantiomer was 
greater than that of the R(+) enantiomer, although here again, the males of each 
strain were more sensitive to anticoagulation than their respective females 
(Figures 3.17 and 3.18.). The same stereoselectivity was noted in both humans 
and rats (Eble et al 1966; Breckenridge and Orme, 1972; Breckenridge et al 1973, 
Hewick and McEwen, 1973), the S(-) enantiomer being 3.8 times more potent in 
man and 5.3-6.6 times more potent in the rat than R(+) warfarin. The 21-day 
feeding tria l, the original test for warfarin-resistance, yielded some very 
interesting results which, although unexpected, gave additional information 
relating to the genetics of warfarin-resistance in the HC mouse strain. As 
expected, the LAC-grey warfarin-susceptible mice succumbed to the 
anticoagulant action of warfarin in an average of approximately 9 days, after
consuming an average dose of 163 and 200mg/kg warfarin in males and females 
respectively, over the 9 days (Table 3.5.). However, in warfarin-resistant mice, 
the results were not as expected. Although 6 out of 10 females and 5 out of 10 
males survived the 0.025% warfarin feeding tria l, it  was those mice which 
succumbed to warfarin’s toxic action which seemed strange, especially since 
most of these were from the same litte r. In males, those mice which died after 
10 days or more can be explained in terms of the fact that the warfarin-resistant 
gene is not fully dominant in this sex of the HC mice, in addition to the fact that 
these mice were not from the litte r  described above. This data would agree well 
with that shown in Figures 3.4.-3.16 and Table 3.1. where males were also more 
susceptible to warfarin's action than were females. However, the fact that 
members of a seemingly warfarin-resistant litte r succumbed to the anticoagulant 
effect of warfarin was explained in terms of the homozygous warfarin-resistant 
HC mice possessing two genes which affected their warfarin sensitivity. One of 
these genes is the major warfarin-resistance gene, War, and the second is a gene 
close to War on chromosome 7. Since War is expressed as an autosomal dominant 
tra it, even mice heterozygous for the gene would be expected to survive the 21- 
day feeding tria l. Clearly, some other effect, coded for by a second gene which 
may be co-expressed in homozygous warfarin-resistant mice, may also cause 
changbs in the pharmacodynamic or pharmacokinetic factors of warfarin’s 
anticoagulant action. These differences in the warfarin-resistant mice were not 
shown by using the test of Martin et al (1979) for warfarin-resistance in rats on 
the basis of an altered vitamin K metabolism. I t  was therefore proposed that in 
most cases, homozygous warfarin-resistant mice possess both the major 
warfarin-resistance gene, War, and the proposed second gene, but in some 
instances, only one gene is present, which gives anomalous results. From this 
study it was shown that the method of Martin et al (1979) developed for
warfarin-resistance determination in rats, was accurate for the house mouse, 
since it has been suggested that the major warfarin-resistance gene, War, does 
not biochemically code for altered vitamin K metabolism which is measured by 
the above test.
Onto this base of knowledge of the exact hypoprothrombinaemic 
responses evoked by treatment of both warfarin-susceptible and warfarin- 
resistant mice with warfarin at various doses, a structured analysis of the 
biochemical consequence(s) of expression of the major warfarin-resistance gene, 
War, may be built. Thus, it is now possible to correlate changes in the 
pharmacokinetics, metabolism and disposition of warfarin in these mice with 
their differential anticoagulant sensitivities after warfarin administration.
These studies are presented in Chapters 4-7 and include plasma 
concentration-time profiles of R(+) and S(-) warfarin after both intravenous and 
oral dosing, in vitro hepatic microsomal metabolite profiles following 
pretreatment with warfarin, phenobarbitone, 8-naphthoflavone and clofibrate, 
excretion of unchanged warfarin enantiomers and warfarin metabolites, and 
finally, plasma protein binding parameters; all determined in both male and 
female warfarin-susceptible LAC-grey and warfarin-resistant HC mouse strains. 
Detailed discussions of the data obtained from these studies are presented at the 
end of each chapter; therefore only the hypothesis put forward in each of these 
chapters will be discussed here, and not the detailed results which led to the 
proposed hypothesis.
Results obtained after comparison of the area under the plasma 
concentration-time curves (AUC) after oral and intravenous dosing showed that a
decrease in the bioavailability (F) of warfarin was not responsible for warfarin- 
resistance in HC mice (Figures 4.1.-4.4. and Table 4.1.). Both R(+) and S(-) 
enantiomers of warfarin were well-absorbed, with on average 89% of orally- 
dosed warfarin reaching the plasma (Table 4.1.). Similarly, warfarin-resistance 
in HC males and females could not be attributed to an increased excretion rate 
of the unchanged R(+) and S(-) warfarin enantiomers. D ifferential excretion of 
the unchanged warfarin enantiomers did take place in urine (Figure 6.2.). 
However, taking into account the very small percentages of the dose of warfarin  
excreted in this form, it was considered highly unlikely that this difference 
accounted for the vast differences in warfarin sensitivity observed between 
LAC-grey and HC mice. The fact that early workers had shown correlations 
between several enzyme activities and warfarin susceptibility in mouse strains 
(Wood and Conney, 1974; Lush and Arnold, 1976), provided the basis for 
investigating pharmacokinetic, rather than pharmacodynamic mechanisms in the 
elucidation of warfarin-resistance. Thus, a differential increase in the plasma 
clearance of the more potent S(-) warfarin enantiomer in the warfarin-resistant 
female was documented (Figure 4.4. and Table 4.1.). However, no such finding 
was observed in the warfarin-resistant male. In addition, both male and female 
warfarin-resistant mice showed significantly increased hepatic uptake of the 
more potent S(-) enantiomer of warfarin (Figures 4.5.-4.8.) compared with LA C - 
grey mice; this phenomenon being explained by the hypothesis that hepatic tissue 
served as a depot for S(-) warfarin in HC mice, but as such was not available for 
anticoagulant action or detoxification by hepatic warfarin-metabolising 
enzymes, in much the same way as if it were bound to albumin of plasma 
proteins. Therefore, the increased hepatic uptake did not account for the 
increased plasma clearance of the S(-) warfarin enantiomer noted in HC females, 
since the same effect was not seen in male HC mice. Clearly, an increased
plasma clearance of the more potent enantiomer of warfarin would contribute to 
the fact that these female mice were resistant to the anticoagulant action of 
warfarin. The most likely explanation for the sex-dependent alteration in plasma 
clearance of S(-) warfarin in warfarin-resistant HC mice was that the expression 
of War, as part of a pleiotropic (multiple biochemical) effect caused a 
stereospecific change in warfarin pharmacokinetics in female HC mice, while 
the same effect was modified in the male. An increased plasma clearance of a 
drug, or enantiomer, may be caused by a number of mechanisms: an increased 
metabolic activity, probably in the liver, increased excretion rate, or decreased 
plasma protein binding. A ll these possibilities were investigated and the results 
are presented in Chapters 3, 6 and 7 of this thesis; bearing in mind the fact that 
a biochemical mechanism for warfarin-resistance in the HC male had not been 
elucidated. The metabolism of warfarin enantiomers in the liver was 
investigated using in vitro microsomal preparations prepared from untreated 
mice of both male and female, warfarin-susceptible and warfarin-resistant mice. 
Results from these incubations showed that R(+) warfarin was preferentially 
metabolised, correlating with the decreased half-life  and increased plasma 
clearance of this enantiomer, compared with S(-) warfarin in male and female 
warfarin-susceptible and warfarin-resistant mice in vivo (Figures 4.1.-4.4. and 
Figures 5.3.). However, increased plasma clearance of S(-) warfarin in HC 
females was not explained by a greater rate of metabolite production by hepatic 
microsomes from these mice. In the same way, increased hepatic microsomal 
production of warfarin metabolites was not seen as the mechanism of warfarin- 
resistance in HC males (Figure 5.3.). Additionally, the excretion rate of 
unchanged S(-) warfarin was not increased in HC females to any signficant 
extent which would account for the 20-fold increase in plasma clearance of these 
mice, compared with their warfarin-susceptible counterparts. However, an
interesting factor with respect to this phenomenon was shown from the warfarin  
excretion studies. This was exemplified by the fact that the HC female excreted 
significantly more warfarin as metabolites than did the LAC-grey females, in 
urine, and especially faeces. This would point to an increased metabolic rate of 
S(-) warfarin at some other site than hepatic microsomes in warfarin-resistant 
females. This site may be extrahepatic in, for example, the kidneys or lung, or 
at an extra-microsomal site in the liver, such as in mitochondria. This postulate 
was also corroborated by the finding that decreased plasma protein binding was 
not responsible for this increased S(-) warfarin elimination (Table 7.1.). Future 
studies may therefore show an increased capacity for S(-) warfarin metabolism 
at one of these sites in warfarin-resistant females, thereby elucidating this 
proposed pleiotropic effect of the major warfarin-resistance gene, War.
The in vivo and in vitro studies of warfarin pharmacokinetics, hepatic 
microsomal metabolism and warfarin excretion showed no differences between 
warfarin-susceptible and warfarin-resistant mice which could explain the 
biochemical manifestation of the major warfarin-resistance gene, War. 
However, plasma protein binding studies yielded results showing increased 
plasma protein binding (p<0.001) of both R(+) and S(-) warfarin, both in vitro and 
in vivo in warfarin-resistant males and females, compared with their warfarin- 
susceptible counterparts. The increase of approximately 1% of the dose of 
warfarin in the free form for each of the warfarin enantiomers represented an 
approximate doubling of the effective warfarin dose in the LAC-grey compared 
with HC mice. Thus, it was proposed that this strain difference may have been a 
result of the expression of the warfarin-resistance gene, War. In conjunction, 
increased plasma protein binding of R(+) and S(-) and increased hepatic uptake of 
S(-) warfarin in both males and females contributed to the fact
that HC mice were less sensitive to the hypoprothrombinaemic effect of 
warfarin than LAC-grey mice. Provided that hepatic uptake of S(-) warfarin 
constituted a depot for the enantiomer, which was not available for metabolism 
or anticoagulant action, which has not been proven, these two factors may have 
been due to the biochemical expression of War. In addition to the pleiotropic 
effect of War to cause increased S(-) warfarin elimination from the plasma of 
warfarin-resistant females; an effect which was proposed to be under the control 
of modifiers in the male; these differential pharmacokinetic mechanisms may 
account not only for the fact that HC mice were resistant to warfarin, compared 
with LAC-grey mice, but also the fact that females were quite markedly more 
tolerant than males to any particular dose of warfarin, or separate warfarin 
enantiomers (Figures 3.4.-3.16.).
It  would be highly speculative to link the differential plasma protein 
binding and hepatic uptake in HC mice directly to the expression of War, in light 
of the fact that the exact gene sequence of the segment of chromosome 7, 
present in HC warfarin-resistant mice, but absent in LAC-grey warfarin- 
susceptible mice is not known. To reiterate, the section of chromosome 7 
transferred from PBI to HC mice contained various marker genes such that their 
arrangement was proposed to be War—fr—sh-1—C —p (Wallace and MacSwiney, 
1976). The expression of one (or more) of the genes in the segments between the 
markers may result in biochemical changes which contribute to warfarin- 
resistance in these mice. Such a mechanism was proposed in Chapter 3, section
3.5. However, since the warfarin-resistant HC mice are in possession of the 
major gene, War, on chromosome 7, which has been shown to be at least partly 
responsible for warfarin resistance (Wallace and MacSwiney, 1976), it is probable 
that either the plasma protein binding parameters or hepatic uptake or
both are pleiotropic effects with an increased S(-) warfarin plasma clearance in 
HC females. The latter effect has been shown to be almost undisputably due to 
the expression of War (Chapter 3, Section 3.3.). Thus, a major contribution to 
the understanding of warfarin-resistance in the house mouse has been made by 
investigating both the nature of the response of LAC-grey and HC mice to 
warfarin administration, in addition to elucidating the metabolism and 
disposition of warfarin in these mice. At the beginning of this thesis it  was 
suggested that mice may have become resistant to the effects of warfarin 
through a mutation resulting in altered pharmacodynamic or pharmacokinetic 
metabolism. In probing the absorption, distribution, metabolism and excretion of 
warfarin in both LAC-grey and HC mice, the latter, pharmacokinetic 
mechanisms have been elucidated. Although warfarin-resistance may be 
contributed to by differential pharmacodynamics, such as alterations in the 
metabolism of vitamin K, so influencing vitamin K-dependent blood clotting 
factor synthesis or haemostasis, there is no doubt that the mechanisms outlined 
in this thesis account for the vast majority of the differences in 
hypoprothrombinaemic responses observed between warfarin-susceptible LA C- 
grey and warfarin-resistant HC mouse strains.
FUTURE WORK
1. The metabolism of warfarin by extra-microsomal organelles and organs, 
such as liver mitochondria, the kidney and the lung, should be investigated 
in an attempt to elucidate whether the increased plasma clearance of S(-) 
warfarin in HC females was due to an increased metabolism as speculated. 
Purification and characterisation of the warfarin-metabolising enzyme(s) 
would aid future work.
2. The pharmacodynamics of warfarin-susceptible LAC-grey and warfarin- 
resistant HC mice should be probed, to discover whether the metabolism of 
vitamin K is altered in any way in HC mice so contributing to their 
resistance to the anticoagulant.
3. The exact gene sequence of chromosome 7, and the biochemical mechanism 
expressed by each gene should be elucidated, in order to simplify the highly 
complex differential relationships which must be unfolded in order to 
propose physiological mechanisms for warfarin-resistance in the house 
mouse.
4. Once the definitive pharmacological mechanism responsible for warfarin- 
resistance in the house mouse has been confirmed, the development of 
rodenticides, effective against warfarin-resistant mice may begin.
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